Methods for editing disease-related genes using adenosine deaminase base editors, including for treating genetic diseases
Novel adenine base editors (ABE8) enhance specificity and efficiency in correcting genetic mutations, effectively treating neurological disorders by converting A to G in target genes, offering rapid symptom relief for conditions like Hurler syndrome, Parkinson's disease, and Rett syndrome.
Patent Information
- Application Number
- JP2021546888
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-01-27
- Filing Date
- 2020-02-13
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-02-13
AI Technical Summary
Current base editors lack the specificity and efficiency needed for targeted nucleic acid sequence modifications, particularly in treating genetic diseases.
Development of novel adenine base editors (ABE8) with enhanced efficiency and specificity, utilizing adenosine deaminase variants to induce A to G nucleobase modifications in target genes associated with neurological disorders.
The ABE8 editors rapidly ameliorate symptoms of neurological disorders such as Hurler syndrome, Parkinson's disease, Rett syndrome, and Stargardt disease by correcting specific SNPs, with reduced off-target effects and improved symptom relief compared to previous editors.
Smart Images

Figure 0007586601000104 
Figure 0007586601000105 
Figure 0007586601000106
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Application No. 62 / 805,271 filed February 13, 2019, U.S. Provisional Application No. 62 / 852,228 filed May 23, 2019, U.S. Provisional Application No. 62 / 852,224 filed May 23, 2019, U.S. Provisional Application No. 62 / 873,138 filed July 11, 2019, U.S. Provisional Application No. 62 / 888,867 filed August 19, 2019, U.S. Provisional Application No. 62 / 931,722 filed November 6, 2019, U.S. Provisional Application No. 62 / 941,569 filed November 27, 2019, U.S. Provisional Application No. 62 / 102,363 filed January 27, 2020, and U.S. Provisional Application No. 62 / 111,2019. No. 966,526, the disclosures of which are incorporated herein by reference in their entireties.
[0002] Incorporation by Reference All publications, patents, and patent applications mentioned herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. Unless otherwise indicated, all publications, patents, and patent applications mentioned herein are incorporated by reference in their entirety. [Background technology]
[0003] Targeted editing of nucleic acid sequences, e.g., targeted cleavage or targeted modification of genomic DNA, is a very promising approach for studying gene function and may also provide new therapeutics for human genetic diseases. Currently available base editors include cytidine base editors (e.g., BE4) that convert targeted C·G base pairs to T·A, and adenine base editors (e.g., ABE7.10) that convert A·T to G·C. There is a need in the art for improved base editors that can induce modifications in targeted sequences with higher specificity and efficiency. Summary of the Invention
[0004] The invention provides compositions comprising novel adenine base editors with increased efficiency (e.g., ABE8) and methods of using base editors comprising adenosine deaminase variants to edit target sequences.
[0005] In an aspect, provided herein is a method of treating a neurological disorder in a subject, comprising administering to the subject (i) an adenosine base editor or a nucleic acid sequence encoding same, and (ii) a guide polynucleotide or a nucleic acid sequence encoding same, wherein the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein the adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein the guide polynucleotide induces the adenosine base editor to effect an A to G nucleobase modification in a target gene or a regulatory element thereof associated with said neurological disorder in the subject, thereby treating said neurological disorder in the subject. In another embodiment of this aspect, the target gene is the alpha-L-iduronidase (IDUA) gene and the neurological disorder is Hurler syndrome. In one embodiment of this aspect, the target gene is the leucine-rich repeat kinase 2 (LRRK2) gene and the neurological disorder is Parkinson's disease. In one embodiment of this aspect, the target gene is the methyl-CpG binding protein 2 (MECP2) gene and the neurological disease is Rett syndrome. In another embodiment of this aspect, the target gene is the ATP-binding cassette subfamily member 4 (ABCA4) gene and the neurological disease is Stargardt disease.
[0006] In certain embodiments, provided herein is a method of treating Hurler Syndrome in a subject, the method comprising administering to the subject (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, wherein said guide polynucleotide induces said adenosine base editor to effect an A to G nucleobase modification in an alpha-L-iduronidase (IDUA) gene, or a regulatory element thereof, of the subject, thereby treating Hurler Syndrome in the subject.
[0007] In some embodiments, the administration ameliorates at least one symptom associated with Hurler Syndrome, hi some embodiments, the administration results in a more rapid amelioration of at least one symptom associated with Hurler Syndrome as compared to treatment with a base editor without the amino acid substitution in adenosine deaminase.
[0008] In one embodiment, the IDUA gene or its regulatory element comprises a SNP associated with Hurler syndrome. In one embodiment, the A to G nucleobase modification is in a SNP associated with Hurler syndrome. In one embodiment, the SNP associated with Hurler syndrome results in a W402X or W401X amino acid variant in the IDUA polypeptide or its variant encoded by the IDUA gene as numbered in SEQ ID NO: 4, where X is a stop codon. In one embodiment, the A to G nucleobase modification changes the SNP associated with Hurler syndrome to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Hurler syndrome to a non-wild-type nucleobase that results in the amelioration of one or more symptoms of Hurler syndrome. In one embodiment, the A to G modification in a SNP associated with Hurler syndrome changes the stop codon encoded by the IDUA gene to a tryptophan in the IDUA polypeptide.
[0009] In some embodiments, the guide polynucleotide comprises a nucleic acid sequence complementary to an IDUA gene or a regulatory element thereof that includes a SNP associated with Hurler syndrome. In some embodiments, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to an IDUA gene or a regulatory element thereof that includes a SNP associated with Hurler syndrome. In some embodiments, the sgRNA comprises a nucleic acid sequence selected from the group consisting of 5'-GACUCUAGGCAGAGGUCUCAA -3', 5'-ACUCUAGGCAGAGGUCUCAA-3', 5'-CUCUAGGCCGAAGUGUCGC -3', and 5'-GCUCUAGGCCGAAGUGUCGC-3'.
[0010] In certain embodiments, provided herein is a method of treating Parkinson's disease in a subject, the method comprising administering to the subject (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, wherein said guide polynucleotide induces said adenosine base editor to effect an A to G nucleobase modification in a leucine-rich repeat kinase 2 (LRRK2) gene, or a regulatory element thereof, of the subject, thereby treating Parkinson's disease in the subject.
[0011] In some embodiments, the administration ameliorates at least one symptom associated with Parkinson's disease, in some embodiments, the administration results in a more rapid improvement of at least one symptom associated with Parkinson's disease compared to treatment with a base editor that does not involve the amino acid substitution in adenosine deaminase.
[0012] In some embodiments, the LRRK2 gene or a regulatory element thereof comprises a SNP associated with Parkinson's disease. In some embodiments, the nucleobase modification from A to G is in a SNP associated with Parkinson's disease. In some embodiments, the SNP associated with Parkinson's disease results in an A419V, R1441C, R1441H, or G2019S amino acid variant in the LRRK2 polypeptide as numbered in SEQ ID NO: 3, or a variant thereof encoded by the LRRK2 gene.
[0013] In some embodiments, the A to G nucleobase modification changes the SNP associated with Parkinson's disease to a wild-type nucleobase. In some embodiments, the A to G nucleobase modification changes the SNP associated with Parkinson's disease to a non-wild-type nucleobase that results in the amelioration of one or more symptoms of Parkinson's disease. In some embodiments, the A to G nucleobase modification changes a cysteine or histidine to an arginine in an LRRK2 polypeptide encoded by the LRRK2 gene. In some embodiments, the A to G modification changes a serine to a glycine in an LRRK2 polypeptide encoded by the LRRK2 gene. In some embodiments, the A to G modification substitutes a cysteine (C) or histidine (H) for an arginine (R) at position 144 or a serine for a glycine (G) at position 2019 of an LRRK2 polypeptide or a variant thereof encoded by the LRRK2 gene in the numbering in SEQ ID NO: 3.
[0014] In certain aspects, provided herein is a method of treating Parkinson's disease in a subject, the method comprising administering to the subject (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said guide polynucleotide induces said adenosine base editor to effect an A to G nucleobase modification at a SNP in a LRRK2 gene associated with Parkinson's disease, wherein said SNP does not encode the G2019S mutation in a LRRK2 polypeptide as numbered in SEQ ID NO:3, or a variant thereof.
[0015] In some embodiments, the adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2. In some embodiments, the guide polynucleotide comprises a nucleic acid sequence complementary to the LRRK2 gene, or a regulatory element thereof, that comprises a SNP associated with Parkinson's disease. In some embodiments, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to the LRRK2 gene, or a regulatory element thereof, that comprises a SNP associated with Parkinson's disease. In some embodiments, the sgRNA comprises the nucleic acid sequence 5'-AAGCGCAAGCCUGGAGGGAA -3'; or 5'-ACUACAGCAUUGCUCAGUAC-3'.
[0016] In certain embodiments, provided herein is a method of treating Rett Syndrome in a subject, comprising administering to the subject (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, wherein said guide polynucleotide induces said adenosine base editor to effect an A to G nucleobase modification in a methyl-CpG binding protein 2 (MECP2) gene, or a regulatory element thereof, of the subject, thereby treating Rett Syndrome in the subject.
[0017] In some embodiments, the administration ameliorates at least one symptom associated with Rett syndrome. In some embodiments, the administration results in a more rapid amelioration of at least one symptom associated with Rett syndrome compared to treatment with a base editor without the amino acid substitution in adenosine deaminase. In some embodiments, the MECP2 gene or regulatory element thereof comprises a SNP associated with Rett syndrome. In some embodiments, the A to G nucleobase modification is in a SNP associated with Rett syndrome. In some embodiments, the SNP associated with Rett syndrome results in a R106W or T158M amino acid variant in an MECP2 polypeptide or a variant thereof encoded by the MECP2 gene as numbered in SEQ ID NO:5. In some embodiments, the SNP associated with Rett syndrome results in a R255X or R270X amino acid variant in an MECP2 polypeptide encoded by the MECP2 gene, where X is a stop codon.
[0018] In one embodiment, the A to G nucleobase modification changes the SNP associated with Rett syndrome to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Rett syndrome to a non-wild-type nucleobase that results in amelioration of Rett syndrome symptoms. In one embodiment, the A to G nucleobase modification in the SNP associated with Rett syndrome changes a stop codon to a tryptophan in the MECP2 polypeptide.
[0019] In some embodiments, the guide polynucleotide comprises a nucleic acid sequence complementary to the MECP2 gene or a regulatory element thereof, comprising a SNP associated with Rett Syndrome. In some embodiments, the adenosine base editor is complexed with a single guide RNA (sgRNA) comprising a nucleic acid sequence complementary to the MECP2 gene or a regulatory element thereof, comprising a SNP associated with Rett Syndrome. In some embodiments, the guide polynucleotide comprises a nucleic acid sequence selected from the group consisting of 5'-CUUUUCACUUCCUGCCGGGG-3', 5'-AGCUUCCAUGUCCAGCCUUC-3', 5'-ACCAUGAAGUCAAAAUCAUU-3', and 5'-GCUUUCAGCCCCGUUUCUUG-3'.
[0020] In certain embodiments, the description provides a method of treating Stargardt's disease in a subject, the method comprising administering to the subject (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein the adenosine base editor comprises a programmable DNA-binding domain and an adenosine deaminase domain, wherein the adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, wherein the guide polynucleotide induces the adenosine base editor to effect an A to G nucleobase modification in an ATP-binding cassette subfamily member 4 (ABCA4) gene, or a regulatory element thereof, of the subject, thereby treating Stargardt's disease in the subject.
[0021] In some embodiments, the administration ameliorates at least one symptom associated with Stargardt's disease, hi some embodiments, the administration results in a more rapid amelioration of at least one symptom associated with Stargardt's disease compared to treatment with a base editor that does not involve the amino acid substitution in adenosine deaminase.
[0022] In one embodiment, the ABCA4 gene comprises a SNP associated with Stargardt's disease. In one embodiment, the A to G nucleobase modification is in a SNP associated with Stargardt's disease. In one embodiment, the SNP associated with Stargardt's disease results in an A1038V or G1961E amino acid variant in the ABCA4 polypeptide numbered as in SEQ ID NO: 6 or a variant thereof encoded by the ABCA4 gene. In one embodiment, the SNP associated with Stargardt's disease results in a G1961E amino acid variant in the ABCA4 polypeptide numbered as in SEQ ID NO: 6 or a variant thereof.
[0023] In one embodiment, the A to G nucleobase modification changes the SNP associated with Stargardt Disease to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Stargardt Disease to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Stargardt Disease. In one embodiment, the guide polynucleotide comprises a nucleic acid sequence complementary to the ABCA4 gene or a regulatory element thereof that includes a SNP associated with Stargardt Disease.
[0024] In one embodiment, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to the ABCA4 gene or a regulatory element thereof that comprises a SNP associated with Stargardt disease, hi one embodiment, the sgRNA comprises the sequence 5'-CUCCAGGGCGAACUUCGACACACAGC-3'.
[0025] In various embodiments, the treatments described herein result in amelioration of symptoms of a neurological disorder as compared to treatment with a base editor that comprises an adenosine deaminase domain without said amino acid substitutions.
[0026] In an aspect, provided herein is a method of editing a target gene or regulatory element thereof associated with a neurological disorder, comprising contacting the target gene or regulatory element thereof with: (i) an adenosine base editor; and (ii) a guide polynucleotide, wherein the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein the adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein the guide polynucleotide induces the adenosine base editor to effect an A to G nucleobase modification in the target gene or regulatory element associated with the neurological disorder. In one embodiment of this aspect, the target gene is the leucine-rich repeat kinase 2 (LRRK2) gene and the neurological disorder is Parkinson's disease. In another embodiment of this aspect, the target gene is the alpha-L-iduronidase (IDUA) gene and the neurological disorder is Hurler syndrome. In one embodiment of this aspect, the target gene is the methyl-CpG binding protein 2 (MECP2) gene and the neurological disease is Rett syndrome. In another embodiment of this aspect, the target gene is the ATP-binding cassette subfamily member 4 (ABCA4) gene and the neurological disease is Stargardt disease.
[0027] In certain aspects, provided herein is a method of editing a leucine-rich repeat kinase 2 (LRRK2) gene or a regulatory element thereof, comprising contacting the LRRK2 gene or a regulatory element thereof with (i) an adenosine base editor, or a nucleic acid sequence encoding same, and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein said guide polynucleotide induces said adenosine base editor to effect an A to G nucleobase modification in the LRRK2 gene or a regulatory element thereof.
[0028] In one embodiment, the A to G nucleobase modification is in a SNP associated with Parkinson's disease. In one embodiment, the SNP associated with Parkinson's disease results in an A419V, R1441C, R1441H, or G2019S amino acid variant in the LRRK2 polypeptide as numbered in SEQ ID NO: 3, or a variant thereof encoded by the LRRK2 gene. In one embodiment, the A to G nucleobase modification changes the SNP associated with Parkinson's disease to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Parkinson's disease to a non-wild-type nucleobase that results in the amelioration of one or more symptoms of Parkinson's disease.
[0029] In one embodiment, the A to G nucleobase modification changes a cysteine or histidine to arginine in the LRRK2 polypeptide encoded by the LRRK2 gene. In one embodiment, the A to G modification changes a serine to glycine in the LRRK2 polypeptide encoded by the LRRK2 gene. In one embodiment, the A to G modification replaces a cysteine (C) or histidine (H) at position 144 of the LRRK2 polypeptide or a variant thereof encoded by the LRRK2 gene with an arginine (R) or replaces a serine at position 2019 with a glycine (G) in the numbering of SEQ ID NO:3.
[0030] In an embodiment, provided herein is a method of editing a leucine-rich repeat kinase 2 (LRRK2) gene or a regulatory element thereof, comprising contacting said LRRK2 gene or a regulatory element thereof with (i) an adenosine base editor, or a nucleic acid sequence encoding same, and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA-binding domain and an adenosine deaminase domain, wherein said guide polynucleotide induces said adenosine base editor to result in an A to G nucleobase modification at a SNP in the LRRK2 gene, wherein said SNP does not encode a G2019S mutation in a LRRK2 polypeptide as numbered in SEQ ID NO:3, or a variant thereof.
[0031] In one embodiment, the adenosine deaminase domain comprises an amino acid substitution at or corresponding to amino acid position 82 or 166 in numbering in SEQ ID NO: 2. In one embodiment, the guide polynucleotide comprises a nucleic acid sequence complementary to the LRRK2 gene or a regulatory element thereof that contains a SNP associated with Parkinson's disease.
[0032] In one embodiment, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to the LRRK2 gene or a regulatory element thereof that contains a SNP associated with Parkinson's disease. In one embodiment, the sgRNA comprises the nucleic acid sequence 5'-AAGCGCAAGCCUGGAGGGAA -3'; or 5'-ACUACAGCAUUGCUCAGUAC-3'.
[0033] In certain embodiments, provided herein is a method of editing an alpha-L-iduronidase (IDUA) gene or a regulatory element thereof, comprising contacting an IDUA gene or a regulatory element thereof with (i) an adenosine base editor, or a nucleic acid sequence encoding same, and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein said guide polynucleotide induces said adenosine base editor to effect an A to G nucleobase modification in said IDUA gene or regulatory element thereof.
[0034] In one embodiment, the IDUA gene or a regulatory element thereof comprises a SNP associated with Hurler syndrome. In one embodiment, the A to G nucleobase modification is in a SNP associated with Hurler syndrome. In one embodiment, the SNP associated with Hurler syndrome results in a W402X or W401X amino acid variant in the IDUA polypeptide or a variant thereof encoded by the IDUA gene, as numbered in SEQ ID NO: 4, where X is a stop codon.
[0035] In one embodiment, the A to G nucleobase modification changes the SNP associated with Hurler syndrome to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Hurler syndrome to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Hurler syndrome. In one embodiment, the A to G modification in the SNP associated with Hurler syndrome changes a stop codon encoded by the IDUA gene to tryptophan in the IDUA polypeptide.
[0036] In some embodiments, the guide polynucleotide comprises a nucleic acid sequence complementary to an IDUA gene or a regulatory element thereof that includes a SNP associated with Hurler syndrome. In some embodiments, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to an IDUA gene or a regulatory element thereof that includes a SNP associated with Hurler syndrome. In some embodiments, the sgRNA comprises a nucleic acid sequence selected from the group consisting of 5'-GACUCUAGGCAGAGGUCUCAA -3', 5'-ACUCUAGGCAGAGGUCUCAA-3', 5'-CUCUAGGCCGAAGUGUCGC -3', and 5'-GCUCUAGGCCGAAGUGUCGC-3'.
[0037] In certain embodiments, provided herein is a method of editing a methyl-CpG binding protein 2 (MECP2) gene, or a regulatory element thereof, comprising administering to a subject (i) an adenosine base editor, or a nucleic acid sequence encoding same, and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein said guide polynucleotide induces said adenosine base editor to effect an A to G nucleobase modification in the MECP2 gene, or a regulatory element thereof.
[0038] In some embodiments, the MECP2 gene or regulatory element thereof comprises a SNP associated with Rett syndrome. In some embodiments, the A to G nucleobase modification is in a SNP associated with Rett syndrome. In some embodiments, the SNP associated with Rett syndrome results in an R106W or T158M amino acid variant in the MECP2 polypeptide or a variant thereof encoded by the MECP2 gene as numbered in SEQ ID NO:5. In some embodiments, the SNP associated with Rett syndrome results in an R255X or R270X amino acid variant in the MECP2 polypeptide encoded by the MECP2 gene, where X is a stop codon.
[0039] In one embodiment, the A to G nucleobase modification changes the SNP associated with Rett Syndrome to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Rett Syndrome to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Rett Syndrome. In one embodiment, the A to G nucleobase modification in a SNP associated with Rett Syndrome changes a stop codon to tryptophan in an MECP2 polypeptide.
[0040] In some embodiments, the guide polynucleotide comprises a nucleic acid sequence complementary to the MECP2 gene or a regulatory element thereof, comprising a SNP associated with Rett Syndrome. In some embodiments, the adenosine base editor is complexed with a single guide RNA (sgRNA) comprising a nucleic acid sequence complementary to the MECP2 gene or a regulatory element thereof, comprising a SNP associated with Rett Syndrome. In some embodiments, the guide polynucleotide comprises a nucleic acid sequence selected from the group consisting of 5'- CUUUUCACUUCCUGCCGGGG-3', 5'-AGCUUCCAUGUCCAGCCUUC-3', 5'- ACCAUGAAGUCAAAAUCAUU-3', and 5'- GCUUUCAGCCCCGUUUCUUG-3'.
[0041] In certain embodiments, provided herein is a method of editing an ATP-binding cassette subfamily member 4 (ABCA4) gene or a regulatory element thereof, comprising contacting the ABCA4 gene or a regulatory element thereof with (i) an adenosine base editor, or a nucleic acid sequence encoding same, and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein the adenosine base editor comprises a programmable DNA-binding domain and an adenosine deaminase domain, wherein the adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein the guide polynucleotide induces the adenosine base editor to effect an A to G nucleobase modification in the ABCA4 gene or a regulatory element thereof.
[0042] In some embodiments, the administration ameliorates at least one symptom associated with Stargardt's disease, hi some embodiments, the administration results in a more rapid amelioration of at least one symptom associated with Stargardt's disease compared to treatment with a base editor that does not involve the amino acid substitution in adenosine deaminase.
[0043] In one embodiment, the ABCA4 gene comprises a SNP associated with Stargardt's disease. In one embodiment, the A to G nucleobase modification is in a SNP associated with Stargardt's disease. In one embodiment, the SNP associated with Stargardt's disease results in an A1038V or G1961E amino acid variant in the ABCA4 polypeptide numbered as in SEQ ID NO: 6 or a variant thereof encoded by the ABCA4 gene. In one embodiment, the SNP associated with Stargardt's disease results in a G1961E amino acid variant in the ABCA4 polypeptide numbered as in SEQ ID NO: 6 or a variant thereof.
[0044] In one embodiment, the A to G nucleobase modification changes the SNP associated with Stargardt Disease to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Stargardt Disease to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Stargardt Disease. In one embodiment, the guide polynucleotide comprises a nucleic acid sequence complementary to the ABCA4 gene or a regulatory element thereof that includes a SNP associated with Stargardt Disease.
[0045] In one embodiment, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to the ABCA4 gene or a regulatory element thereof that comprises a SNP associated with Stargardt disease. In one embodiment, the sgRNA comprises the sequence 5'-CUCCAGGGCGAACUUCGACACACAGC-3'.
[0046] In various embodiments of the above aspect, the contacting occurs in a cell. In some embodiments, the contacting causes less than 10% indels in the genome of the cell, where the indel rate is measured by the mismatch frequency between the sequence adjacent to the single nucleotide modification and the unmodified sequence. In some embodiments, the contacting causes less than 5% indels in the genome of the cell, where the indel rate is measured by the mismatch frequency between the sequence adjacent to the single nucleotide modification and the unmodified sequence. In some embodiments, the contacting causes less than 1% indels in the genome of the cell, where the indel rate is measured by the mismatch frequency between the sequence adjacent to the single nucleotide modification and the unmodified sequence.
[0047] In various embodiments of the above aspects, the cells are neurons. In some embodiments, the contacting occurs within a population of cells. In some embodiments, the contacting results in an A to G nucleobase modification in at least 40% of the population of cells after the contacting step. In some embodiments, the contacting results in an A to G nucleobase modification in at least 50% of the population of cells after the contacting step. In some embodiments, the contacting results in an A to G nucleobase modification in at least 70% of the population of cells after the contacting step. In some embodiments, at least 90% of the cells are viable after the contacting step. In some embodiments, the population of cells was not enriched after the contacting step. In some embodiments, the population of cells is neurons. In some embodiments, the contacting occurs in vivo or ex vivo.
[0048] In various aspects and embodiments above, the polynucleotide-programmable DNA binding domain is Cas9. In some embodiments, the Cas9 is SpCas9, SaCas9, or a variant thereof. In some embodiments, the polynucleotide-programmable DNA binding domain comprises a modified SpCas9 with modified protospacer adjacent motif (PAM) specificity. In some embodiments, the Cas9 has specificity for a PAM sequence selected from the group consisting of NGG, NGA, NGCG, NGN, NNGRRT, NNNRRT, NGCG, NGCN, NGTN, and NGC, where N is A, G, C, or T and R is A or G. In some embodiments, the polynucleotide-programmable DNA binding domain is a nuclease-inactive variant. In some embodiments, the polynucleotide-programmable DNA binding domain is a nickase variant. In some embodiments, the nickase variant comprises the amino acid substitution D10A or a corresponding amino acid substitution. In aspects and embodiments provided herein, the adenosine deaminase domain comprises a TadA domain. In certain embodiments, the adenosine deaminase comprises a TadA deaminase comprising a V82S modification and / or a T166R modification.
[0049] In various aspects and embodiments above, the adenosine deaminase further comprises one or more modifications of Y147T, Y147R, Q154S, Y123H, Q154R, or combinations thereof. In aspects and embodiments provided herein, the adenosine deaminase comprises a combination of modifications selected from the group consisting of Y147R + Q154R + Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y147T + Q154R; Y147T + Q154S; and Y123H + Y147R + Q154R + I76Y. In aspects and embodiments provided herein, the adenosine base editor domain comprises an adenosine deaminase monomer. In aspects and embodiments provided herein, the adenosine base editor comprises an adenosine deaminase dimer. In one embodiment, the TadA deaminase is a TadA*8 variant. In one embodiment, the TadA*8 variant is selected from the group consisting of TadA*8.1, TadA*8.2, TadA*8.3, TadA*8.4, TadA*8.5, TadA*8.6, TadA*8.7, TadA*8.8, TadA*8.9, TadA*8.10, TadA*8.11, TadA*8.12, and TadA*8.13. In some embodiments, the adenosine base editor is an ABE8 base editor selected from the group consisting of ABE8.1, ABE8.2, ABE8.3, ABE8.4, ABE8.5, ABE8.6, ABE8.7, ABE8.8, ABE8.9, ABE8.10, ABE8.11, ABE8.12, and ABE8.13.
[0050] In some aspects, provided herein are cells produced by the methods described in various aspects and embodiments disclosed herein. In some aspects, provided herein are populations of cells produced by the methods described in various aspects and embodiments disclosed herein.
[0051] In an aspect, provided herein is a base editor system comprising: (i) an adenosine base editor or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide or a nucleic acid sequence encoding same, wherein the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein the adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein the guide polynucleotide directs the adenosine base editor to effect an A to G nucleobase modification in a target gene or a regulatory element thereof associated with a neurological disorder. In one embodiment of the above aspect, the target gene is the leucine-rich repeat kinase 2 (LRRK2) gene and the neurological disorder is Parkinson's disease. In another embodiment of this aspect, the target gene is the alpha-L-iduronidase (IDUA) gene and the neurological disorder is Hurler syndrome. In one embodiment of this aspect, the target gene is the methyl-CpG binding protein 2 (MECP2) gene and the neurological disease is Rett syndrome. In another embodiment of this aspect, the target gene is the ATP-binding cassette subfamily member 4 (ABCA4) gene and the neurological disease is Stargardt disease.
[0052] In certain embodiments, provided herein is a base editor system comprising: (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein said guide polynucleotide directs said adenosine base editor to effect an A to G nucleobase modification in the LRRK2 gene, or a regulatory element thereof.
[0053] In one embodiment, the A to G nucleobase modification is in a SNP associated with Parkinson's disease in the LRRK2 gene or a regulatory element thereof. In one embodiment, the SNP associated with Parkinson's disease results in an A419V, R1441C, R1441H, or G2019S amino acid variant in the LRRK2 polypeptide as numbered in SEQ ID NO:3, or a variant thereof encoded by the LRRK2 gene.
[0054] In some embodiments, the A to G nucleobase modification changes the Parkinson's disease associated SNP to a wild-type nucleobase. In some embodiments, the A to G nucleobase modification changes the Parkinson's disease associated SNP to a non-wild-type nucleobase that results in amelioration of Parkinson's disease symptoms. In some embodiments, the A to G nucleobase modification changes a cysteine or histidine to an arginine in an LRRK2 polypeptide encoded by the LRRK2 gene. In some embodiments, the A to G modification changes a serine to a glycine in an LRRK2 polypeptide encoded by the LRRK2 gene. In some embodiments, the A to G modification substitutes a cysteine (C) or histidine (H) for an arginine (R) at position 144 or a serine for a glycine (G) at position 2019 of an LRRK2 polypeptide or a variant thereof encoded by the LRRK2 gene, as numbered in SEQ ID NO: 3. In one embodiment, the adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2.
[0055] In some embodiments, the guide polynucleotide comprises a nucleic acid sequence complementary to the LRRK2 gene or a regulatory element thereof that contains a SNP associated with Parkinson's disease. In some embodiments, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to the LRRK2 gene or a regulatory element thereof that contains the SNP associated with Parkinson's disease. In some embodiments, the sgRNA comprises the nucleic acid sequence 5'-AAGCGCAAGCCUGGAGGGAA -3'; or 5'-ACUACAGCAUUGCUCAGUAC-3'.
[0056] In certain embodiments, provided herein is a base editor system comprising: (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein said guide polynucleotide directs said adenosine base editor to effect an A to G nucleobase modification in an alpha-L-iduronidase (IDUA) gene, or a regulatory element thereof.
[0057] In one embodiment, the IDUA gene or a regulatory element thereof comprises a SNP associated with Hurler syndrome. In one embodiment, the A to G nucleobase modification is in a SNP associated with Hurler syndrome. In one embodiment, the SNP associated with Hurler syndrome results in a W402X or W401X amino acid variant in the IDUA polypeptide or a variant thereof encoded by the IDUA gene, as numbered in SEQ ID NO: 4, where X is a stop codon.
[0058] In one embodiment, the A to G nucleobase modification changes the SNP associated with Hurler syndrome to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Hurler syndrome to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Hurler syndrome. In one embodiment, the A to G modification in the SNP associated with Hurler syndrome changes a stop codon to tryptophan in the IDUA polypeptide encoded by the IDUA gene.
[0059] In some embodiments, the guide polynucleotide comprises a nucleic acid sequence complementary to an IDUA gene or a regulatory element thereof that includes a SNP associated with Hurler syndrome. In some embodiments, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to an IDUA gene or a regulatory element thereof that includes a SNP associated with Hurler syndrome. In some embodiments, the sgRNA comprises a nucleic acid sequence selected from the group consisting of 5'-GACUCUAGGCAGAGGUCUCAA -3', 5'-ACUCUAGGCAGAGGUCUCAA-3', 5'-CUCUAGGCCGAAGUGUCGC -3', and 5'-GCUCUAGGCCGAAGUGUCGC-3'.
[0060] In some embodiments, provided herein is a base editor system comprising: (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein said guide polynucleotide directs said adenosine base editor to effect an A to G nucleobase modification in methyl-CpG binding protein 2 (MECP2) gene, or a regulatory element thereof.
[0061] In some embodiments, the MECP2 gene or regulatory element thereof comprises a SNP associated with Rett syndrome. In some embodiments, the A to G nucleobase modification is in a SNP associated with Rett syndrome. In some embodiments, the SNP associated with Rett syndrome results in an R106W or T158M amino acid variant in the MECP2 polypeptide or a variant thereof encoded by the MECP2 gene as numbered in SEQ ID NO:5. In some embodiments, the SNP associated with Rett syndrome results in an R255X or R270X amino acid variant in the MECP2 polypeptide encoded by the MECP2 gene, where X is a stop codon.
[0062] In one embodiment, the A to G nucleobase modification changes the SNP associated with Rett Syndrome to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Rett Syndrome to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Rett Syndrome. In one embodiment, the A to G nucleobase modification in the SNP associated with Rett Syndrome changes a stop codon to tryptophan in the MECP2 polypeptide.
[0063] In some embodiments, the guide polynucleotide comprises a nucleic acid sequence complementary to the MECP2 gene or a regulatory element thereof, comprising a SNP associated with Rett Syndrome. In some embodiments, the adenosine base editor is complexed with a single guide RNA (sgRNA) comprising a nucleic acid sequence complementary to the MECP2 gene or a regulatory element thereof, comprising a SNP associated with Rett Syndrome. In some embodiments, the guide polynucleotide comprises a nucleic acid sequence selected from the group consisting of 5'-CUUUUCACUUCCUGCCGGGG-3', 5'-AGCUUCCAUGUCCAGCCUUC-3', 5'-ACCAUGAAGUCAAAAUCAUU-3', and 5'-GCUUUCAGCCCCGUUUCUUG-3'.
[0064] In certain embodiments, provided herein is a base editor system comprising contacting (i) an adenosine base editor, or a nucleic acid sequence encoding same, and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same, wherein said adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain, wherein said adenosine deaminase domain comprises an amino acid substitution at amino acid position 82 or 166, or a position corresponding thereto, as numbered in SEQ ID NO:2, and wherein said guide polynucleotide induces said adenosine base editor to effect an A to G nucleobase modification in an ATP-binding cassette subfamily member 4 (ABCA4) gene, or a regulatory element thereof.
[0065] In some embodiments, the administration ameliorates at least one symptom associated with Stargardt's disease. In some embodiments, the administration results in a more rapid amelioration of at least one symptom associated with Stargardt's disease compared to treatment with a base editor without said amino acid substitution in adenosine deaminase. In some embodiments, the ABCA4 gene comprises a SNP associated with Stargardt's disease. In some embodiments, the A to G nucleobase modification is in a SNP associated with Stargardt's disease. In some embodiments, the SNP associated with Stargardt's disease results in an A1038V or G1961E amino acid variant in an ABCA4 polypeptide numbered as in SEQ ID NO: 6 or a variant thereof encoded by the ABCA4 gene. In some embodiments, the SNP associated with Stargardt's disease results in a G1961E amino acid variant in an ABCA4 polypeptide numbered as in SEQ ID NO: 6 or a variant thereof.
[0066] In one embodiment, the A to G nucleobase modification changes the SNP associated with Stargardt Disease to a wild-type nucleobase. In one embodiment, the A to G nucleobase modification changes the SNP associated with Stargardt Disease to a non-wild-type nucleobase that results in amelioration of Stargardt Disease symptoms. In one embodiment, the guide polynucleotide comprises a nucleic acid sequence complementary to the ABCA4 gene or a regulatory element thereof that includes a SNP associated with Stargardt Disease.
[0067] In one embodiment, the adenosine base editor is complexed with a single guide RNA (sgRNA) that comprises a nucleic acid sequence complementary to the ABCA4 gene or a regulatory element thereof that comprises the SNP associated with Stargardt disease. In one embodiment, the sgRNA comprises the sequence 5'-CUCCAGGGCGAACUUCGACACACAGC-3'.
[0068] In various aspects and embodiments provided herein, the polynucleotide-programmable DNA-binding domain is Cas9. In some embodiments, the Cas9 is SpCas9, SaCas9, or a variant thereof. In some embodiments, the polynucleotide-programmable DNA-binding domain comprises a modified SpCas9 with modified protospacer adjacent motif (PAM) specificity. In some embodiments, the Cas9 has specificity for a PAM sequence selected from the group consisting of NGG, NGA, NGCG, NGN, NNGRRT, NNNRRT, NGCG, NGCN, NGTN, and NGC, where N is A, G, C, or T, and R is A or G. In some embodiments, the polynucleotide-programmable DNA-binding domain is a nuclease-inactive variant. In some embodiments, the polynucleotide-programmable DNA-binding domain is a nickase variant. In some embodiments, the nickase variant comprises the amino acid substitution D10A or a corresponding amino acid substitution.
[0069] In various aspects and embodiments provided herein, the adenosine deaminase domain comprises a TadA domain. In certain embodiments, the adenosine deaminase comprises a TadA deaminase comprising a V82S modification and / or a T166R modification.
[0070] In various aspects and embodiments provided herein, the adenosine deaminase further comprises one or more modifications of Y147T, Y147R, Q154S, Y123H, Q154R, or combinations thereof. In various aspects and embodiments provided herein, the adenosine deaminase comprises a combination of modifications selected from the group consisting of Y147R + Q154R + Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y147T + Q154R; Y147T + Q154S; and Y123H + Y147R + Q154R + I76Y. In some embodiments, the adenosine base editor domain comprises an adenosine deaminase monomer. In some embodiments, the adenosine base editor comprises an adenosine deaminase dimer.
[0071] In various aspects and embodiments provided herein, the TadA deaminase is a TadA*8 variant. In some embodiments, the TadA*8 variant is selected from the group consisting of TadA*8.1, TadA*8.2, TadA*8.3, TadA*8.4, TadA*8.5, TadA*8.6, TadA*8.7, TadA*8.8, TadA*8.9, TadA*8.10, TadA*8.11, TadA*8.12, and TadA*8.13. In some embodiments, the adenosine base editor is an ABE8 base editor selected from the group consisting of ABE8.1, ABE8.2, ABE8.3, ABE8.4, ABE8.5, ABE8.6, ABE8.7, ABE8.8, ABE8.9, ABE8.10, ABE8.11, ABE8.12, and ABE8.13.
[0072] In one aspect, provided herein is a vector comprising a nucleic acid sequence encoding an adenosine base editor described herein. In one aspect, provided herein is a vector comprising a nucleic acid sequence encoding an adenosine base editor described herein and a guide polynucleotide. In one embodiment, the vector is a viral vector, a lentiviral vector, or an AAV vector.
[0073] In some aspects, provided herein is a cell comprising a base editor system or vector described herein. In some embodiments, the cell is a central nervous system cell. In some embodiments, the cell is a neuron. In some embodiments, the cell is a photoreceptor. In some embodiments, the cell is in vitro, in vivo, or ex vivo.
[0074] In certain aspects, provided herein is a pharmaceutical composition comprising a base editor, vector, or cell described herein and a pharma- ceutically acceptable carrier. In one embodiment, the pharmaceutical composition described herein further comprises a lipid. In another embodiment, the pharmaceutical composition described herein further comprises a virus.
[0075] In some embodiments, provided herein are kits that include a base editor or a vector described herein.
[0076] In various embodiments of the methods described herein, at least one nucleotide of the guide polynucleotide comprises a non-natural modification. In various embodiments of the methods described herein, at least one nucleotide of the nucleic acid sequence comprises a non-natural modification. In various embodiments, at least one nucleotide of the nucleic acid sequence comprises a non-natural modification. In some embodiments, the non-natural modification is a chemical modification. In some embodiments, the chemical modification is 2'-O-methylation. In some embodiments, the nucleic acid sequence comprises a phosphorothioate.
[0077] The description and examples herein illustrate the embodiments of the present disclosure in detail. It should be understood that the present disclosure is not limited to the specific embodiments described herein and may therefore vary. Those skilled in the art will recognize that the present disclosure has numerous variations and modifications that fall within its scope.
[0078] The practice of the embodiments disclosed herein will employ conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA that are within the skill of those of ordinary skill in the art, unless otherwise indicated.See, for example, Sambrook and Green, Molecular Cloning: A Laboratory Manual, 4th Edition (2012); the series Current Protocols in Molecular Biology (FM Ausubel, et al. eds.); the series Methods In Enzymology (Academic Press, Inc.), PCR 2: A Practical Approach (MJ MacPherson, BD Hames and GR Taylor eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual, and Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, 6th Edition (RI Freshney, ed. (2010)).
[0079] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0080] Although various features of the present disclosure may be described in relation to a single embodiment, these features may also be provided separately or in any suitable combination. Conversely, although the present disclosure may be described in the context of separate embodiments for clarity, the present disclosure may also be implemented in a single embodiment. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0081] The features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description, which sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and in consideration of the accompanying drawings, which are described below.
[0082] definition The following definitions are supplemental to those in the art and are directed to this application, and are not to be construed as attributable to any related or unrelated matter, such as commonly owned patents or applications. Although any methods and materials similar or equivalent to those described herein can be used in carrying out the testing of the present disclosure, the preferred materials and methods are described herein. Thus, the terms used herein are for the purpose of describing specific embodiments only, and are not intended to be limiting.
[0083] Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the present invention belongs.The following references provide those skilled in the art with the general definitions of many terms used in the present invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991).
[0084] In this application, the use of the singular includes the plural unless specifically stated otherwise. It should be noted that, as used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" is understood to mean and include "and / or" unless otherwise stated. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," and "included," is non-limiting.
[0085] As used in the specification and claims, the terms "comprising" (and any of its forms, such as "comprise" and "comprises"), "having" (and any of its forms, such as "have" and "has"), "including" (and any of its forms, such as "include" and "includes"), or "containing" (and any of its forms, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the disclosure, and vice versa. Additionally, the compositions of the disclosure can be used to achieve the methods of the disclosure.
[0086] The term "about" or "approximately" means within an acceptable error range for a particular value, as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, according to the practice in the art. Alternatively, "about" can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean a value within the same order of magnitude, e.g., within 5-fold, or within 2-fold. When a particular value is described in the application and claims, the term "about" should be presumed to mean within an acceptable error range for that particular value, unless otherwise stated.
[0087] Ranges provided herein are understood to be shorthand for all values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or subranges from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0088] References in the specification to "some embodiments," "an embodiment," "one embodiment," or "other embodiments" mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least some embodiments of the present disclosure, but not necessarily in all embodiments.
[0089] By "abasic base editor" is meant an agent that can excise a nucleobase and insert a DNA nucleobase (A, T, C, or G). An abasic base editor comprises a nucleic acid glycosylase polypeptide or a fragment thereof. In one embodiment, the nucleic acid glycosylase is a mutant human uracil DNA glycosylase or an active fragment thereof that contains an Asp at amino acid 204 of the sequence below, or the corresponding position of uracil DNA glycosylase (e.g., substituting Asn at amino acid 204) and has cytosine-DNA glycosylase activity. In one embodiment, the nucleic acid glycosylase is a mutant human uracil DNA glycosylase or an active fragment thereof that contains an Ala, Gly, Cys, or Ser at amino acid 147 of the sequence below, or the corresponding position of uracil DNA glycosylase (e.g., substituting Tyr at amino acid 147) and has thymine-DNA glycosylase activity. The sequence of an exemplary human uracil-DNA glycosylase, isoform 1, is as follows: 1 mgvfclgpwg lgrklrtpgk gplqllsrlc gdhlqaipak kapagqeepg tppssplsae 61 qldriqrnka aallrlaarn vpvgfgeswk khlsgefgkp yfiklmgfva eerkhytvyp 121 pphqvftwtq mcdikdvkvv ilgqdp y hgp nqahglcfsv qrpvppppsl eniykelstd 181 iedfvhpghg dlsgwakqgv lll n avltvr ahqanshker gweqftdavv swlnqnsngl 241 vfllwgsyaq kkgsaidrkr hhvlqtahps p l svy r gffg crhfsktnel lqksgkkpid 301 wkel
[0090] The sequence of human uracil-DNA glycosylase, isoform 2 is as follows: 1 migqktlysf fspsparkrh apspepavqg tgvagvpees gdaaaipakk apagqeepgt 61 ppssplsaeq ldriqrnkaa allrlaarnv pvgfgeswkk hlsgefgkpy fiklmgfvae 121 erkhytvypp phqvftwtqm cdikdvkvvi lgqdp y hgpn qahglcfsvq rpvppppsle 181 niykelstdi edfvhpghgd lsgwakqgvl ll n avltvra hqanshkerg weqftdavvs 241 wlnqnsnglv fllwgsyaqk kgsaidrkrh hvlqtahpsp l svy r gffgc rhfsktnell 301 qksgkkpidwkel
[0091] In other embodiments, the abasic editor is any of the abasic editors described in PCT / JP205 / 080958 and US20170321210, which are incorporated herein by reference. In certain embodiments, the abasic editor comprises a mutation at the position indicated in bold, underlined in the above sequence, or at any other abasic editor known in the art or at the corresponding amino acid in uracil deglycosylase. In one embodiment, the abasic editor comprises a mutation at Y147, N204, L272, and / or R276 or at the corresponding position. In another embodiment, the abasic editor comprises a Y147A or Y147G mutation or a corresponding mutation. In another embodiment, the abasic editor comprises a N204D mutation or a corresponding mutation. In another embodiment, the abasic editor comprises a L272A mutation or a corresponding mutation. In another embodiment, the abasic editor comprises a R276E or R276C mutation or a corresponding mutation.
[0092] "Adenosine deaminase" refers to a polypeptide or fragment thereof that can catalyze the hydrolytic deamination of adenine or adenosine. In some embodiments, the deaminase or deaminase domain is an adenosine deaminase that catalyzes the hydrolytic deamination of adenosine to inosine or deoxyadenosine to deoxyinosine. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenine or adenosine in deoxyribonucleic acid (DNA). The adenosine deaminase provided herein (e.g., engineered adenosine deaminase, evolved adenosine deaminase) can be from any organism, such as bacteria.
[0093] In some embodiments, the adenosine deaminase is TadA deaminase. In some embodiments, the TadA deaminase is a TadA variant. In some embodiments, the TadA variant is TadA*8. In some embodiments, the deaminase or deaminase domain is a variant of a natural deaminase from an organism, such as, for example, human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain is non-naturally occurring. For example, in some embodiments, the deaminase or deaminase domain has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identity to a naturally occurring deaminase. For example, deaminase domains are described in International PCT Application Nos. PCT / 2007 / 045381 (WO2018 / 027078) and PCT / US2016 / 058344 (WO 2017 / 070632), each of which is incorporated by reference in its entirety.Also, Komor, AC, et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage” Nature 533, 420-424 (2016); Gaudelli, NM, et al., “Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage” Nature 551, 464-471 (2017); Komor, AC, et al., “Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity” Science Advances 3:eaao4774 (2017) ), and Rees, HA, et al., “Base editing: precision chemistry on the genome and transcriptome of living cells.” Nat Rev Genet. 2018 Dec;19(12):770-788. doi: See also 10.1038 / s41576-018-0059-1, the entire contents of which are incorporated herein by reference.
[0094] The wild-type TadA (wt) adenosine deaminase has the following sequence (also referred to as the TadA reference sequence): MSEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWNRPIGRHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRIGRVVFGARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDFFRMRRQEIKAQKKAQSSTD (SEQ ID NO: 2).
[0095] In some embodiments, the adenosine deaminase comprises a modification in the following sequence: MSEVEFSHEY WMRHALTLAK RARDEREVPV GAVLVLNNRV IGEGWNRAIG LHDPTAHAEI MALRQGGLVM QNYRLIDATL YVTFEPCVMC AGAMIHSRIG RVVFGVRNAK TGAAGSLMDV LHYPGMNHRV EITEGILADE CAALLCYFFR MPRQVFNAQK KAQSSTD (Also known as TadA*7.10).
[0096] In some embodiments, TadA*7.10 comprises at least one modification. In some embodiments, TadA*7.10 comprises modifications at amino acids 82 and / or 166. In certain embodiments, the variant of the reference sequence comprises one or more of the following modifications: Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R. The modification Y123H is also referred to herein as H123H (the modification H123Y in TadA*7.10 reverted to Y123H(wt)). In other embodiments, the variant of the TadA*7.10 sequence comprises a combination of alterations selected from the group consisting of: Y147T + Q154R; Y147T + Q154S; Y147R + Q154S; V82S + Q154S; V82S + Y147R; V82S + Q154R; V82S + Y123H; I76Y + V82S; V82S + Y123H + Y147T; V82S + Y123H + Y147R; V82S + Y123H + Q154R; Y147R + Q154R +Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y123H + Y147R + Q154R + I76Y; V82S+Y123H+Y147R+Q154R; and I76Y+V82S+Y123H+Y147R+Q154R.
[0097] In other embodiments, the invention provides adenosine deaminase variants containing deletions, e.g., TadA*8, including C-terminal deletions beginning at residues 149, 150, 151, 152, 153, 154, 155, 156, or 157. In other embodiments, the adenosine deaminase variant is a TadA (e.g., TadA*8) monomer that contains one or more of the following modifications: Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R. In other embodiments, the adenosine deaminase variant is a TadA (e.g., TadA*8) monomer comprising a combination of modifications selected from the group consisting of: Y147T + Q154R; Y147T + Q154S; Y147R + Q154S; V82S + Q154S; V82S + Y147R; V82S + Q154R; V82S + Y123H; I76Y + V82S; V82S + Y123H + Y147T; V82S + Y123H + Y147R; V82S + Y123H + Q154R; Y147R + Q154R +Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y123H + Y147R + Q154R+I76Y; V82S+Y123H+Y147R+Q154R; and I76Y+V82S+Y123H+Y147R+Q154R.
[0098] In yet other embodiments, the adenosine deaminase variant is a homodimer comprising two adenosine deaminase domains (e.g., TadA*8), each having one or more of the following modifications Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R. In other embodiments, the adenosine deaminase variant is a homodimer comprising two adenosine deaminase domains (e.g., TadA*8) each having a combination of modifications selected from the group consisting of: Y147T + Q154R; Y147T + Q154S; Y147R + Q154S; V82S + Q154S; V82S + Y147R; V82S + Q154R; V82S + Y123H; I76Y + V82S; V82S + Y123H + Y147T; V82S + Y123H + Y147R; V82S + Y123H + Q154R; Y147R + Q154R +Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y123H+Y147R+Q154R+I76Y; V82S+Y123H+Y147R+Q154R; and I76Y+V82S+Y123H+Y147R+Q154R.
[0099] In other embodiments, the adenosine deaminase variant is a heterodimer comprising a wild-type TadA adenosine deaminase domain and an adenosine deaminase variant domain that includes one or more of the following modifications Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R (e.g., TadA*8). In other embodiments, the adenosine deaminase variant is a heterodimer comprising a wild-type TadA adenosine deaminase domain and an adenosine deaminase variant domain (e.g., TadA*8) that comprises a combination of modifications selected from the group consisting of: Y147T + Q154R; Y147T + Q154S; Y147R + Q154S; V82S + Q154S; V82S + Y147R; V82S + Q154R; V82S + Y123H; I76Y + V82S; V82S + Y123H + Y147T; V82S + Y123H + Y147R; V82S + Y123H + Q154R; Y147R + Q154R +Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y123H + Y147R + Q154R + I76Y; V82S + Y123H + Y147R + Q154R; and I76Y + V82S + Y123H + Y147R + Q154R.
[0100] In other embodiments, the adenosine deaminase variant is a heterodimer comprising a TadA*7.10 domain and an adenosine deaminase variant domain (e.g., TadA*8) that includes one or more of the following modifications Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R. In other embodiments, the adenosine deaminase variant is a heterodimer comprising a TadA*7.10 domain and an adenosine deaminase variant domain comprising the following combinations of modifications (e.g., TadA*8): Y147T + Q154R; Y147T + Q154S; Y147R + Q154S; V82S + Q154S; V82S + Y147R; V82S + Q154R; V82S + Y123H; I76Y + V82S; V82S + Y123H + Y147T; V82S + Y123H + Y147R; V82S + Y123H + Q154R; Y147R + Q154R +Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y123H+Y147R+Q154R+I76Y; V82S+Y123H+Y147R+Q154R; or I76Y+V82S+Y123H+Y147R+Q154R.
[0101] In one embodiment, the adenosine deaminase is TadA*8 comprising or consisting essentially of the following sequence, or a fragment thereof having adenosine deaminase activity: MSEVEFSHEYWMRHALTLAKRADEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCTFFRMPRQVFNAQKKAQSSTD.
[0102] In some embodiments, TadA*8 is truncated. In some embodiments, the truncated TadA*8 lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 N-terminal amino acid residues relative to full-length TadA*8. In some embodiments, the truncated TadA*8 lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 C-terminal amino acid residues compared to full-length TadA*8. In some embodiments, the adenosine deaminase variant is full-length TadA*8.
[0103] In certain embodiments, the adenosine deaminase heterodimer comprises a TadA*8 domain and an adenosine deaminase domain selected from one of the following:
[0104] In certain embodiments, the adenosine deaminase heterodimer comprises a TadA*8 domain and an adenosine deaminase domain selected from one of the following:
[0105] Escherichia coli TadA: MRRAFITGVFFLSEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWNRPIGRHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRIGRVVFGARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDFFRMRRQEIKAQKKAQSSTD
[0106] E. coli TadA (N-terminal truncated): MSEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWNRPIGRHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRIGRVVFGARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDFFRMRRQEIKAQKKAQSSTD
[0107] Staphylococcus aureus (S. aureus) TadA: MGSHMTNDIYFMTLAIEEAKKAAQLGEVPIGAIITKDDEVIARAHNLRETLQQPTAHAEHIAIERAAKVLGSWRLEGCTLYVTLEPCVMCAGTIVMSRIPRVVYGADDPKGGCSGSLMNLLQQSNFNHRAIVDKGVLKEACSTLLTTFFKNLRANKKSTN
[0108] Bacillus subtilis (B. subtilis) TadA: MTQDELYMKEAIKEAKKAEEKGEVPIGAVLVINGEIIARAHNLRETEQRSIAHAEMLVIDEACKALGTWRLEGATLYVTLEPCPMCAGAVVLSRVEKVVFGAFDPKGGCSGTLMNLLQEERFNHQAEVVSGVLEEECGGMLSAFFRELRKKKKAARKNLSE
[0109] Salmonella typhimurium (S. typhimurium) TadA: MPPAFITGVTSLSDVELDHEYWMRHALTLAKRAWDEREVPVGAVLVHNHRVIGEGWNRPIGRHDPTAHAEIMALRQGGLVLQNYRLLDTTLYVTLEPCVMCAGAMVHSRIGRVVFGARDAKTGAAGSLIDVLHHPGMNHRVEIIEGVLRDECATLLSDFFRMRRQEIKALKKADRAEGAGPAV
[0110] Shewanella putrefaciens (S. putrefaciens) TadA: MDEYWMQVAMQMAEKAEAAGEVPVGAVLVKDGQQIATGYNLSISQHDPTAHAEILCLRSAGKKLENYRLLDATLYITLEPCAMCAGAMVHSRIARVVYGARDEKTGAAGTVVNLLQHPAFNHQVEVTSGVLAEACSAQLSRFFKRRRDEKKALKLAQRAQQGIE
[0111] Haemophilus influenzae F3031 (H. influenzae) TadA: MDAAKVRSEFDEKMMRYALELADKAEALGEIPVGAVLVDDARNIIGEGWNLSIVQSDPTΑΗAEIIALRNGAKNIQNYRLLNSTLYVTLEPCTMCAGAILHSRIKRLVFGASDYKTGAIGSRFHFFDDYKMNHTLEITSGVLAEECSQKLSTFFQKRREEKKIEKALLKSLSDK
[0112] Caulobacter crescentus (C. crescentus) TadA: MRTDESEDQDHRMMRLALDAARAAAEAGETPVGAVILDPSTGEVIATAGNGPIAAHDPTAHAEIIAAMRAAAAKLGNYRLTDLTVVTLEPCAMCAGAISHARIGRVVFGADDPKGGAVVHGPKFFAQPTCHWRPEVTGGVLADESADLLRGFFRARRKAKI
[0113] Geobacter sulfurreducens (G. sulfurreducens) TadA: MSSLKKTPIRDDAYWMGKAIREAAKAAAARDEVPIGAVIVRDGAVIGRGHNLREGSNDPSAHAEMIAIRQAARRSANWRLTGATLYVTLEPCLMCMGAIILARLERVVFGCYDPKGGAAGSLYDLSADPRLNHQVRLSPGVCQEECGTMLSDFFRDLRRRKKAKATPALFIDERKVPPEP
[0114] TadA*7.10 MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD
[0115] Additional TadA7.10 or TadA7.10 variants contemplated as components of heterodimers with TadA*8 include:
[0116] GSSGSETPGTSESATPESSGSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD
[0117] TadA7.10 CP65 TAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTDGSSGSETPGTSESATPESSGSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDP
[0118] TadA7.10 CP83 YRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTDGSSGSETPGTSESATPESSGSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQN
[0119] TadA7.10 CP136 MNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTDGSSGSETPGTSESATPESSGSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPG
[0120] TadA7.10 C-truncated GSSGSETPGTSESATPESSGSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFN
[0121] TadA7.10 C-truncated 2 GSSGSETPGTSESATPESSGSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQ
[0122] TadA7.10 delta59-66+C-truncated GSSGSETPGTSESATPESSGSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFN
[0123] TadA7.10 delta 59-66 GSSGSETPGTSESATPESSGSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD.
[0124] In some embodiments, the adenosine deaminase variant comprises a modification in TadA7.10. In some embodiments, TadA7.10 comprises a modification at amino acid 82 or 166. In certain embodiments, the variant of the reference sequence comprises one or more of the following modifications: Y147T, Y147R, Q154S, Y123H, V82S, T166R, and Q154R. In other embodiments, the adenosine deaminase variant comprises a combination of modifications selected from the group consisting of Y147R + Q154R + Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y147T + Q154R; Y147T + Q154S; and Y123H + Y147R + Q154R + I76Y.
[0125] In other embodiments, the invention provides adenosine deaminase variants that include deletions, for example, TadA7.10, that include C-terminal deletions starting at residues 149, 150, 151, 152, 153, 154, 155, 156, or 157. In other embodiments, the adenosine deaminase variant is a TadA monomer that includes one or more of the following modifications: Y147T, Y147R, Q154S, Y123H, V82S, T166R, Q154R. In other embodiments, the adenosine deaminase variant is a monomer comprising the following modifications: Y147R + Q154R + Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y147T + Q154R; Y147T + Q154S; and Y123H + Y147R + Q154R + I76Y. In yet other embodiments, the adenosine deaminase variant is a homodimer comprising two adenosine deaminase domains, each having one or more of the following modifications: Y147T, Y147R, Q154S, Y123H, V82S, T166R, Q154R. In other embodiments, the adenosine deaminase variant is a heterodimer comprising a wild-type adenosine deaminase domain or a TadA7.10 domain and an adenosine deaminase variant domain comprising one or more of the following modifications: Y147T, Y147R, Q154S, Y123H, V82S, T166R, Q154R. In other embodiments, the adenosine deaminase variant is a heterodimer comprising a TadA7.10 domain and an adenosine deaminase variant of TadA7.10 comprising the following modifications: Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y147T + Q154R; Y147T + Q154S; and Y123H + Y147R + Q154R + I76Y.
[0126] "Administering" is referred to herein as providing one or more compositions described herein to a patient or subject. By way of example, and not limitation, administration, e.g., injection, of a composition can be by intravenous (iv), subcutaneous (sc), intradermal (id), intraperitoneal (ip) or intramuscular (im) injection. One or more such routes can be used. Parenteral administration can be by, for example, bolus injection or by gradual perfusion over time. In some embodiments, parenteral administration includes intravascular, intravenous, intramuscular, intraarterial, intrathecal, intratumoral, intradermal, intraperitoneal, transtracheal, subcutaneous, subkeratinous, intraarticular, intracapsular, subarachnoid and intrasternal infusion or injection. Alternatively, or concurrently, administration can be by oral route.
[0127] By "agent" is meant any small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide, or fragments thereof.
[0128] By "alteration" is meant a change (e.g., an increase or decrease) in the structure, expression level or activity of a gene or polypeptide as detected by standard art known methods as described herein. As used herein, alteration includes a change in the sequence of a polynucleotide or polypeptide, or a change in expression level, e.g., a 10% change, a 25% change, a 40% change, a 50% change, or more change in expression level.
[0129] By "ameliorate" is meant to lessen, inhibit, attenuate, reduce, halt, or stabilize the occurrence or progression of a disease.
[0130] "Analog" refers to a molecule that is not identical but has similar functional or structural characteristics. For example, a polynucleotide or polypeptide analog has certain modifications that enhance the function of the analog compared to the native polynucleotide or polypeptide while retaining the biological activity of the corresponding native polynucleotide or polypeptide. Such modifications can increase the DNA affinity, efficiency, specificity, protease or nuclease resistance, membrane permeability, and / or half-life of the analog, for example, without altering ligand binding. Analogs can include non-natural polynucleotides or amino acids.
[0131] "Base editor (BE)" or alternatively "nucleobase editor (NBE)" refers to an agent that binds to a polynucleotide and has nucleobase modifying activity. In various embodiments, the base editor comprises a nucleobase modifying polypeptide (e.g., a deaminase) and a nucleic acid programmable nucleotide binding domain together with a guide polynucleotide (e.g., a guide RNA). In various embodiments, the agent is a biomolecular complex that comprises a protein domain with base editing activity, i.e., a domain that can modify a base (e.g., A, T, C, G, U) in a nucleic acid molecule (e.g., DNA). In some embodiments, the polynucleotide programmable DNA binding domain is fused or linked to a deaminase domain. In one embodiment, the agent is a fusion protein that comprises a domain with base editing activity. In another embodiment, the protein domain with base editing activity is linked to a guide RNA (e.g., via an RNA binding motif on the guide RNA and an RNA binding domain fused to a deaminase). In some embodiments, the domain with base editing activity is capable of deaminating a base in a nucleic acid molecule. In some embodiments, the base editor is capable of deaminating one or more bases in a DNA molecule. In some embodiments, the base editor can deaminate an adenosine (A) in DNA. In some embodiments, the base editor is an adenosine base editor (ABE).
[0132] "Cytidine deaminase" refers to a polypeptide or fragment thereof capable of catalyzing a deamination reaction that converts an amino group to a carbonyl group. In some embodiments, the cytidine deaminase has at least about 85% identity to an APOBEC or AID. In one embodiment, the cytidine deaminase converts cytosine to uracil or 5-methylcytosine to thymine. PmCDA1 from Petromyzon marinus (Petromyzon marinus cytosine deaminase 1, "PmCDA1"), or AID (activation-induced cytidine deaminase; AICDA) from mammals (e.g., human, pig, cow, horse, monkey, etc.), and APOBEC are exemplary cytidine deaminases.
[0133] In some embodiments, the base editor is a reprogrammable base editor fused to a deaminase (e.g., adenosine deaminase or cytidine deaminase). In some embodiments, the base editor is Cas9 fused to a deaminase (e.g., adenosine deaminase or cytidine deaminase). In some embodiments, the base editor is a nuclease-inactive Cas9 (dCas9) fused to a deaminase (e.g., adenosine deaminase or cytidine deaminase). In some embodiments, the Cas9 is a circular permutant Cas9 (e.g., spCas9 or saCas9). Circular permutant Cas9s are known in the art and are described, for example, in Oakes et al., Cell 176, 254-267, 2019. In some embodiments, the base editor is fused to an inhibitor of base excision repair, such as a UGI domain or a dISN domain. In some embodiments, the fusion protein comprises a Cas9 nickase fused to a deaminase and an inhibitor of base excision repair, such as a UGI domain or a dISN domain, hi other embodiments, the base editor is an abasic base editor.
[0134] In some embodiments, the base editor is an adenosine base editor (ABE). In some embodiments, the adenosine deaminase is evolved from TadA. In some embodiments, the base editor of the present invention comprises a napDNAbp domain with an internally fused catalytic (e.g., deaminase) domain. In some embodiments, the napDNAbp is Cas12a (Cpf1) with an internally fused deaminase domain. In some embodiments, the napDNAbp is Cas12b (c2c1) with an internally fused deaminase domain. In some embodiments, the napDNAbp is Cas12c (c2c3) with an internally fused deaminase domain. In some embodiments, the napDNAbp is Cas12d (CasX) with an internally fused deaminase domain. In some embodiments, the napDNAbp is Cas12e (CasY) with an internally fused deaminase domain. In some embodiments, the napDNAbp is Cas12g with a deaminase domain fused internally. In some embodiments, the napDNAbp is Cas12h with a deaminase domain fused internally. In some embodiments, the napDNAbp is Cas12i with a deaminase domain fused internally. In some embodiments, the base editor is a catalytically dead Cas12 (dCas12) fused to a deaminase domain. In some embodiments, the base editor is a Cas12 nickase (nCas12) fused to a deaminase domain.
[0135] In some embodiments, the base editor is generated by cloning an adenosine deaminase variant (e.g., TadA*8) into a scaffold that includes a circularly permuted Cas9 (e.g., spCAS9 or saCAS9) and a bipartite nuclear localization sequence (e.g., ABE8). Circularly permuted Cas9s are known in the art and are described, for example, in Oakes et al., Cell 176, 254-267, 2019. Exemplary circular permutations are described below, where bolded sequences indicate sequences derived from Cas9, italicized sequences indicate linker sequences, and underlined sequences indicate bipartite nuclear localization sequences.
[0136] TIFF0007586601000001.tif188168
[0137] In some embodiments, ABE8 is selected from a base editor from Tables 6-9, 13, or 14 below. In some embodiments, ABE8 comprises an adenosine deaminase variant evolved from TadA. In some embodiments, the adenosine deaminase variant of ABE8 is a TadA*8 variant as described in Tables 7, 9, 13, or 14 below. In some embodiments, the adenosine deaminase variant is a TadA*7.10 variant (e.g., TadA*8) that includes one or more modifications selected from the group of Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R. In various embodiments, ABE8 is selected from the group consisting of Y147T + Q154R; Y147T + Q154S; Y147R + Q154S; V82S + Q154S; V82S + Y147R; V82S + Q154R; V82S + Y123H; I76Y + V82S; V82S + Y123H + Y147T; V82S + Y123H + Y147R; V82S + Y123H + Q154R; Y147R + Q154R +Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y123H + Y147R + Q154R + I76Y; V82S + Y123H + Y147R + and I76Y + V82S + Y123H + Y147R + Q154R (e.g., TadA*8). In some embodiments, ABE8 is a monomeric construct. In some embodiments, ABE8 is a heterodimeric construct. In some embodiments, the ABE8 base editor comprises the following sequence: MSEVEFSHEYWMRHALTLAKRADEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCTFFRMPRQVFNAQKKAQSSTD.
[0138] In some embodiments, the polynucleotide programmable DNA binding domain is a CRISPR-associated (e.g., Cas or Cpf1) enzyme. In some embodiments, the base editor is a catalytically dead Cas9 (dCas9) fused to a deaminase domain. In some embodiments, the base editor is a Cas9 nickase (nCas9) fused to a deaminase domain. In some embodiments, the base editor is fused to an inhibitor of base excision repair (BER). In some embodiments, the inhibitor of base excision repair is a uracil DNA glycosylase inhibitor (UGI). In some embodiments, the inhibitor of base excision repair is an inosine base excision repair inhibitor.
[0139] Details of base editors are described in International PCT Application Nos. PCT / 2017 / 045381 (WO 2018 / 027078) and PCT / US 2016 / 058344 (WO 2017 / 070632), each of which is incorporated by reference in its entirety. Komor, AC, et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage” Nature 533, 420-424 (2016); Gaudelli, NM, et al., “Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage” Nature 551, 464-471 (2017); Komor, AC, et al. al., “Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity” Science Advances 3:eaao4774 (2017), and Rees, HA, et al., “Base editing: precision chemistry on the genome and transcriptome of living cells.” Nat Rev Genet. 2018 Dec;19(12):770-788. doi: See also 10.1038 / s41576-018-0059-1, the entire contents of which are incorporated herein by reference.
[0140] By way of example, a cytidine base editor used in the base editing compositions, systems, and methods described herein has the following nucleic acid sequence (8877 base pairs) (Addgene, Watertown, MA.; Komor AC, et al., 2017, Sci Adv., 30;3(8):eaao4774. doi: 10.1126 / sciadv.aao4774). Polynucleotide sequences having at least 95% or greater identity to the BE4 nucleic acid sequence are also encompassed.
[0141] 1 atatgccaag tacgccccct attgacgtca atgacggtaa atggcccgcc tggcattatg 61 cccagtacat gaccttatgg gactttccta cttggcagta catctacgta ttagtcatcg 121 ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag cggtttgact 181 cacggggatt tccaagtctc caccccattg acgtcaatgg gagtttgttt tggcaccaaa 241 atcaacggga ctttccaaaa tgtcgtaaca actccgcccc attgacgcaa atgggcggta 301 ggcgtgtacg gtgggaggtc tatataagca gagctggttt agtgaaccgt cagatccgct 361 agagatccgc ggccgctaat acgactcact atagggagag ccgccaccat gagctcagag 421 actggcccag tggctgtgga ccccacattg agacggcgga tcgagcccca tgagtttgag 481 gtattcttcg atccgagaga gctccgcaag gagacctgcc tgctttacga aattaattgg 541 gggggccggc actccatttg gcgacataca tcacagaaca ctaacaagca cgtcgaagtc 601 aacttcatcg agaagttcac gacagaaaga tatttctgtc cgaacacaag gtgcagcatt 661 acctggtttc tcagctggag cccatgcggc gaatgtagta gggccatcac tgaattcctg 721 tcaaggtatc cccacgtcac tctgtttatt tacatcgcaa ggctgtacca ccacgctgac 781 ccccgcaatc gacaaggcct gcgggatttg atctcttcag gtgtgactat ccaaattatg 841 actgagcagg agtcaggata ctgctggaga aactttgtga attatagccc gagtaatgaa 901 gcccactggc ctaggtatcc ccatctgtgg gtacgactgt acgttcttga actgtactgc 961 atcatactgg gcctgcctcc ttgtctcaac attctgagaa ggaagcagcc acagctgaca 1021 ttctttacca tcgctcttca gtcttgtcat taccagcgac tgcccccaca cattctctgg 1081 gccaccgggt tgaaatctgg tggttcttct ggtggttcta gcggcagcga gactcccggg 1141 acctcagagt ccgccacacc cgaaagttct ggtggttctt ctggtggttc tgataaaaag 1201 tattctattg gtttagccat cggcactaat tccgttggat gggctgtcat aaccgatgaa 1261 tacaaagtac cttcaaagaa atttaaggtg ttggggaaca cagaccgtca ttcgattaaa 1321 aagaatctta tcggtgccct cctattcgat agtggcgaaa cggcagaggc gactcgcctg 1381 aaacgaaccg ctcggagaag gtatacacgt cgcaagaacc gaatatgtta cttacaagaa 1441 atttttagca atgagatggc caaagttgac gattctttct ttcaccgttt ggaagagtcc 1501 ttccttgtcg aagaggacaa gaaacatgaa cggcacccca tctttggaaa catagtagat 1561 gaggtggcat atcatgaaaa gtacccaacg atttatcacc tcagaaaaaa gctagttgac 1621 tcaactgata aagcggacct gaggttaatc tacttggctc ttgcccatat gataaagttc 1681 cgtgggcact ttctcattga gggtgatcta aatccggaca actcggatgt cgacaaactg 1741 1801 ggcgtggatg cgaaggctat tcttagcgcc cgcctctcta aatcccgacg gctagaaaac 1861 ctgatcgcac aattacccgg agagaagaaa aatgggttgt tcggtaacct tagatcgctc 1921 tcactaggcc tgacaccaaa ttttaagtcg aacttcgact tagctgaaga tgccaaattg 1981 cagcttagta aggacacgta cgatgacgat ctcgacaatc tactggcaca attggagat 2041 cagtagcgg acttatttt ggctgccaa aaccttagcg atgcaatcct cctactcgac 2101 atactgagag ttatactga gattaccaag gcgccgtta ccgctcaat gatcaaagg 2161 tacgatgaac atcaccaga cttgacactt ctcaagccc tagtccgtca gcaactgcct 2221 gagaaata aggaaatatt cttgatcag tcgaaaaacg ggtacgcagg ttatattgac 2281 ggcggagcga gtcagagga attctacaag tttatcaac ccatattaga gagatggat 2341 gggacggaag agttgcttgt aaaaccaat cgcgagatc tactgcgaaa gcagcggact 2401 ttcgacacg gtagcattcc acatcaatc cacttaggcg aattgcatgc tatacttaga 2461 aggcaggagg atttttacc gttcccaaa gatacgtg aaagattga gaaaatccta 2521 acctttcgca taccttacta tgtgggaccc ctggcccgag ggaactcg gttcgcatgg 2581 atgacagaa agtccgaaga aacgattact ccatggaatt tgaggaagt tgtcgataaa 2641 gtgcgtcag ctcaatcgtt catcgagagg atgaccact ttgacagaa tttaccgac 2701 gaaaagtat tgcctaagca cagtttactt tacgagtatt tcacagtgta caatgaactc 2761 acgaaagtta agtatgtcac tgaggcatg cgtaaacccg cctttctaag cggagacag 2821 aagaaagcaa tagtagatct gttattcaag accaccgca aagtgacagt tagcattg 2881 aagaggact actttaagaa attgaatgc tcgattctg tcgagatc cggggtagaa 2941 gatcgattta atgcgtcact tgtacgtat catgacctcc taagataat taagataag 3001 gacttcctgg ataacgaaga gatgagat atcttagaag atagtgtt gactcttacc 3061 ctctttgaag atcgggaat gattgaggaa agactaaaa catacgctca cctgttcgac 3121 gataagtta tgaacagtt aaagaggcgt cgctatacgg gctgggacg attgtcgcgg 3181 aaacttatca acggataag agacaagcaa agtggtaaa ctattctcga ttttctaaag 3241 agcgacggct tcgccatag gaactttatg cagctgatcc atgatgactc tttaccttc 3301 aagaggata tacaaaggc acaggttcc ggacaagggg actcattgca cgaacatatt 3361 gcgaatcttg ctggttcgcc agccatcaa aagggcatac tccacagt caagtagtg 3421 gatgagctag ttaaggtcat gggacgtcac aaaccggaaa acattgtaat cgagatggca 3481 cgcgaaaatc aaacgactca gaagggcaa aaaaacagtc gagagcggat gaagagaata 3541 gaagggta ttaaagaact gggcagccag atcttaaagg agcatcctgt ggaaaatacc 3601 3661 3721 tccttttga aggacgattc aatcgacaat aaagtgctta cacgctcgga taagaaccga 3781 gggaaaagtg acaatgttcc aagcgaggaa gtcgtaaaga aaatgaagaa ctattggcgg 3841 3901 aggggtggct tgtctgaact tgacaaggcc ggatttatta aacgtcagct cgtggaaacc 3961 cgccaaatca caaagcatgt tgcacagata ctagattccc gaatgaatac gaatacgac 4021 gagaacgata agctgattcg ggaagtcaaa gtaatcactt taagtcaaa attggtgtcg 4081 4141 cacgacgctt atcttaatgc cgtcgtaggg accgcactca ttaagaata cccgaagcta 4201 gaagtgagt ttgtgtatgg tgattacaaa gtttatgacg tccgtagat gatcgcgaaa 4261 agcgacagg agataggcaa ggctacagcc aaatactct tttattctaa cattatgaat 4321 ttctttaga cggaatcac tctgcaac gagagagat gcaacgacc tttattgac 4381 accaatgggg agacaggtga aatcgtatgg gataagggcc gggactcgc gacggtgaga 4441 aaagttttgt ccatgcccca agtcacata gtaagaaaa ctgaggtgca gaccggaggg 4501 tttcaagg atcgattct tccaaaagg atagtgata agctcatcgc tcgtaaaag 4561 gactgggacc cgaaaagta cggtggctc gatagcccta cagttgccta ttctgtccta 4621 gtagtggcaa aagttgagaa gggaaaatcc aagaactga agtcagtcaa agaatttg 4681 gggataacga ttatggagcg ctcgtctttt gaaaagaacc ccatcgactt ccttgaggcg 4741 aaggttaca aggaagtaa aaaggatctc ataatttaac taccaagta tagtctgttt 4801 gagttagaaa atggccgaaa acggatgttg gctagcgccg gagagcttca aaagggaac 4861 gaactcgcac taccgtctaa atacgtgaat ttcctgtatt tagcgtccca ttacgagaag 4921 ttgaaaggtt cacctgaaga taacgaacag aagcaacttt ttgttgagca gcacaaacat 4981 tatctcgacg aaatcataga gcaaatttcg gaattcagta agagagtcat cctagctgat 5041 gccaatctgg acaaagtatt aagcgcatac aacaagcaca gggataaacc catacgtgag 5101 caggcggaaa atattatcca tttgtttact cttaccaacc tcggcgctcc agccgcattc 5161 aagtattttg acacaacgat agatcgcaaa cgatacactt ctaccaagga ggtgctagac 5221 gcgacactga ttcaccaatc catcacggga ttatatgaaa ctcggataga tttgtcacag 5281 cttgggggtg actctggtgg ttctggagga tctggtggtt ctactaatct gtcagatatt 5341 attgaaaagg agaccggtaa gcaactggtt atccaggaat ccatcctcat gctcccagag 5401 gaggtggaag aagtcattgg gaacaagccg gaaagcgata tactcgtgca caccgcctac 5461 gacgagagca ccgacgagaa tgtcatgctt ctgactagcg acgcccctga atacaagcct 5521 tgggctctgg tcatacagga tagcaacggt gagaacaaga ttaagatgct ctctggtggt 5581 tctggaggat ctggtggttc tactaatctg tcagatatta ttgaaaagga gaccggtaag 5641 caactggtta tccaggaatc catcctcatg ctcccagagg aggtggaaga agtcattggg 5701 aacaagccgg aaagcgatat actcgtgcac accgcctacg acgagagcac cgacgagaat 5761 gtcatgcttc tgactagcga cgcccctgaa tacaagcctt gggctctggt catacaggat 5821 agcaacggtg agaacaagat taagatgctc tctggtggtt ctcccaagaa gaagaggaaa 5881 gtctaaccgg tcatcatcac catcaccatt gagtttaaac ccgctgatca gcctcgactg 5941 tgccttctag ttgccagcca tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg 6001 aaggtgccac tcccactgtc ctttcctaat aaaatgagga aattgcatcg cattgtctga 6061 gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg gaggattggg 6121 aagacaatag caggcatgct ggggatgcgg tgggctctat ggcttctgag gcggaaagaa 6181 ccagctgggg ctcgataccg tcgacctcta gctagagctt ggcgtaatca tggtcatagc 6241 tgtttcctgt gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca 6301 taaagtgtaa agcctagggt gcctaatgag tgagctaact cacattaatt gcgttgcgct 6361 cactgcccgc tttccagtcg ggaaacctgt cgtgccagct gcattaatga atcggccaac 6421 gcgcggggag aggcggtttg cgtattgggc gctcttccgc ttcctcgctc actgactcgc 6481 tgcgctcggt cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggt 6541 tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg 6601 ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg 6661 agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat 6721 accaggcgtt tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta 6781 ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct 6841 gtaggtatct cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc 6901 ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa 6961 gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg 7021 taggcggtgc tacagagttc ttgaagtggt ggcctaacta cggctacact agaagaacag 7081 tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagt ggtagctctt 7141 gatccggcaa acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta 7201 cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc 7261 agtggaacga aaactcacgt taagggattt tggtcatgag attatcaaaa agatcttca 7321 cctagatcct ttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa 7381 cttggtctga cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgctat 7441 ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 7501 taccatctgg ccccagtgct gcaatgac cgcgagaccc acgctcaccg gctccagatt 7561 tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat 7621 ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta 7681 atagtttgcg caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 7741 gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt 7801 tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg 7861 cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 7921 taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 7981 ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa 8041 ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac 8101 cgctgttgag atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt 8161 ttactttcac cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaagg 8221 gaataagggc gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa 8281 gcattatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaata 8341 aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc gacggatcgg 8401 gagatcgatc tcccgatccc ctagggtcga ctctcagtac aatctgctct gatgccgcat 8461 agttaagcca gtatctgctc cctgcttgtg tgttggaggt cgctgagtag tgcgcgagca 8521 aaatttaagc tacaacaagg caaggcttga ccgacaattg catgaagaat ctgcttaggg 8581 ttaggcgttt tgcgctgctt cgcgatgtac gggccagata tacgcgttga cattgattat 8641 tgactagtta ttaatagtaa tcaattacgg ggtcattagt tcatagccca tatatggagt 8701 tccgcgttac ataacttacg gtaaatggcc cgcctggctg accgcccaac gacccccgcc 8761 cattgacgtc aataatgacg tatgttccca tagtaacgcc aatagggact ttccattgac 8821 gtcaatgggt ggagtattta cggtaaactg cccacttggc agtacatcaa gtgtatc
[0142] BE4 amino acid sequence:
[0143] By way of example, an adenine base editor (ABE) used in the base editing compositions, systems, and methods described herein has the nucleic acid sequence (8877 base pairs) provided below (Addgene, Watertown, MA.; Gaudelli NM, et al., Nature. 2017 Nov 23;551(7681):464-471. doi: 10.1038 / nature24644; Koblan LW, et al., Nat Biotechnol. 2018 Oct;36(9):843-846. doi: 10.1038 / nbt.4172.). Polynucleotide sequences having at least 95% or greater identity to the ABE nucleic acid sequence are also encompassed.
[0144] ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACAT GACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGG TTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGATTTCCAAGTCTCCACCCCATTG ACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCC ATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGT CAGATCCGCTAGAGATCCGCGGCCGCTAATACGACTCACTATAGGGAGAGCCGCCACCATGAAACGGACA GCCGACGGAAGCGAGTTCGAGTCACCAAAGAAGAAGCGGAAAGTCTCTGAAGTCGAGTTTAGCCACGAGT ATTGGATGAGGCACGCACTGACCCTGGCAAAGCGAGCATGGGATGAAAGAGAAGTCCCCGTGGGCGCCGT GCTGGTGCACAACAATAGAGTGATCGGAGAGGGATGGAACAGGCCAATCGGCCGCCACGACCCTACCGCA CACGCAGAGATCATGGCACTGAGGCAGGGAGGCCTGGTCATGCAGAATTACCGCCTGATCGATGCCACCC TGTATGTGACACTGGAGCCATGCGTGATGTGCGCAGGAGCAATGATCCACAGCAGGATCGGAAGAGTGGT GTTCGGAGCACGGGACGCCAAGACCGGCGCAGCAGGCTCCCTGATGGATGTGCTGCACCACCCCGGCATG AACCACCGGGTGGAGATCACAGAGGGAATCCTGGCAGACGAGTGCGCCGCCCTGCTGAGCGATTTCTTTA GAATGCGGAGACAGGAGATCAAGGCCCAGAAGAAGGCACAGAGCTCCACCGACTCTGGAGGATCTAGCGG AGGATCCTCTGGAAGCGAGACACCAGGCACAAGCGAGTCCGCCACACCAGAGAGCTCCGGCGGCTCCTCC GGAGGATCCTCTGAGGTGGAGTTTTCCCACGAGTACTGGATGAGACATGCCCTGACCCTGGCCAAGAGGG CACGCGATGAGAGGGAGGTGCCTGTGGGAGCCGTGCTGGTGCTGAACAATAGAGTGATCGGCGAGGGCTG GAACAGAGCCATCGGCCTGCACGACCCAACAGCCCATGCCGAAATTATGGCCCTGAGACAGGGCGGCCTG GTCATGCAGAACTACAGACTGATTGACGCCACCCTGTACGTGACATTCGAGCCTTGCGTGATGTGCGCCG GCGCCATGATCCACTCTAGGATCGGCCGCGTGGTGTTTGGCGTGAGGAACGCAAAAACCGGCGCCGCAGG CTCCCTGATGGACGTGCTGCACTACCCCGGCATGAATCACCGCGTCGAAATTACCGAGGGAATCCTGGCA GATGAATGTGCCGCCCTGCTGTGCTATTTCTTTCGGATGCCTAGACAGGTGTTCAATGCTCAGAAGAAGG CCCAGAGCTCCACCGACTCCGGAGGATCTAGCGGAGGCTCCTCTGGCTCTGAGACACCTGGCACAAGCGA GAGCGCAACACCTGAAAGCAGCGGGGGCAGCAGCGGGGGGTCAGACAAGAAGTACAGCATCGGCCTGGCC ATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGG TGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGA AACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGC TATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGT CCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGC CTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGAC CTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACC TGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGA GGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGA CGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGGAGAAAGAATGGCCTGTTCGGAAACCTGATTGCCC TGAGCCTGGGCCTGACCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAG CAAGGACACCTACGACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGGCCGACCTGTTTT CTGGCCGCCAAGAACCTGCTCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCA AGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGC TCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCC GGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGG ACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAA CGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTAC CCATTCCTGAAGGACAACCGGGAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCC CTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAA CTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAG AACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGC TGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGC CATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAG AAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACAT ACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGA AGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCC CACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCC GGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGG CTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAA GCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTA AGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGA GAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGA ATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACA CCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGA ACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGAC TCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAG AGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTT CGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAG CTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACG ACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCG GAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAAC GCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACA AGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTT CTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGG CCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGC GGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAA AGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAG TACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGT CCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAA TCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAG TACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAA ACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGG CTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATC GAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCT ACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAA TCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAA GAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTC AGCTGGGAGGTGACTCTGGCGGCTCAAAAAGAACCGCCGACGGCAGCGAATTCGAGCCCAAGAAGAAGAG GAAAGTCTAACCGGTCATCATCACCATCACCATTGAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTT CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCAC TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGT GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCT CTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCGATACCGTCGACCTCTAGCTAGAGCTTGGCGTA ATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGA AGCATAAAGTGTAAAGCCTAGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGC CCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGG TTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGA GCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACA TGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCT CCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAA AGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGAT ACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTC GGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTA TCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTA ACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTA CACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGC TCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCA GAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACACTCAGTGGAACGAAAACTC ACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGA AGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGG CACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTAC GATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCA GATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCT CCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGT TGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCC CAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGA TCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTAC TGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGT ATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAA AAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG TTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGA GCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATAC TCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATG TATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACGGA TCGGGAGATCGATCTCCCGATCCCCTAGGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAA GCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAAC AAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGAT GTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCAT TAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCAT TGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
[0145] "Base editing activity" refers to acting to chemically modify a base in a polynucleotide. In one embodiment, a first base is converted to a second base. In one embodiment, the base editing activity is a cytidine deaminase activity, e.g., converting a target C·G to T·A. In another embodiment, the base editing activity is an adenosine or adenine deaminase activity, e.g., converting an A·T to G·C. In another embodiment, the base editing activity is a cytidine deaminase activity, e.g., converting a target C·G to T·A, or an adenosine or adenine deaminase activity, e.g., converting an A·T to G·C. In some embodiments, the base editing activity is assessed by the efficiency of editing. Base editing efficiency can be measured by any suitable means, e.g., Sanger sequencing or next-generation sequencing. In some embodiments, base editing efficiency is measured by the percentage of all sequencing reads with a nucleobase conversion caused by a base editor, e.g., the percentage of all sequencing reads with a targeted AT base pair that is converted to a GC base pair. In some embodiments, base editing efficiency is measured by the percentage of all cells with a nucleobase conversion caused by a base editor when base editing is performed in a population of cells.
[0146] The term "base editor system" refers to a system for editing a nucleobase of a target nucleotide sequence. In various embodiments, the base editor system comprises: (1) a polynucleotide programmable nucleotide binding domain (e.g., Cas9); (2) a deaminase domain for deaminating the nucleobase (e.g., adenosine deaminase or cytidine deaminase); and (3) one or more guide polynucleotides (e.g., guide RNA). In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the base editor is an adenine or adenosine base editor (ABE). In some embodiments, the base editor system is ABE8.
[0147] In some embodiments, the base editor system may include two or more base editing components. For example, the base editor system may include multiple deaminases. In some embodiments, the base editor system may include one or more adenosine deaminases. In some embodiments, a single guide polynucleotide may be utilized to target different deaminases to a target nucleic acid sequence. In some embodiments, a single pair of guide polynucleotides may be utilized to target different deaminases to a target nucleic acid sequence.
[0148] The deaminase domain and the polynucleotide programmable nucleotide binding component of the base editor system may be bound to each other covalently or non-covalently, or any combination of such binding and interaction. For example, in some embodiments, the deaminase domain may be targeted to a target nucleotide sequence by a polynucleotide programmable nucleotide binding domain. In certain embodiments, the polynucleotide programmable nucleotide binding domain may be fused or linked to the deaminase domain. In some embodiments, the polynucleotide programmable nucleotide binding domain may target the deaminase domain to a target nucleotide sequence by interacting or binding non-covalently with the deaminase domain. For example, in some embodiments, the deaminase domain may include an additional heterologous moiety or domain that may interact, associate, or form a complex with an additional heterologous moiety or domain that is part of the polynucleotide programmable nucleotide binding domain. In some embodiments, the additional heterologous moiety may bind, interact, associate, or form a complex with a polypeptide. In some embodiments, the additional heterologous moiety may bind, interact, associate, or form a complex with a polynucleotide. In some embodiments, an additional heterologous moiety can be attached to a guide polynucleotide. In some embodiments, an additional heterologous moiety can be attached to a polypeptide linker. In some embodiments, an additional heterologous moiety can be attached to a polynucleotide linker. The additional heterologous moiety can be a protein domain. In some embodiments, the additional heterologous moiety can be a K homology (KH) domain, an MS2 coat protein domain, a PP7 coat protein domain, an SfMu Com coat protein domain, a steryl alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or an RNA recognition motif.
[0149] The base editor system may further comprise a guide polynucleotide component. It should be understood that the components of the base editor system may be bound to each other via covalent bonds, non-covalent interactions, or any combination of such bonds and interactions. In some embodiments, the deaminase domain may be targeted to a target nucleotide sequence by a guide polynucleotide. For example, in some embodiments, the deaminase domain may include an additional heterologous moiety or domain (e.g., a polynucleotide binding domain, such as an RNA or DNA binding protein) that may interact, bind, or form a complex with a portion or segment (e.g., a polynucleotide motif) of the guide polynucleotide. In some embodiments, the additional heterologous moiety or domain (e.g., a polynucleotide binding domain, such as an RNA or DNA binding protein) may be fused or linked to the deaminase domain. In some embodiments, the additional heterologous moiety may bind, interact, associate, or form a complex with a polypeptide. In some embodiments, the additional heterologous moiety may bind, interact, associate, or form a complex with a polynucleotide. In some embodiments, the additional heterologous moiety may be bound to a guide polynucleotide. In some embodiments, the additional heterologous moiety may be bound to a polypeptide linker. In some embodiments, additional heterologous moieties can be linked to polynucleotide linkers. Additional heterologous moieties can be protein domains. In some embodiments, additional heterologous moieties can be K homology (KH) domains, MS2 coat protein domains, PP7 coat protein domains, SfMu Com coat protein domains, sterile alpha motifs, telomerase Ku binding motifs and Ku protein, telomerase Sm7 binding motifs and Sm7 protein, or RNA recognition motifs.
[0150] In certain embodiments, the base editor system may further comprise a base excision repair (BER) inhibitor component. It should be understood that the components of the base editor system may be bound to each other via covalent bonds, non-covalent interactions, or any combination of such bonds and interactions. The inhibitor of the BER component may comprise a BER inhibitor. In certain embodiments, the BER inhibitor may be a uracil DNA glycosylase inhibitor (UGI). In certain embodiments, the BER inhibitor may be an inosine BER inhibitor. In certain embodiments, the BER inhibitor may be targeted to a target nucleotide sequence by a polynucleotide programmable nucleotide binding domain. In certain embodiments, the polynucleotide programmable nucleotide binding domain may be fused or linked to a BER inhibitor. In certain embodiments, the polynucleotide programmable nucleotide binding domain may be fused or linked to a deaminase domain and a BER inhibitor. In some embodiments, the polynucleotide programmable nucleotide binding domain may target the BER inhibitor to a target nucleotide sequence by non-covalently interacting with or associating with the BER inhibitor. For example, in some embodiments, an inhibitor of a BER component may include an additional heterologous moiety or domain that may interact, associate, or complex with an additional heterologous moiety or domain that is part of a polynucleotide programmable nucleotide binding domain.
[0151] In some embodiments, the BER inhibitor can be targeted to a target nucleotide sequence by a guide polynucleotide. For example, in some embodiments, the BER inhibitor can include an additional heterologous moiety or domain (e.g., a polynucleotide binding domain, such as an RNA or DNA binding protein) that can interact, associate, or complex with a portion or segment (e.g., a polynucleotide motif) of the guide polynucleotide. In some embodiments, the additional heterologous moiety or domain (e.g., a polynucleotide binding domain, such as an RNA or DNA binding protein) of the guide polynucleotide can be fused or linked to the BER inhibitor. In some embodiments, the additional heterologous moiety can bind, interact, associate, or complex with the polynucleotide. In some embodiments, the additional heterologous moiety can be linked to the guide polynucleotide. In some embodiments, the additional heterologous moiety can be linked to a polypeptide linker. In some embodiments, the additional heterologous moiety can be linked to a polynucleotide linker. The additional heterologous moiety can be a protein domain. In some embodiments, the additional heterologous moiety can be a K homology (KH) domain, an MS2 coat protein domain, a PP7 coat protein domain, an SfMu Com coat protein domain, a sterile alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or an RNA recognition motif.
[0152] The term "Cas9" or "Cas9 domain" refers to an RNA-guided nuclease that includes the Cas9 protein or a fragment thereof (e.g., a protein that includes an active, inactive, or partially active DNA cleavage domain of Cas9, and / or a gRNA-binding domain of Cas9). Cas9 nuclease is sometimes referred to as casnl nuclease or CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease. CRISPR is an adaptive immune system that provides defense against mobile genetic elements (viruses, transposable elements, conjugative plasmids). CRISPR clusters contain a spacer, a sequence complementary to the preceding mobile element, and a target invading nucleic acid. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems, correct processing of the pre-crRNA requires a transcoding small RNA (tracrRNA), endogenous ribonuclease 3 (rnc), and the Cas9 protein. The tracrRNA guides the processing of the pre-crRNA by ribonuclease 3. Cas9 / crRNA / tracrRNA then endonucleolytically cleaves linear or circular dsDNA targets that are complementary to the spacer. The target strand that is not complementary to the crRNA is first endonucleolytically cleaved and then exonucleolytically trimmed 3'-5'. In nature, DNA binding and cleavage typically requires both proteins and both RNAs. However, single guide RNAs ("sgRNAs", or simply "gRNAs") can be engineered to incorporate both crRNA and tracrRNA aspects into a single RNA species. See, for example, Jinek M.et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Cas9 recognizes short motifs (PAM or protospacer adjacent motifs) in the CRISPR repeats to help distinguish self from non-self.The sequence and structure of Cas9 nuclease are well known to those of skill in the art (see, e.g., “Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti et al., Proc. Natl. Acad. Sci. USA 98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E. et al., Nature 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M. et al., Science 337:816-821(2012), the entire contents of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, including Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737, the entire contents of which are incorporated herein by reference.
[0153] An exemplary Cas9 is Streptococcus pyogenes Cas9 (spCas9), the amino acid sequence of which is provided below. TIFF0007586601000002.tif161169 (single underline: HNH domain; double underline: RuvC domain)
[0154] Nuclease-inactivated Cas9 protein may be interchangeably referred to as "dCas9" protein (for nuclease-"dead" Cas9) or catalytically inactive Cas9. Methods for generating Cas9 protein (or fragments thereof) with an inactive DNA cleavage domain are known (see, e.g., Jinek et al, Science. 337:816-821(2012); Qi et al, "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression"(2013) Cell. 28; 152(5): 1173-83, the contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to contain two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, and the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can suppress the nuclease activity of Cas9. For example, mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al, Science. 337:816-821(2012); Qi et al, Cell. 28;152(5): 1173-83 (2013)). In some embodiments, the Cas9 nuclease has an inactive (e.g., inactivated) DNA cleavage domain, i.e., Cas9 is a nickase, referred to as a "nCas9" protein (for "nickase" Cas9). In some embodiments, proteins comprising a fragment of Cas9 are provided. For example, in some embodiments, the protein comprises one of the following two Cas9 domains: (1) the gRNA binding domain of Cas9; (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9 or a fragment thereof are referred to as "Cas9 variants." The Cas9 variants share homology with Cas9 or a fragment thereof.For example, a Cas9 variant has at least about 70% identity, at least about 80% identity, at least about 90% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, or at least about 99.9% identity to a wild-type Cas9. In some embodiments, the Cas9 mutant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to wild-type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA cleavage domain) that has at least about 70% identity, at least about 80% identity, at least about 90% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, or at least about 99.9% identity to the corresponding fragment of wild-type Cas9. In certain embodiments, a fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild-type Cas9.
[0155] In certain embodiments, the fragments are at least 100 amino acids in length. In certain embodiments, the fragments are at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length.
[0156] In one embodiment, the wild-type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_017053.1, nucleotide and amino acid sequences are as follows): TIFF0007586601000003.tif165169 (single underline: HNH domain; double underline: RuvC domain)
[0157] In certain embodiments, the wild-type Cas9 corresponds to or comprises the following nucleotide and / or amino acid sequence: TIFF0007586601000004.tif163169 (single underline: HNH domain; double underline: RuvC domain)
[0158] In some embodiments, the wild-type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_002737.2 (nucleotide sequence below) and Uniprot Reference Sequence: Q99ZW2 (amino acid sequence below). TIFF0007586601000005.tif164168 (SEQ ID NO: 1) (Single underline: HNH domain; double underline: RuvC domain)
[0159] In certain embodiments, Cas9 is Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Cas9 from Streptococcus thermophilus (NCBI Ref: YP_820832.1), Listeria innocua (NCBI Ref: NP_472073.1), Campylobacter jejuni (NCBI Ref: YP_002344900.1) or Neisseria meningitidis (NCBI Ref: YP_002342100.1), or any other organism.
[0160] In some embodiments, the dCas9 corresponds to, or comprises a portion or all of, a Cas9 amino acid sequence having one or more mutations that inactivate Cas9 nuclease activity. For example, in some embodiments, the dCas9 domain comprises the D10A and H840A mutations as numbered in SEQ ID NO: 1, or corresponding mutations in another Cas9. In some embodiments, the dCas9 comprises the amino acid sequence of dCas9 (D10A and H840A): TIFF0007586601000006.tif163168 (single underline: HNH domain; double underline: RuvC domain)
[0161] In some embodiments, the Cas9 domain comprises a D10A mutation, while the residue at position 840 in the amino acid sequence provided above, or the residue at the corresponding position in any of the amino acid sequences provided herein, remains a histidine.
[0162] In other embodiments, dCas9 variants are provided that have mutations other than D10A and H840A, e.g., that result in nuclease-inactivated Cas9 (dCas9). Such mutations include, e.g., other amino acid substitutions at D10 and H840, or other substitutions within the nuclease domain of Cas9 (e.g., substitutions in the HNH nuclease subdomain and / or the RuvC1 subdomain). In some embodiments, variants or homologs of dCas9 are provided that have at least about 70% identity, at least about 80% identity, at least about 90% identity, at least about 95% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, or at least about 99.9% identity. In some embodiments, variants of dCas9 are provided that have amino acid sequences that are shorter or longer by about 5 amino acids, about 10 amino acids, about 15 amino acids, about 20 amino acids, about 25 amino acids, about 30 amino acids, about 40 amino acids, about 50 amino acids, about 75 amino acids, about 100 amino acids or more.
[0163] In some embodiments, the Cas9 fusion proteins provided herein comprise the full-length amino acid sequence of a Cas9 protein, e.g., one of the Cas9 sequences provided herein. However, in other embodiments, the fusion proteins provided herein do not comprise the full-length Cas9 sequence, but only one or more fragments thereof. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein, and further suitable sequences of Cas9 domains and fragments will be apparent to one of skill in the art.
[0164] It should be understood that additional Cas9 proteins (e.g., nuclease-dead Cas9 (dCas9), Cas9 nickase (nCas9), or nuclease-active Cas9), including variants and homologs thereof, are within the scope of this disclosure. Exemplary Cas9 proteins include, but are not limited to, those provided below. In some embodiments, the Cas9 protein is a nuclease-dead Cas9 (dCas9). In some embodiments, the Cas9 protein is a Cas9 nickase (nCas9). In some embodiments, the Cas9 protein is a nuclease-active Cas9.
[0165] Exemplary catalytically inactive Cas9 (dCas9):
[0166] Exemplary catalytic Cas9 nickases (nCas9):
[0167] Exemplary catalytically active Cas9:
[0168] In some embodiments, Cas9 refers to Cas9 from Archaea (e.g., Nanoarchaea), which constitute the domain and kingdom of unicellular prokaryotic microorganisms. In some embodiments, Cas9 refers to CasX or CasY, e.g., as described in Burstein et al., "New CRISPR-Cas systems from uncultivated microbes." Cell Res. 2017 Feb 21. doi: 10.1038 / cr.2017.21, the entire contents of which are incorporated herein by reference. Using genome-resolved metagenomics, many CRISPR-Cas systems have been identified, including the first reported Cas9 in the Archaea domain of life. This divergent Cas9 protein was discovered as part of an active CRISPR-Cas system in the little-studied Nanoarchaea. In bacteria, two previously unknown systems, CRISPR-CasX and CRISPR-CasY, have been discovered, which are among the most compact systems ever discovered. In some embodiments, Cas9 represents CasX or a variant of CasX. In some embodiments, Cas9 represents CasY or a variant of CasY. It should be understood that other RNA-guided DNA binding proteins may also be used as nucleic acid programmable DNA binding proteins (napDNAbp) and are within the scope of the present disclosure.
[0169] In certain embodiments, napDNAbp useful in the methods of the invention comprise circular permutations, which are known and described, for example, in Oakes et al., Cell 176, 254-267, 2019. Below are exemplary circular permutations, where the bolded sequences show sequences derived from Cas9, the italicized sequences represent linker sequences, and the underlined sequences represent bipartite nuclear localization sequences. TIFF0007586601000007.tif189168
[0170] Non-limiting examples of polynucleotide programmable nucleotide binding domains that can be incorporated into base editors include domains from CRISPR proteins, restriction nucleases, meganucleases, TAL nucleases (TALENs), and zinc finger nucleases (ZFNs).
[0171] In some embodiments, the nucleic acid programmable DNA binding protein (napDNAbp) of any of the fusion proteins provided herein can be a CasX or CasY protein. In some embodiments, the napDNAbp is a CasX protein. In some embodiments, the napDNAbp is a CasY protein. In some embodiments, the napDNAbp comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to a naturally occurring CasX or CasY protein. In some embodiments, the napDNAbp is a naturally occurring CasX or CasY protein. In some embodiments, the napDNAbp comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to any CasX or CasY protein described herein. It is understood that Cas12b / C2c1, CasX, and CasY from other bacterial species may also be used in accordance with the present disclosure.
[0172] Cas12b / C2c1 (uniprot.org / uniprot / T0D7A2#2) sp|T0D7A2|C2C1_ALIAG CRISPR-associated endo- nuclease C2c1 OS = Alicyclobacillus acido- terrestris (strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) GN=c2c1 PE=1 SV=1
[0173] CasX (uniprot.org / uniprot / F0NN87; uniprot.org / uniprot / F0NH53) >tr|F0NN87|F0NN87_SULIH CRISPR-associated Casx protein OS = Sulfolobus islandicus (strain HVE10 / 4) GN = SiH_0402 PE=4 SV=1 MEVPLYNIFGDNYIIQVATEAENSTIYNNKVEIDDEELRNVLNLAYKIAKNNEDAAAERRGKAKKKGEEGETTTSNIILPLSGNDKNPWTETLKCYNFPTTVALSEVFKNFSQVKECEEVSAPSFVKPEFYEFGRSPGMVERTRRVKLE VEPHYLIIAAAGWVLTRLGKVSEGDYVGVNVFTRPTRGILYSLIQNVNGIVPGIKPETAFGLWIARKVSSVTNPNVSVVRIYTISDAVGQNPTTINGGFSIDLTKLLEKRYLLSERLEAIARNALSISSNMRYIVLANIYEYLTG SKRLEDLLYFANRDLIMNLNSDDGKVRDLKLISAIVNGELIRGEG
[0174] >tr|F0NH53|F0NH53_SULIR CRISPR associated protein, Casx OS = Sulfolobus islandicus (strain REY15A) GN=SiRe_0771 PE=4 SV=1 MEVPLYNIFGDNYIIQVATEAENSTIYNNKVEIDDEELRNVLNLAYKIAKNNEDAAAERRGKAKKKKGEEGETTTSNIILPLSGNDKNPWTETLKCYNFPTTVALSEVFKNFSQVKECEEVSAPSFVKPEFYKFGRSPGMVERTRRVKLEVEPHYLIMAAAGWVLTRLGKAK VSEGDYVGVNVFTPTRGILYSLIQNVNGIVPGIKPETAFGLWIARKVVSSVTNPNVSVVSIYTISDAVGQNPTTINGGFSIDLTKLLEKRDLLSERLEAIARNALSISSNMRERYIVLANYIYEYLTGSKRLEDLLYFANRDLIMNLNSDDGKVRDLKLISAYVNGELIRGEG
[0175] Deltaproteobacteria CasX MEKRINKIRKKLSADNATKPVSRSGPMKTLLVRVMTDDLKKRLEKRRKKPEVMPQVISNNAANNLRMLLDDYTKMKEAILQVYWQEFKDDHVGLMCKFAQPASKKIDQNKLKPEMDEKGNLTTAGFACSQCGQPLFVYKLEQVSEKGKAYTNYFGRCNVAEHEKLILLAQLKPVKDSDEAVTYSLGKFGQRALDFYSIHVTKESTHPVKPLAQIAGNRYASGPVGKALSDACMGTIASFLSKYQDIIIEHQKVVKGNQKRLESLRELAGKENLEYPSVTLPPQPHTKEGVDAYNEVIARVRMWVNLLWQKLKLSRDDAKPLLRLKGFPSFPVVERRENEVDWWNTINEVKKLIDAKRDMGRVFWSGVTAEKRNTILEGYNYLPNENDHKKREGSLENPKKPAKRQFGDLLLYLEKKYAGDWGKVFDEAWERIDKKIAGLTSHIEREEARNAEDAQSKAVLTDWLRAKASFVLERLKEMDEKEFYACEIQLQK WYGDLRGNPFAVEAENRVVDISGFSIGSDGHSIQYRNLLAWKYLENGKREFYLLMNYGKKGRIRFTDGTDIKKSGKWQGLLYGGGAKVIDLTFDPDDEQLIILPLAFGTRQGREFIWNDLLSLETGLIKLANGRVIEKTIYNKKIGRDEPALFVALTFERREVVDPSNIKPVNLIGVARGENIPAVIALTDPEGCPLPEFKDSSGGPTDILRIGEGYKEKQRAIQAAKEVEQRRAGGYSRKFASKSRNLADDMVRNSARDLFYHAVTHDAVLVFANLSRGFGRQGKRTFMTERQYTKMEDWLTAKLAYEGLTSKTYLSKTLAQYTSKTCSNCGFTITYADMDVMLVRLKKTSDGWATTLNNKELKAEYQITYYNRYKRQTVEKELSAELDRLSEESGNNDISKWTKGRRDEALFLLKKRFSHRPVQEQFVCLDCGHEVHAAEQAALNIARSWLFLNSNSTEFKSYKSGKQPFVGAWQAFYKRRLKEVWKPNA
[0176] CasY (ncbi.nlm.nih.gov / protein / APG80656.1) >APG80656.1 CRISPR-associated protein CasY [uncultured Parcubacteria group bacterium]
[0177] The term "Cas12" or "Cas12 domain" refers to an RNA-guided nuclease that includes a Cas12 protein or a fragment thereof (e.g., a protein that includes an active, inactive, or partially active DNA cleavage domain of Cas12 and / or a gRNA binding domain of Cas12). Cas12 belongs to the class 2, type V CRISPR / Cas system. Cas12 nucleases are sometimes referred to as CRISPR (clustered regularly interspaced short palindromic repeat)-associated nucleases. An exemplary Bacillus hisashii Cas 12b (BhCas12b) Cas 12 domain sequence is provided below.
[0178] Amino acid sequences having at least 85% or more identity to the BhCas12b amino acid sequence are also useful in the methods of the invention.
[0179] "Cytidine deaminase" refers to a polypeptide or fragment thereof capable of catalyzing a deamination reaction that converts an amino group to a carbonyl group. In one embodiment, the cytidine deaminase converts cytosine to uracil or 5-methylcytosine to thymine. PmCDA1 from Petromyzon marinus (Petromyzon marinus cytosine deaminase 1, "PmCDA1"), or AID (Activation-Induced Cytidine Deaminase; AICDA) from mammals (e.g., human, pig, cow, horse, monkey, etc.), and APOBEC are exemplary cytidine deaminases.
[0180] The term "conservative amino acid substitution" or "conservative mutation" refers to the replacement of one amino acid with another amino acid that has common properties. A functional method for defining common properties between individual amino acids is to analyze the normalized frequency of amino acid changes between corresponding proteins of homologous organisms (Schulz, GE and Schirmer, RH, Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such an analysis, it is possible to define groups of amino acids where the amino acids within the group are preferentially exchanged with each other and are therefore most similar to each other in their effect on the overall protein structure (Schulz, GE and Schirmer, RH, supra). Non-limiting examples of conservative mutations include, for example, the amino acid arginine to lysine and vice versa, which can maintain a positive charge; aspartic acid to glutamic acid and vice versa, which can maintain a negative charge; threonine to serine, which maintains a free -OH; and free NH 2Examples of amino acid substitutions that can maintain the above structure include asparagine to glutamine.
[0181] The terms "coding sequence" or "protein coding sequence," as used interchangeably herein, refer to a segment of a polynucleotide that encodes a protein. This region or sequence is bounded at the 5'-proximal end by a start codon and at the 3'-proximal end by a stop codon. A coding sequence is also called an open reading frame.
[0182] As used herein, the term "deaminase" or "deaminase domain" refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase is an adenosine deaminase that catalyzes the hydrolytic deamination of adenine to hypoxanthine. In some embodiments, the deaminase is an adenosine deaminase that catalyzes the hydrolytic deamination of adenosine or adenine (A) to inosine (I). In some embodiments, the deaminase or deaminase domain is an adenosine deaminase that catalyzes the hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenosine in deoxyribonucleic acid (DNA). The adenosine deaminase provided herein (e.g., engineered adenosine deaminase, evolved adenosine deaminase) can be from any organism, such as a bacterium. In some embodiments, the adenosine deaminase is from a bacterium, such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium, Shewanella putrefaciens, Haemophilus influenzae, or Caulobacter crescentus.
[0183] In some embodiments, the adenosine deaminase is TadA deaminase. In some embodiments, the TadA deaminase is a TadA variant. In some embodiments, the TadA variant is TadA*8. In some embodiments, the deaminase or deaminase domain is a variant of a natural deaminase from an organism, such as, for example, human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain is non-naturally occurring. For example, in some embodiments, the deaminase or deaminase domain has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identity to a naturally occurring deaminase. For example, deaminase domains are described in International PCT Application Nos. PCT / 2017 / 045381 (WO2018 / 027078) and PCT / US2016 / 058344 (WO2017 / 070632), each of which is incorporated by reference in its entirety.Komor, AC, et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage” Nature 533, 420-424 (2016); Gaudelli, NM, et al., “Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage”Nature 551, 464-471 (2017); Komor, AC, et al., “Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity”Science Advances 3:eaao4774 (2017) and Rees, HA, et al., “Base editing: precision chemistry on the genome and transcriptome of living cells.” Nat Rev Genet. 2018 Dec;19(12):770-788. doi: See also 10.1038 / s41576-018-0059-1, the entire contents of which are incorporated herein by reference.
[0184] "Detection" refers to identifying the presence, absence or amount of an analyte to be detected. In one embodiment, a sequence variation in a polynucleotide or polypeptide is detected. In another embodiment, the presence of an indel is detected.
[0185] By "detectable label" is meant a composition that, when linked to a molecule of interest, renders the latter detectable via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioisotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (such as those commonly used in enzyme-linked immunosorbent assays (ELISAs)), biotin, digoxigenin, or haptens.
[0186] By "disease" is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.
[0187] The term "effective amount" as used herein means an amount of a biologically active agent sufficient to induce a desired biological response. The effective amount of the active agent(s) used to practice the present invention for therapeutic treatment of a disease will vary depending on the mode of administration, the age, weight, and general health of the subject. Ultimately, the attending physician or veterinarian will determine the appropriate amount and dosage. Such an amount is referred to as an "effective" amount. In one embodiment, an effective amount is an amount of the base editor (e.g., programmable DNA binding protein, nucleobase editor, and gRNA) of the present invention sufficient to introduce a modification into a gene of interest in a cell (e.g., a cell in vitro or in vivo). In some embodiments, an effective amount of a fusion protein provided herein, for example, an effective amount of a nucleobase editor comprising an nCas9 domain and a deaminase domain (e.g., adenosine deaminase or cytidine deaminase), may refer to an amount of the fusion protein sufficient to induce editing of a target site specifically bound and edited by the nucleobase editor. In one embodiment, an effective amount is the amount of the base editor necessary to achieve a therapeutic effect (e.g., reducing or controlling a disease or a symptom or condition thereof). Such a therapeutic effect need not be sufficient to alter the gene of interest in all cells of a subject, tissue or organ, but need only alter the gene of interest in about 1%, 5%, 10%, 25%, 50%, 75% or more of the cells present in the subject, tissue or organ.
[0188] In some embodiments, an effective amount of a nucleobase editor comprising a fusion protein provided herein (e.g., an nCas9 domain and a deaminase domain (e.g., adenosine deaminase, cytidine deaminase) refers to the amount of fusion protein sufficient to induce editing of a target site specifically bound and edited by the nucleobase editor described herein. As will be appreciated by one of skill in the art, an effective amount of an agent (e.g., a fusion protein, a nuclease, a hybrid protein, a protein dimer, a complex of a protein (or protein dimer) and a polynucleotide, or a polynucleotide) can vary depending on a variety of factors, such as, for example, the desired biological response, e.g., the particular allele, genome, or target site to be edited, the cell or tissue being targeted, and / or the agent used.
[0189] By "fragment" is meant a portion of a polypeptide or nucleic acid molecule. The portion comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the full length of the reference nucleic acid molecule or polypeptide. A fragment can comprise 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
[0190] "Guide RNA" or "gRNA" refers to a polynucleotide that can be specific to a target sequence and can form a complex with a polynucleotide-programmable nucleotide-binding domain protein (e.g., Cas9 or Cpf1). In one embodiment, the guide polynucleotide is a guide RNA (gRNA). A gRNA can exist as a complex of two or more RNAs or as a single RNA molecule. A gRNA that exists as a single RNA molecule is sometimes referred to as a single guide RNA (sgRNA), while "gRNA" is used interchangeably to refer to a guide RNA that exists as a single molecule or as a complex of two or more molecules. Typically, a gRNA that exists as a single RNA species contains two domains: (1) a domain that shares homology with the target nucleic acid (e.g., directs binding of the Cas9 complex to the target); and (2) a domain that binds to the Cas9 protein. In one embodiment, domain (2) corresponds to a sequence known as tracrRNA and contains a stem-loop structure. For example, in some embodiments, domain (2) is identical or homologous to tracrRNA as provided in Jinek et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Other examples of gRNAs (e.g., those containing domain 2) can be found in U.S. Provisional Patent Application USSN 61 / 874,682, entitled "Switchable Cas9 Nucleases and Uses Thereof," filed September 6, 2013, and U.S. Provisional Patent Application USSN 61 / 874,746, entitled "Delivery System For Functional Nucleases," filed September 6, 2013, the entire contents of each of which are incorporated herein by reference. In some embodiments, the gRNA comprises two or more of domains (1) and (2), and may be referred to as an "extended gRNA." The extended gRNA binds to two or more Cas9 proteins, as described herein, and binds to the target nucleic acid in two or more distinct regions.The gRNA contains a nucleotide sequence complementary to the target site, which mediates binding of the nuclease / RNA complex to the target site and provides sequence specificity for the nuclease:RNA complex.
[0191] "Hybridization" refers to hydrogen bonding between complementary nucleobases, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding. For example, adenine and thymine are complementary nucleobases that form hydrogen bonds to pair.
[0192] The term "inhibitor of base repair" or "IBR" refers to a protein that can inhibit the activity of a nucleic acid repair enzyme, such as a base excision repair (BER) enzyme. In one embodiment, the IBR is an inhibitor of inosine base excision repair. Examples of inhibitors of base repair include inhibitors of APE1, Endo III, Endo IV, Endo V, Endo VIII, Fpg, hOGGl, hNEILl, T7 Endol, T4 PDG, UDG, hSMUGL, and hAAG. In one embodiment, the IBR is an inhibitor of Endo V or hAAG. In one embodiment, the IBR is catalytically inactive EndoV or catalytically inactive hAAG. In one embodiment, the base repair inhibitor is an inhibitor of Endo V or hAAG. In one embodiment, the base repair inhibitor is catalytically inactive EndoV or catalytically inactive hAAG.
[0193] In some embodiments, the base repair inhibitor is a uracil glycosylase inhibitor (UGI). UGI refers to a protein that can inhibit the base excision repair enzyme uracil-DNA glycosylase. In some embodiments, the UGI domain comprises wild-type UGI or a fragment thereof. In some embodiments, the UGI proteins provided herein comprise fragments of UGI and proteins homologous to UGI or UGI fragments. In some embodiments, the base repair inhibitor is an inhibitor of inosine base excision repair. In some embodiments, the base repair inhibitor is a "catalytically inactive inosine-specific nuclease" or a "dead inosine-specific nuclease." Without wishing to be bound by any particular theory, catalytically inactive inosine glycosylase (e.g., alkyladenine glycosylase (AAG)) can bind to inosine but cannot create an abasic site or remove inosine, thereby sterically blocking the newly formed inosine moiety from DNA damage / repair mechanisms. In some embodiments, catalytically inactive inosine-specific nuclease can bind to inosine in nucleic acid, but does not cleave nucleic acid.Representative catalytically inactive inosine-specific nucleases include, but are not limited to, catalytically inactive alkyl adenosine glycosylase (AAG nuclease) (e.g., from human) and catalytically inactive endonuclease V (EndoV nuclease) (e.g., from E. coli).In some embodiments, catalytically inactive AAG nuclease comprises E125Q mutation or the corresponding mutation in another AAG nuclease.
[0194] By "increase" is meant a positive change of at least 10%, 25%, 50%, 75%, or 100%.
[0195] An "intein" is a fragment of a protein that can excise itself and link the remaining fragment (extein) with a peptide bond in a process known as protein splicing. Inteins are also called "protein introns." The process by which an intein excises itself and links the remaining portion of a protein is referred to herein as "protein splicing" or "intein-mediated protein splicing." In some embodiments, the inteins of a precursor protein (the intein-containing protein prior to intein-mediated protein splicing) are derived from two genes. Such inteins are referred to herein as split inteins (e.g., split intein-N and split intein-C). For example, in cyanobacteria, DnaE, the catalytic subunit a of DNA polymerase III, is encoded by two separate genes, dnaE-n and dnaE-c. The intein encoded by the dnaE-n gene may be referred to herein as "intein N." The intein encoded by the dnaE-c gene may be referred to herein as "intein C."
[0196] Other intein systems can also be used. For example, synthetic inteins based on dnaE intein, i.e., Cfa-N (e.g., split intein-N) and Cfa-C (e.g., split intein-C) intein pairs have been described (e.g., Stevens et al., J Am Chem Soc. 2016 Feb. 24; 138(7):2162-5, incorporated herein by reference). Non-limiting examples of intein pairs that can be used according to the present disclosure include Cfa DnaE intein, Ssp GyrB intein, Ssp DnaX intein, Ter DnaE3 intein, Ter ThyX intein, Rma DnaB intein, and Cne Prp8 intein (e.g., as described in U.S. Patent No. 8,394,604, incorporated herein by reference).
[0197] Exemplary nucleotide and amino acid sequences of inteins are provided. DnaE intein-N DNA: TGCCTGTCATACGAACCGAGATACTGACAGTAGAATATGGCCTTCTGCCAATCGGGAAGATTGTGGAGAAACGGATAGAATGCACAGTTTACTCTGTCGATAACAATGGTAACATTTATACTCAGCCAGTTGCCCAGTGGCACGACCGGGGA GAGCAGGAAGTATTCGAATACTGTCTGGAGGATGGAAGTCTCATTAGGGCCACTAAGGACCACAAATTTATGACAGTCGATGGCCAGATGCTGCCTATAGACGAAATCTTTGAGCGAGAGTTGGACCTCATGCGAGTTGACAACCTTCCTAAT DnaE Intein-N Protein: CLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDR GEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPN DnaE Intein-C DNA: ATGATCAAGATAGCTACAAGGAAGTATCTTGGCAAACAAAACGTTTATGA TATTGGAGTCGAAAGAGATCACAACTTTGCTCTGAAGAACGGATTCATAGCTTCTAAT Intein-C: MIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASN Cfa-N DNA: TGCCTGTCTTATGATACCGAGATACTTACCGTTGAATATGGCTTCTTGCCTATTGGAAAGATTGTCGAAGAGGAATTGAATGCACAGTATATACTGTAGACAAGAATGGTTTCGTTTACACACAGCCCATTGCTCAATGCACAATCGCGGCGAACAAGAAGTATTTGAGTACTGTCTCGAGGATGGAAGCATCATACGAGCAACTAAAGATCATAAATTCATGACCACTGACGGGCAGATGTTGCCAATGAGATATTCGAGCGGGGCTTGGATCTCAAACAAGTGGATGGATTGCCA Cfa-N protein: CLSYDTEILTVEYGFLPIGKIVEERIECTVYTVDKNGFVYTQPIAQWHNRGEQEVFEYCLEDGSIIRATKDHKFMTTDGQMLPIDEIFERGDLLKQVDGLP Cfa-C DNA: ATGAAGAGGACTGCCGATGGATCAGAGTTTGAATCTCCCAAGAAGAAGAGGAAAGTAAAGATAATATCTCGAAAAGTCTTGGTACCCAAAATGTCTATGATATTGGAGTGGAGAAAGATCACAACTTCCTTCTCAAGAACGGTCTCGTAGCCAGCAAC Cfa-C protein: MKRTADGSEFESPKKKRKVKIISRKSLGTQNVYDIGVEKDHNFLLKNGLVASN
[0198] To join the N-terminal portion of split Cas9 with the C-terminal portion of split Cas9, an intein-N and an intein-C can be fused to the N-terminal portion of split Cas9 and the C-terminal portion of split Cas9, respectively. For example, in some embodiments, an intein-N is fused to the C-terminus of the N-terminal portion of split Cas9, i.e., forming a structure of N--[N-terminal portion of split Cas9]-[intein-N]--C. In some embodiments, an intein-C is fused to the N-terminus of the C-terminal portion of split Cas9, i.e., forming a structure of N--[intein-C]--[C-terminal portion of split Cas9]-C. Mechanisms of intein-mediated protein splicing for linking proteins (e.g., split Cas9) to which an intein is fused are known in the art, for example, as described in Shah et al., Chem Sci. 2014; 5(1):446-461, which is incorporated herein by reference. Methods for designing and using inteins are known in the art and are described, for example, by WO2014004336, WO2017132580, US20150344549, and US20180127780, each of which is incorporated herein by reference in its entirety.
[0199] The terms "isolated," "purified," or "biologically pure" refer to a material that has been removed to various degrees from components that normally accompany it when found in its native state. "Isolated" refers to a degree of separation from the original source or surrounding environment. "Purified" refers to a degree of separation greater than isolation. A "purified" or "biologically pure" protein has been sufficiently free of other materials such that the impurities do not substantially affect the biological properties of the protein or cause other deleterious consequences. That is, a nucleic acid or peptide of the invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA technology, or substantially free of chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high performance liquid chromatography. The term "purified" can mean that the nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For proteins that can undergo modifications, such as phosphorylation or glycosylation, different modifications can give rise to different isolated proteins that can be purified separately.
[0200] By "isolated polynucleotide" is meant a nucleic acid (e.g., DNA) that is free of the genes that flank the gene in the naturally occurring genome of the organism from which the nucleic acid molecule of the invention is derived. Thus, the term includes recombinant DNA that is present as a separate molecule independent of other sequences (e.g., cDNA or genomic or cDNA fragments generated by PCR or restriction endonuclease digestion), for example, incorporated into a vector; incorporated into an autonomously replicating plasmid or virus; incorporated into the genomic DNA of a prokaryote or eukaryote; or as a separate molecule independent of other sequences. In addition, the term includes RNA molecules that are transcribed from a DNA molecule, as well as recombinant DNA that is part of a hybrid gene that encodes additional polypeptide sequences.
[0201] By "isolated polypeptide" is meant a polypeptide of the invention separated from components that naturally accompany it. Typically, a polypeptide is isolated when it is at least 60% free, by weight, from proteins and naturally occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, a polypeptide of the invention. An isolated polypeptide of the invention can be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
[0202] The term "linker" as used herein can refer to a covalent linker (e.g., a covalent bond), non-covalent linker, chemical group, or molecule that connects two molecules or moieties (e.g., two components of a protein complex or ribonucleocomplex, or two domains of a fusion protein, such as a polynucleotide programmable DNA binding domain (e.g., dCas9) and a deaminase domain (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase), or a napDNAbp domain (e.g., Cas12b) and a deaminase domain (e.g., adenosine deaminase or cytidine deaminase). In certain embodiments, the linker flanks the deaminase domain inserted within a Cas protein or a fragment thereof. The linker can connect different components or different parts of a component of a base editor system. For example, in some embodiments, the linker can connect the guide polynucleotide binding domain of a polynucleotide programmable nucleotide binding domain and the catalytic domain of a deaminase. In some embodiments, the linker can link the CRISPR polypeptide and the deaminase. In some embodiments, the linker can link the Cas9 and the deaminase. In some embodiments, the linker can link the dCas9 and the deaminase. In some embodiments, the linker can link the nCas9 and the deaminase. For example, in some embodiments, the linker can link Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, or Cas12i and the deaminase. In some embodiments, the linker can link the guide polynucleotide and the deaminase. In some embodiments, the linker can link the deamination component of the base editor system and the polynucleotide programmable nucleotide binding component. In some embodiments, a linker can join the RNA binding portion of the deaminating component of the base editor system and the napDNAbp component.In some embodiments, a linker can connect the RNA binding portion of a deaminating component of a base editor system to a polynucleotide programmable nucleotide binding component. In some embodiments, a linker can connect the RNA binding portion of a deaminating component of a base editor system to a polynucleotide programmable nucleotide binding component. A linker can be disposed between or sandwiched between two groups, molecules, or other moieties and linked to each via covalent or non-covalent interactions, thus linking the two. In some embodiments, a linker can be an organic molecule, group, polymer, or chemical moiety. In some embodiments, a linker can be a polynucleotide. In some embodiments, a linker can be a DNA linker. In some embodiments, a linker can be an RNA linker. In some embodiments, a linker can include an aptamer capable of binding to a ligand. In some embodiments, a ligand can be a carbohydrate, peptide, protein, or nucleic acid. In some embodiments, a linker can include an aptamer derived from a riboswitch. The riboswitch from which the aptamer is derived can be selected from a theophylline riboswitch, a thiamine pyrophosphate (TPP) riboswitch, an adenosine cobalamin (AdoCbl) riboswitch, an S-adenosylmethionine (SAM) riboswitch, a SAH riboswitch, a flavin mononucleotide (FMN) riboswitch, a tetrahydrofolate riboswitch, a lysine riboswitch, a glycine riboswitch, a purine riboswitch, a GlmS riboswitch, or a prequeosin 1 (PreQ1) riboswitch. In some embodiments, the linker can include an aptamer bound to a protein domain, such as a polypeptide or a polypeptide ligand. In some embodiments, the polypeptide ligand can be a K homology (KH) domain, an MS2 coat protein domain, a PP7 coat protein domain, an SfMu Com coat protein domain, a sterile alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or an RNA recognition motif.In some embodiments, the polypeptide ligand can be part of a base editor system component. For example, the nucleobase editing component can include a deaminase domain and an RNA recognition motif.
[0203] In some embodiments, the linker can be an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker can be about 5-100 amino acids in length, e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-100 amino acids in length. In some embodiments, the linker can be about 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, or 450-500 amino acids in length. Longer or shorter linkers are also contemplated.
[0204] In some embodiments, the linker connects the gRNA binding domain of the RNA programmable nuclease, including the Cas9 nuclease domain, and the catalytic domain of the nucleic acid editing protein (e.g., cytidine or adenosine deaminase). In some embodiments, the linker connects dCas9 and the nucleic acid editing protein. For example, the linker is placed between or flanked by two groups, molecules, or other moieties, and is linked to each other via a covalent bond, thus linking the two. In some embodiments, the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In certain embodiments, the linker is between 5 and 200 amino acids in length, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 35, 45, 50, 55, 60, 60, 65, 70, 70, 75, 80, 85, 90, 90, 95, 100, 101, 102, 103, 104, 105, 110, 120, 130, 140, 150, 160, 175, 180, 190, or 200 amino acids in length. Longer or shorter linkers are also contemplated.
[0205] In some embodiments, the nucleobase editor domain is fused via a linker comprising the amino acid sequence of SGGSSGSETPGTSESATPESSGGS, SGGSSGGSSGSETPGTSESATPESSGGSSGGS, or GGSGGSPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTE PSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGGSGGS. In some embodiments, the nucleobase editor domain is fused via a linker comprising the amino acid sequence SGSETPGTSESATPES, which may be referred to as an XTEN linker. In some embodiments, the linker comprises the amino acid sequence SGGS. In some embodiments, the linker is (SGGS) n , (GGGS) n , (GGGGS) n , (G)n、 (EAAAK) n , (GGS) n , SGSETPGTSESATPES, or (XP) n In some embodiments, the amino acid sequence includes any one of the following: a) a nucleotide sequence, b) a nucleotide sequence, c) a nucleotide sequence, d) a nucleotide sequence, e) a nucleotide sequence, f ...
[0206] In some embodiments, the linker is 24 amino acids in length. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPES. In some embodiments, the linker is 40 amino acids in length. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGSSGGSSGGS. In some embodiments, the linker is 64 amino acids in length. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGSSGGSSGGSSGSETPGTSESATPESSGGS SGGS. In some embodiments, the linker is 92 amino acids in length. In some embodiments, the linker comprises the amino acid sequence PGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATS.
[0207] By "marker" is meant any protein or polynucleotide having an alteration in expression levels or activity that is associated with a disease or disorder.
[0208] As used herein, the term "mutation" refers to the replacement of a residue in a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or the deletion or insertion of one or more residues in a sequence. Mutations are typically described herein by identifying the original residue, then identifying the position of the residue in the sequence, and identifying the newly replaced residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art and are provided, for example, by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)). In some embodiments, the base editors of the present disclosure can efficiently generate "intended mutations," e.g., point mutations, in a nucleic acid (e.g., a nucleic acid in a subject's genome) without generating a significant number of unintended mutations, e.g., unintended point mutations. In some embodiments, the intended mutation is a mutation caused by a particular base editor (e.g., a cytidine base editor or an adenosine base editor) bound to a guide polynucleotide (e.g., a gRNA) that is specifically designed to produce the intended mutation.
[0209] Generally, mutations made or identified in a sequence (e.g., an amino acid sequence described herein) are numbered relative to a reference (or wild-type) sequence, i.e., a sequence that does not contain the mutation. Those skilled in the art will readily understand how to determine the location of mutations in amino acid and nucleic acid sequences relative to a reference sequence.
[0210] The term "non-conservative mutation" refers to amino acid substitutions between different groups, such as tryptophan to lysine or serine to phenylalanine. In this case, the non-conservative amino acid substitution preferably does not interfere with or inhibit the biological activity of the functional variant. The non-conservative amino acid substitution can enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased compared to the wild-type protein.
[0211] The term "nuclear localization sequence", "nuclear localization signal" or "NLS" refers to an amino acid sequence that promotes the import of a protein into the cell nucleus. Nuclear localization sequences are known in the art and are described, for example, in Plank et al., International PCT Application PCT / EP 2000 / 011690, filed November 23, 2000, and published May 31, 2001 as WO / 2001 / 038547, the contents of which are incorporated herein by reference for disclosure of exemplary nuclear localization sequences. In other embodiments, the NLS is an optimized NLS, for example, as described by Koblan et al., Nature Biotech. 2018 doi:10.1038 / nbt.4172. In certain embodiments, the NLS comprises the amino acid sequence KRTADGSEFESPKKKRKV, KRPAATKKAGQAKKKK, KKTELQTTNAENKTKKL, KRGINDRNFWRGENGRKTR, RKSGKIAAIVVKRPRK, PKKKRKV, or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC.
[0212] As used herein, the terms "nucleic acid" and "nucleic acid molecule" refer to a compound, such as a nucleoside, a nucleotide, or a polymer of nucleotides, that contains a nucleobase and an acidic moiety. Typically, a polymeric nucleic acid, such as a nucleic acid molecule that contains three or more nucleotides, is a linear molecule in which adjacent nucleotides are linked to each other via phosphodiester bonds. In some embodiments, "nucleic acid" refers to an individual nucleic acid residue (e.g., a nucleotide and / or a nucleoside). In some embodiments, "nucleic acid" refers to an oligonucleotide chain that contains three or more individual nucleotide residues. As used herein, the terms "oligonucleotide" and "polynucleotide" can be used interchangeably to refer to a polymer of nucleotides (e.g., a chain of at least three nucleotides). In some embodiments, "nucleic acid" encompasses RNA as well as single-stranded and / or double-stranded DNA. Nucleic acids can occur naturally, for example, in the context of a genome, a transcript, an mRNA, a tRNA, a rRNA, a siRNA, a snRNA, a plasmid, a cosmid, a chromosome, a chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule can be, for example, a non-naturally occurring molecule, recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragments thereof, or synthetic DNA, RNA, DNA / RNA hybrids, or non-naturally occurring molecules that contain non-naturally occurring nucleotides or nucleosides. Additionally, the terms "nucleic acid", "DNA", "RNA", and / or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. In the case of chemically synthesized molecules, the nucleic acid can include, where appropriate, nucleoside analogs, e.g., chemically modified bases or sugars, and analogs having backbone modifications. Nucleic acid sequences are shown in the 5' to 3' direction unless otherwise indicated.In certain embodiments, nucleic acids are selected from the group consisting of natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5- chemically modified bases; biologically modified bases (e.g., methylated bases); inserted bases; modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioate and 5'-N-phosphoramidite linkages).
[0213] The term "nucleic acid programmable DNA binding protein" or "napDNAbp" may be used interchangeably with "polynucleotide programmable nucleotide binding domain" and refers to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide nucleic acid or guide polynucleotide (e.g., gRNA) that guides the napDNAbp to a specific nucleic acid sequence. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 protein. The Cas9 protein can bind to a guide RNA that guides the Cas9 protein to a specific DNA sequence complementary to the guide RNA. In some embodiments, the napDNAbp is a Cas9 domain, such as a nuclease-active Cas9, Cas9 nickase (nCas9), or a nuclease-inactive Cas9 (dCas9). Non-limiting examples of nucleic acid programmable DNA binding proteins include Cas9 (e.g., dCas9 and nCas9), Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i.Non-limiting examples of Cas enzymes include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (also called Csn1 or Csx12), Cas10, Cas10d, Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, Csy1, Csy2, Csy3, Csy4, Cse 1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3 , Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csx11, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, Type II Cas effector proteins include type V Cas effector proteins, type VI Cas effector proteins, CARF, DinG, their homologs, or modified or engineered versions thereof. Other nucleic acid programmable DNA binding proteins are also within the scope of this disclosure, although they may not be specifically listed in this disclosure. See, for example, Makarova et al. "Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?" CRISPR J. 2018 Oct;1:325-336. doi: 10.1089 / crispr.2018.0033; Yan et al., "Functionally diverse type V CRISPR-Cas systems" Science. 2019 Jan 4;363(6422):88-91. doi: 10.1126 / science.aav7271 (the entire contents of each are incorporated herein by reference).
[0214] The terms "nucleobase", "nitrogenous base", or "base" are used interchangeably herein and refer to nitrogen-containing biological compounds that form nucleosides, which are components of nucleotides. The ability of nucleobases to base pair and stack with one another directly results in long-chain helical structures such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The five nucleobases, adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U), are referred to as primary or standard bases. Adenine and guanine are derived from purines, while cytosine, uracil, and thymine are derived from pyrimidines. DNA and RNA may also contain other (non-primary) bases that are modified. Non-limiting exemplary modified nucleobases include hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine (m5C), and 5-hydromethylcytosine. Hypoxanthine and xanthine can be produced in the presence of mutagens, and both are produced by deamination (replacement of an amine group with a carbonyl group). Hypoxanthine can be modified from adenine. Xanthine can be modified from guanine. Uracil can result from the deamination of cytosine. A "nucleoside" consists of a nucleobase and a five-carbon sugar (ribose or deoxyribose). Examples of nucleosides include adenosine, guanosine, uridine, cytidine, 5-methyluridine (m5U), deoxyadenosine, deoxyguanosine, thymidine, deoxyuridine, and deoxycytidine. Nucleosides having modified nucleobases include inosine (I), xanthosine (X), 7-methylguanosine (m7G), dihydrouridine (D), 5-methylcytidine (m5C), pseudouridine (Ψ), etc. A nucleotide consists of a nucleobase, a five-carbon sugar (ribose or deoxyribose), and at least one phosphate group.
[0215] The term "nucleic acid programmable DNA binding protein" or "napDNAbp" refers to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide nucleic acid, that directs the napDNAbp to a specific nucleic acid sequence. For example, a Cas12 protein can bind to a guide RNA that directs the Cas12 protein to a specific DNA sequence that is complementary to the guide RNA. In some embodiments, the napDNAbp is a Cas12 domain, e.g., a nuclease-active Cas12 domain. Examples of napDNAbps include Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i. Other napDNAbps are within the scope of this disclosure, even though they may not be specifically listed in this disclosure. See, e.g., Makarova et al. "Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?" CRISPR J. 2018 Oct;1:325-336. doi: 10.1089 / crispr.2018.0033; Yan et al., "Functionally diverse type V CRISPR-Cas systems" Science. 2019 Jan 4;363(6422):88-91. doi: 10.1126 / science.aav7271 (the entire contents of each of which are incorporated herein by reference).
[0216] The term "nucleobase editing domain" or "nucleobase editing protein" as used herein refers to a protein or enzyme that can catalyze nucleobase modifications in RNA or DNA, such as deamination of cytosine (or cytidine) to uracil (or uridine) or thymine (or thymidine), and adenine (or adenosine) to hypoxanthine (or inosine), and non-templated nucleotide addition and insertion. In some embodiments, the nucleobase editing domain is a deaminase domain (e.g., adenine deaminase or adenosine deaminase; or cytidine deaminase or cytosine deaminase). In some embodiments, the nucleobase editing domain is a multiple deaminase domain (e.g., adenine deaminase or adenosine deaminase and cytidine or cytosine deaminase). In some embodiments, the nucleobase editing domain can be a naturally occurring nucleobase editing domain. In some embodiments, the nucleobase editing domain can be a nucleobase editing domain engineered or evolved from a naturally occurring nucleobase editing domain. The nucleobase editing domain can be from any organism, such as bacteria, human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. For example, nucleobase editing proteins are described in International PCT Application Nos. PCT / 2017 / 045381 (WO 2018 / 027078) and PCT / US2016 / 058344 (WO 2017 / 070632), each of which is incorporated herein by reference in its entirety.See also Komor, AC, et al., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage" Nature 533, 420-424 (2016); Gaudelli, NM, et al., "Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage" Nature 551, 464-471 (2017); and Komor, AC, et al., "Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity" Science Advances 3:eaao4774 (2017), the entire contents of which are incorporated herein by reference.
[0217] As used herein, "obtaining," as in "obtaining an agent," includes synthesizing, purchasing, or otherwise acquiring the agent.
[0218] As used herein, "patient" or "subject" refers to a mammalian subject or individual who has been diagnosed with, is at risk of developing, or is suspected of having or developing a disease or disorder. In some embodiments, the term "patient" refers to a mammalian subject who has a higher than average chance of developing a disease or disorder. Exemplary patients may be humans, non-human primates, cats, dogs, pigs, cows, cats, horses, camels, llamas, goats, sheep, rodents (e.g., mice, rabbits, rats, guinea pigs), and other mammals that may benefit from the treatments disclosed herein. Exemplary human patients may be male and / or female.
[0219] A "patient in need thereof" or a "subject in need thereof" is referred to herein as a patient who has been diagnosed with, is at risk of having, has been predetermined to have, or is suspected of having a disease or disorder.
[0220] The terms "pathogenic mutation," "pathogenic variant," "disease-causing mutation," "disease-causing variant," "deleterious mutation," or "predisposing mutation" refer to a genetic alteration or mutation that increases an individual's susceptibility or predisposition to a particular disease or disorder. In certain embodiments, a pathogenic mutation comprises the replacement of at least one wild-type amino acid in a protein encoded by a gene with at least one pathogenic amino acid.
[0221] The term "pharmaceutically acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, magnesium talc, calcium or zinc stearate, or stearic acid), or solvent encapsulating material, involved in carrying or transporting a compound from one site in the body (e.g., a delivery site) to another site (e.g., an organ, tissue, or part of the body). A pharma- ceutically acceptable carrier is "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the tissue of the subject (e.g., physiological compatibility, sterility, physiological pH, etc.). Terms such as "excipient," "carrier," "pharma- ceutically acceptable carrier," "vehicle," and the like, are used interchangeably herein.
[0222] The term "pharmaceutical composition" may refer to a composition formulated for pharmaceutical use.
[0223] The terms "protein", "peptide", "polypeptide" and their grammatical equivalents are used interchangeably herein and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The term refers to a protein, peptide or polypeptide of any size, structure or function. Typically, a protein, peptide, or polypeptide is at least three amino acids long. A protein, peptide, or polypeptide can refer to an individual protein or a group of proteins. One or more amino acids in a protein, peptide, or polypeptide can be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification. A protein, peptide, or polypeptide can also be a single molecule or a multi-molecular complex. A protein, peptide, or polypeptide can be simply a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide can be naturally occurring, recombinant, or synthetic, or any combination thereof. As used herein, the term "fusion protein" refers to a hybrid polypeptide that contains protein domains from at least two different proteins. One protein can be located at the amino-terminal (N-terminal) portion or the carboxy-terminal (C-terminal) portion of the fusion protein, thus forming an amino-terminal fusion protein or a carboxy-terminal fusion protein, respectively. The protein can include different domains, such as a nucleic acid binding domain (e.g., the gRNA binding domain of Cas9, which guides the protein to bind to the target site) and a nucleic acid cleavage domain, or a catalytic domain of a nucleic acid editing protein. In some embodiments, the protein includes a proteinaceous portion, such as an amino acid sequence that constitutes a nucleic acid binding domain, and an organic compound, such as a compound that can act as a nucleic acid cleavage agent. In some embodiments, the protein is complexed with or associated with a nucleic acid (e.g., RNA or DNA).Any protein provided herein can be produced by any method known in the art.For example, the protein provided herein can be produced through recombinant protein expression and purification, which is particularly suitable for fusion proteins that contain peptide linkers.Methods for recombinant protein expression and purification are well known, including those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)), the entire contents of which are incorporated herein by reference.
[0224] The polypeptides and proteins disclosed herein (including functional portions and functional variants thereof) can contain synthetic amino acids in place of one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, norleucine, α-amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexylalanine, cyclohexylglycine, indoline-2-carboxylic acid, and the like. , 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyllysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, α-aminocyclopentane carboxylic acid, aminocyclohexane carboxylic acid, aminocyclohexane carboxylic acid, α-aminocycloheptane carboxylic acid, α-(2-amino-2-norbornane)-carboxylic acid, α,γ-diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine, and α-tert-butylglycine. Polypeptides and proteins can be associated with post-translational modifications of one or more amino acids of the polypeptide construct. Non-limiting examples of post-translational modifications include phosphorylation, acylation, including acetylation and formylation, glycosylation (including N-linked and O-linked), amidation, hydroxylation, alkylation, including methylation and ethylation, ubiquitination, addition of pyrrolidone carboxylic acid, formation of disulfide bridges, sulfation, myristoylation, palmitoylation, isoprenylation, farnesylation, geranylation, glypiation, lipoylation and iodination.
[0225] The term "polynucleotide programmable nucleotide binding domain" or "nucleic acid programmable DNA binding protein (napDNAbp)" refers to a protein that binds to a nucleic acid (e.g., DNA or RNA), such as a guide polynucleotide (e.g., guide RNA), that directs the polynucleotide programmable nucleotide binding domain to a specific nucleic acid sequence. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas12 protein.
[0226] The term "recombinant" as used herein with respect to a protein or nucleic acid refers to a protein or nucleic acid that does not occur in nature but is the product of human engineering. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that contains at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations compared to any naturally occurring sequence.
[0227] By "reduce" is meant a negative change of at least 10%, 25%, 50%, 75%, or 100%.
[0228] "Reference" refers to a standard or control condition. In one embodiment, the reference is a wild-type or healthy cell. In another embodiment, without limitation, the reference is an untreated cell that is not exposed to the test condition or is exposed to a placebo or normal saline, medium, buffer, and / or a control vector that does not carry the polynucleotide of interest.
[0229] A "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence can be a subset or the entirety of a particular sequence; for example, a segment of a full-length cDNA or gene sequence, or a complete cDNA or gene sequence. For polypeptides, the length of a reference polypeptide sequence is generally at least about 16 amino acids, at least about 20 amino acids, at least about 25 amino acids, about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of a reference nucleic acid sequence is generally at least about 50 nucleotides, at least about 60 nucleotides, at least about 75 nucleotides, about 100 nucleotides, or about 300 nucleotides, or any integer number therebetween or thereabout. In some embodiments, the reference sequence is a wild-type sequence of a protein of interest. In other embodiments, the reference sequence is a polynucleotide sequence that encodes a wild-type protein.
[0230] The terms "RNA programmable nuclease" and "RNA-guided nuclease" are used with (e.g., bound to or associated with) one or more RNAs that are not targets for cleavage. In some embodiments, when an RNA programmable nuclease is complexed with an RNA, it may be referred to as a nuclease:RNA complex. Typically, the bound RNA is referred to as a guide RNA (gRNA). A gRNA may exist as a complex of two or more RNAs or as a single RNA molecule. A gRNA that exists as a single RNA molecule may be referred to as a single guide RNA (sgRNA), although "gRNA" is used interchangeably to refer to a guide RNA that exists as a single molecule or as a complex of two or more molecules. Typically, a gRNA that exists as a single RNA species contains two domains: (1) a domain that shares homology with a target nucleic acid (e.g., directs binding of the Cas9 complex to the target); and (2) a domain that binds to the Cas9 protein. In some embodiments, domain (2) corresponds to a sequence known as tracrRNA and contains a stem-loop structure. For example, in some embodiments, domain (2) is identical or homologous to tracrRNA as provided in Jinek et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Other examples of gRNAs (e.g., those containing domain 2) can be found in U.S. Provisional Patent Application USSN 61 / 874,682, entitled "Switchable Cas9 Nucleases and Uses Thereof," filed September 6, 2013, and U.S. Provisional Patent Application USSN 61 / 874,746, entitled "Delivery System For Functional Nucleases," filed September 6, 2013, the entire contents of each of which are incorporated herein by reference. In some embodiments, the gRNA comprises two or more of domains (1) and (2), and may be referred to as an "extended gRNA."For example, the extended gRNA binds, e.g., to two or more Cas9 proteins and binds to a target nucleic acid in two or more distinct regions, as described herein. The gRNA comprises a nucleotide sequence complementary to the target site, which mediates binding of the nuclease / RNA complex to the target site and provides sequence specificity for the nuclease:RNA complex.
[0231] In some embodiments, the RNA programmable nuclease is a (CRISPR-associated system) Cas9 endonuclease, e.g., Cas9 (Casnl) from Streptococcus pyogenes (see, e.g., "Complete genome sequence of an Ml strain of Streptococcus pyogenes." Ferretti JJ et al., Proc. Natl. Acad. Sci. USA 98:4658-4663(2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E. et al., Nature 471:602-607(2011)).
[0232] Because RNA-programmable nucleases (e.g., Cas9) use RNA:DNA hybridization to target DNA cleavage sites, these proteins can, in principle, target any sequence specified by a guide RNA. Methods of using RNA-programmable nucleases such as Cas9 for site-specific cleavage (e.g., to modify genomes) are known in the art (e.g., Cong, L. et al., Multiplex genome engineering using CRISPR / Cas systems. Science 339, 819-823 (2013); Mali, P. et al., RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, WY et al., Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013); Jinek, M. et al., RNA-programmed genome editing in human cells. eLife 2, e00471 (2013); Dicarlo, JE et al., Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic acids research (2013); Jiang, W. et al., RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013), the entire contents of each of which are incorporated herein by reference.
[0233] The term "single nucleotide polymorphism (SNP)" refers to a variation of a single nucleotide occurring at a specific position in the genome, where each variation is present to a degree that is recognizable in a population (e.g., >1%). For example, at a particular base position in the human genome, a C nucleotide can occur in most individuals, but in a small number of individuals, the position is occupied by an A. This means that there is a SNP at this particular position, and the two nucleotide variations, C or A, are alleles at this position. SNPs underlie differences in susceptibility to disease. The severity of disease and the body's response to treatment are also manifestations of genetic variation. SNPs can be present in the coding region of a gene, in the non-coding region of a gene, or in intergenic regions (regions between genes). In certain embodiments, SNPs in the coding sequence do not necessarily change the amino acid sequence of the protein produced due to the degeneracy of the genetic code. There are two types of SNPs in coding regions: synonymous SNPs and non-synonymous SNPs. Synonymous SNPs do not affect the protein sequence, whereas non-synonymous SNPs change the amino acid sequence of the protein. There are two types of nonsynonymous SNPs: missense and nonsense. SNPs that are not in protein-coding regions can affect gene splicing, transcription factor binding, messenger RNA degradation, or the sequence of noncoding RNA. Gene expression affected by this type of SNP is called eSNP (expressed SNP) and can be upstream or downstream of the gene. Single-nucleotide variants (SNVs) are single-nucleotide variations with unlimited frequency that can occur somatically. Somatic single-nucleotide variations can also be called single-base alterations.
[0234] By "specifically binds" is meant a nucleic acid molecule, polypeptide, or complex thereof (e.g., a nucleic acid programmable DNA binding domain and a guide nucleic acid), compound, or molecule that recognizes and binds to a polypeptide and / or nucleic acid molecule of the invention, but does not substantially recognize and bind to other molecules in a sample (e.g., a biological sample).
[0235] Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecule encoding a polypeptide of the present invention or a fragment thereof. Such nucleic acid molecules do not need to be 100% identical to an endogenous nucleic acid sequence, but typically exhibit substantial identity. A polynucleotide having "substantial identity" to an endogenous sequence can typically hybridize with at least one strand of a double-stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecule encoding a polypeptide of the present invention or a fragment thereof. Such nucleic acid molecules do not need to be 100% identical to an endogenous nucleic acid sequence, but typically exhibit substantial identity. A polynucleotide having "substantial identity" to an endogenous sequence can typically hybridize with at least one strand of a double-stranded nucleic acid molecule. "Hybridize" refers to pairing to form a double-stranded molecule between complementary polynucleotide sequences (e.g., genes described herein) or between parts thereof under various stringency conditions. (See, e.g., Wahl, GM and SL Berger (1987) Methods Enzymol. 152:399; Kimmel, AR (1987) Methods Enzymol. 152:507).
[0236] For example, stringent salt concentrations are usually less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, more preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvents, such as formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, more preferably at least about 50% formamide. Stringent temperature conditions will usually include a temperature of at least about 30°C, more preferably at least about 37°C, and most preferably at least about 42°C. Various additional parameters, such as hybridization time, concentration of detergent (e.g., sodium dodecyl sulfate (SDS)), and inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are achieved by combining these various conditions as necessary. In one embodiment, hybridization occurs in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS at 30° C. In another embodiment, hybridization occurs in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg / ml denatured salmon sperm DNA (ssDNA) at 37° C. In another embodiment, hybridization occurs in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg / ml ssDNA at 42° C. Useful variations of these conditions will be readily apparent to one of skill in the art.
[0237] In most applications, the washing steps following hybridization also vary in stringency. Wash stringency conditions can be defined by salt concentration and temperature. As mentioned above, washing stringency can be increased by decreasing salt concentration or increasing temperature. For example, stringent salt concentrations for the washing steps are preferably less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the washing steps usually include a temperature of at least about 25°C, more preferably at least about 42°C, and even more preferably at least about 68°C. In one embodiment, the washing steps are performed at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, the washing steps are performed at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps are performed in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS at 68° C. Further variations of these conditions will be readily apparent to those of skill in the art.Hybridization techniques are well known to those of skill in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.
[0238] "Split" means divided into two or more pieces.
[0239] "Split Cas9 protein" or "split-Cas9" refers to a Cas9 protein that is provided as an N-terminal fragment and a C-terminal fragment encoded by two separate nucleotide sequences. Polypeptides corresponding to the N-terminal and C-terminal portions of the Cas9 protein can be spliced to form a "reconstituted" Cas9 protein. In certain embodiments, the Cas9 protein is split into two fragments within a disordered region of the protein, e.g., as described in Nishimasu et al., Cell, Volume 156, Issue 5, pp. 935-949, 2014, or as described in Jiang et al. (2016) Science 351: 867-871. PDB file: 5F9R, each of which is incorporated herein by reference. In some embodiments, the protein is split into two fragments at any C, T, A, or S within the region between approximately amino acids A292-G364, F445-K483, or E565-T637 of SpCas9, or at the corresponding positions in any other Cas9, Cas9 variant (e.g., nCas9, dCas9), or other napDNAbp. In some embodiments, the protein is split into two fragments at SpCas9 T310, T313, A456, S469, or C574. In some embodiments, the process of splitting a protein into two fragments is referred to as "splitting" the protein.
[0240] In other embodiments, the N-terminal portion of the Cas9 protein comprises amino acids 1-573 or 1-637 of S. pyogenes Cas9 wild-type (SpCas9) (NCBI Reference Sequence: NC_002737.2; Uniprot Reference Sequence: Q99ZW2) and the C-terminal portion of the Cas9 protein comprises amino acids 574-1368 or 638-1368 of SpCas9 wild-type.
[0241] The C-terminal portion of the split Cas9 can be joined with the N-terminal portion of the split Cas9 to form a complete Cas9 protein. In some embodiments, the C-terminal portion of the Cas9 protein begins where the N-terminal portion of the Cas9 protein ends. Thus, in some embodiments, the C-terminal portion of the split Cas9 comprises a portion of amino acids (551-651)-1368 of spCas9. By "(551-651)-1368" is meant beginning with an amino acid between amino acids 551 and 651 (inclusive) and ending with amino acid 1368.For example, the C-terminal portion of the split Cas9 is composed of amino acids 551-1368, 552-1368, 553-1368, 554-1368, 555-1368, 556-1368, 557-1368, 558-1368, 559-1368, 560-1368, 561-1368, 562-1368, 563-1368, 564-1368, 565-1368, 566-1368, 567-1368, 568-1368, 569-1368, 570-1368, 571-1368, 572-1368, 573-1368, 574 -1368, 575-1368, 576-1368, 577-1368, 578-1368, 579-1368, 580-1368, 581-1368, 582-1368, 583-1368, 584-1368, 585-1368, 586-1368, 587-1368, 588-1368, 589-1368, 590-1368, 591-1368, 592-1368, 593-1368, 594-1368, 595-1368, 596-1368, 597-1368, 598-1368, 599-1368, 600-1368 , 601-1368, 602-1368, 603-1368, 604-1368, 605-1368, 606-1368, 607-1368, 608-1368, 609-1368, 610-1368, 611-1368, 612-1368, 613-1368, 614-1368, 615-1368, 616-1368, 617-1368, 618-1368, 619-1368, 620-1368, 621-1368, 622-1368, 623-1368, 624-1368, 625-1368, 626-1368, 627- 1368, 628-1368, 629-1368, 630-1368, 631-1368, 632-1368, 633-1368, 634-1368, 635-1368, 636-1368, 637-1368, 638-1368, 639-1368, 640-1368, 641-1368, 642-1368, 643-1368, 644-1368, 645-1368, 646-1368, 647-1368, 648-1368, 649-1368, 650-1368, or 651-1368.In some embodiments, the C-terminal portion of the split Cas9 protein comprises a portion of amino acids 574-1368 or 638-1368 of SpCas9.
[0242] "Subject" means a mammal, including, but not limited to, a human or a non-human mammal, such as a cow, horse, dog, sheep, or cat. Subjects include livestock, farm animals that are kept to produce labor and provide goods such as food, including, but not limited to, cows, goats, chickens, horses, pigs, rabbits, and sheep.
[0243] By "substantially identical" is meant a polypeptide or nucleic acid molecule that exhibits at least 50% identity to a reference amino acid sequence (e.g., any one of the amino acid sequences described herein) or nucleic acid sequence (e.g., any one of the nucleic acid sequences described herein). In one embodiment, such a sequence has at least 60%, 80%, or even 85%, 90%, 95%, or even 99% identity at the amino acid level or nucleic acid to the sequence used for comparison.
[0244] Sequence identity is typically measured using sequence analysis software (e.g., the Sequence Analysis Software Package, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; phenylalanine, tyrosine. In an exemplary approach to determine the degree of identity, the BLAST program can be used, e.g., -3 and e -100 A probability score between indicates closely related sequences. COBALT can be used, for example, with the following parameters: a) Alignment parameters: Gap penalties-11,-1 and End-Gap penalties-5,-1, b) CDD parameters: Use RPS BLAST on; Blast E-value 0.003; Find Conserved columns and Recompute on c) Query clustering parameters: Use query clusters on; Word Size 4; Max cluster distance 0.8; Alphabet Regular. EMBOSS Needle is used, for example, with the following parameters: a) Matrix: BLOSUM62; b) GAP OPEN: 10; c) GAP EXTEND: 0.5; d) OUTPUT FORMAT: pair; e) END GAP PENALTY: false; f) END GAP OPEN: 10; and g) END GAP EXTEND: 0.5.
[0245] The term "target site" refers to a sequence within a nucleic acid molecule that is modified by a nucleobase editor. In one embodiment, the target site is deaminated by a deaminase (e.g., a cytidine or adenine deaminase) or a fusion protein comprising same.
[0246] As used herein, the terms "treat", "treating", "treatment" and the like refer to alleviating or ameliorating a disorder and / or symptoms associated therewith, or obtaining a desired pharmacological and / or physiological effect. It will be understood that treating a disorder or condition does not require (nor is complete elimination excluded) the associated disorder, condition or symptoms to be completely eliminated. In some embodiments, the effect is therapeutic, i.e., without limitation, the effect partially or completely reduces, reduces, eliminates, alleviates, alleviates, reduces the intensity, or cures the disease and / or adverse symptoms resulting therefrom. In some embodiments, the effect is prophylactic, i.e., the effect protects against or prevents the onset or recurrence of the disease or condition. To this end, the methods of the present disclosure include administering a therapeutically effective amount of a composition as described herein.
[0247] "Uracil glycosylase inhibitor" or "UGI" refers to an agent that inhibits the uracil excision repair system. In one embodiment, the agent is a protein or fragment thereof that binds to host uracil-DNA glycosylase and prevents the removal of uracil residues from DNA. In one embodiment, UGI is a protein, fragment, or domain that can inhibit uracil-DNA glycosylase base excision repair enzyme. In some embodiments, the UGI domain comprises wild-type UGI or a modified version thereof. In some embodiments, the UGI domain comprises a fragment of an exemplary amino acid sequence provided below. In some embodiments, the UGI fragment comprises an amino acid sequence that comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of an exemplary UGI sequence provided below. In some embodiments, UGI comprises an amino acid sequence that is homologous to an exemplary UGI amino acid sequence or a fragment thereof, as described below. In some embodiments, UGI or a portion thereof has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identity to wild-type UGI or a UGI sequence or a portion thereof, as described below. An exemplary UGI comprises the following amino acid sequence: >splP14739IUNGI_BPPB2 Uracil-DNA glycosylase inhibitor MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSD APEYKPWALVIQDSNGENKIKML.
[0248] The term "vector" refers to a means for introducing a nucleic acid sequence into a cell resulting in a transformed cell. Vectors include plasmids, transposons, phages, viruses, liposomes, and episomes. An "expression vector" is a nucleic acid sequence that contains a nucleotide sequence that is expressed in a recipient cell. Expression vectors may contain additional nucleic acid sequences to enhance and / or promote expression of the introduced sequence, such as initiation sequences, termination sequences, enhancer sequences, promoter sequences, and secretion sequences.
[0249] Any composition or method provided herein can be combined with any one or more of the other compositions and methods provided herein.
[0250] DNA editing has emerged as a viable means to modify disease states by correcting pathogenic mutations at the genetic level. Until recently, all DNA editing platforms worked by inducing DNA double-strand breaks (DSBs) at specific genomic sites and relying on endogenous DNA repair pathways to determine product outcomes in a semi-stochastic manner, resulting in a complex population of genetic products. Although precise and user-defined repair outcomes can be achieved via the homology-directed repair (HDR) pathway, numerous challenges have prevented highly efficient repair using HDR in therapeutically relevant cell types. In practice, this pathway is inefficient compared to the competing, error-prone non-homologous end-joining pathway. Furthermore, HDR is strictly restricted to the G1 and S phases of the cell cycle, preventing precise repair of DSBs in post-mitotic cells. As a result, it has proven difficult or impossible to modify genomic sequences with high efficiency in a user-defined and programmable manner in these populations.
[0251] Any composition or method provided herein can be combined with any one or more of the other compositions and methods provided herein.
[0252] DNA editing has emerged as a viable means to modify disease states by correcting pathogenic mutations at the genetic level. Until recently, all DNA editing platforms worked by inducing DNA double-strand breaks (DSBs) at specific genomic sites and relying on endogenous DNA repair pathways to determine product outcomes in a semi-stochastic manner, resulting in a complex population of genetic products. Although precise and user-defined repair outcomes can be achieved via the homology-directed repair (HDR) pathway, numerous challenges have prevented highly efficient repair using HDR in therapeutically relevant cell types. In practice, this pathway is inefficient compared to the competing, error-prone non-homologous end-joining pathway. Furthermore, HDR is strictly restricted to the G1 and S phases of the cell cycle, preventing precise repair of DSBs in post-mitotic cells. As a result, it has proven difficult or impossible to modify genomic sequences with high efficiency in a user-defined and programmable manner in these populations. [Brief description of the drawings]
[0253] [Figure 1] Figures 1A-1C show plasmids. Figure 1A is an expression vector encoding the TadA7.10-dCas9 base editor. Figure 1B is a plasmid containing a nucleic acid molecule encoding a protein that confers chloramphenicol resistance (CamR) and spectinomycin resistance (SpectR). The plasmid also contains a kanamycin resistance gene disabled by two point mutations. Figure 1C is a plasmid containing a nucleic acid molecule encoding a protein that confers chloramphenicol resistance (CamR) and spectinomycin resistance (SpectR). The plasmid also contains a kanamycin resistance gene disabled by three point mutations. [Diagram 2]Figure 2 is an image of a bacterial colony transduced with the expression vector shown in Figure 1, which contains a non-functional kanamycin resistance gene. The vector contained an ABE7.10 variant that was generated using error-prone PCR. Bacterial cells expressing these "evolved" ABE7.10 variants were selected for kanamycin resistance using increasing concentrations of kanamycin. Bacteria expressing ABE7.10 variants with adenosine deaminase activity were able to correct the mutation introduced into the kanamycin resistance gene and restore kanamycin resistance. Kanamycin-resistant cells were selected for further analysis. [Diagram 3] Figures 3A and 3B show editing of the regulatory region of the hemoglobin subunit gamma (HGB1) locus, a therapeutically relevant site for upregulation of fetal hemoglobin. Figure 3A is a diagram of a portion of the regulatory region of the HGB1 gene. Figure 3B quantifies the efficiency and specificity of adenosine deaminase variants. Editing was assayed at the hemoglobin subunit gamma 1 (HGB1) locus in HEK293T cells, which is a therapeutically relevant site for upregulation of fetal hemoglobin. The top panel shows the nucleotide residues in the targeted region of the regulatory sequence of the HGB1 gene. A5, A8, A9, and A11 show the edited adenosine residues in HGB1. [Figure 4] Figure 4 shows the relative efficacy of adenosine base editors, including dCas9, that recognize non-canonical PAM sequences. The top panel shows the coding sequences for hemoglobin subunits. The bottom panel is a graph showing the efficiency of adenosine deaminase variant base editors with guide RNAs of various lengths. [Diagram 5] 5 is a graph showing the efficiency and specificity of the ABE8 base editor, where the percent of editing at the intended target nucleotide and at unintended target nucleotides (bystanders) is quantified. [Figure 6]Figure 6 is a graph showing the efficiency and specificity of the ABE8 base editor, quantitating the percent editing at intended and unintended target nucleotides (bystanders). [Figure 7] Figures 7A-7D show that 8th generation adenine base editors mediate better A·T to G·C conversion in human cells. Figure 7A shows an overview of adenine base editing: i) ABE8 creates an R-loop at the sgRNA targeting site in the genome; ii) TadA* deaminase chemically converts adenine to inosine via hydrolytic deamination of the ss-DNA portion of the R-loop; iii) D10A nickase of Cas9 nicks the strand opposite the inosine-containing strand; iv) The inosine-containing strand can be used as a template during DNA replication; v) For DNA polymerase, inosine preferentially base pairs with cytosine; vi) After replication, inosine is replaced by guanosine. Figure 7B shows the architecture of ABE8.xm and ABE8.xd. Figure 7C shows three perspective views of E. coli TadA deaminase (PDB 1Z3A) aligned with S. aureus TadA (not shown) in complex with tRNA Arg2 (PDB 2B3J). Mutations identified over eight rounds of evolution are highlighted. Figure 7D is a graph showing the A·T to G·C base editing efficiency of the core ABE8 construct relative to the ABE7.10 construct across eight genomic sites in Hek293T cells. Values and error bars reflect the mean and s.d. of three independent biological replicates performed on different days.
[0254] [Figure 8]Figures 8A-C show that the Cas9 PAM variant ABE8 and catalytically inactive Cas9 ABE8 variants mediate higher A·T→G·C conversion in human cells than the corresponding ABE7.10 variants. Values and error bars reflect the mean and sd of three independent biological replicates performed on different days. Figure 8A shows A·T to G·C conversion in Hek293T cells with NG-Cas9 ABE8s (-NG PAM). Figure 8B shows A·T to G·C conversion in Hek293T cells with Sa-Cas9 ABE8s (-NNGRRT PAM). Figure 8C shows A·T to G·C conversion in Hek293T cells with catalytically inactive dCas9-ABE8s (D10A, H840A of S. pyogenes Cas9). [Figure 9] Figures 9A-9E show a comparison of on-target and off-target editing frequencies between ABE7.10, ABEmax and ABEmax with one BPNLS in Hek293T cells. Individual data points are shown for n=3 independent biological replicates performed on different days, and error bars represent sd. Figures 9A and 9B show graphs of on-target DNA editing frequencies. Figures 9B and 9C show graphs of sgRNA-induced DNA off-target editing frequencies. Figure 9E shows RNA off-target editing frequencies. [Figure 10] Figures 10A-10B show median A·T to G·C conversions and corresponding INDEL formation for TadA, C-terminal α-helical truncated ABE constructs in HEK293T cells. Figure 10A is a heatmap showing median A·T to G·C editing conversions across eight genomic sites. Figure 10B is a heatmap showing indel formation. Delta residue values correspond to deletion positions in TadA. Median values generated from n=3 biological replicates. [Figure 11]Figure 11 is a heatmap showing the median A T to G C conversions of 40 ABE8 constructs across eight genomic sites in HEK293T cells. Medians were determined from two or more biological replicates. [Figure 12] Figure 12 is a heatmap showing the median % indels of 40 ABE8 constructs across eight genomic sites in HEK293T cells. Medians were determined from two or more biological replicates. [Figure 13] Figure 13 is a graph showing fold change in editing (ABE8:ABE7). Representation of average ABE8:ABE7 A·T→G·C editing across all A positions within targets at eight different genomic sites in Hek293T cells. Positions 2-12 indicate the position of the targeted adenine within the 20 nt protospacer, with position 20 immediately 5' to the -NGG PAM. [Figure 14] Figure 14 shows a dendrogram of ABE8. The core ABE8 constructs selected for further study are highlighted in black. [Figure 15] Figure 15 is a heatmap showing the median A T to G C conversions of the eight core ABE8 constructs across eight genomic sites in HEK293T cells. Medians were determined from three or more biological replicates.
[0255] [Figure 16] FIG. 16 is a heatmap showing the median indel frequencies of the eight core ABE8s examined at eight genomic sites in HEK293T cells. [Figure 17] Figure 17 is a heatmap showing median A·T to G·C conversions of core NG-ABE8 construct 9 (-NG PAM) at six genomic sites in HEK293T cells. Median values generated from n=3 biological replicates. [Figure 18]Figure 18 is a heatmap showing the median indel frequencies of core NG-ABE8 tested at six genomic sites in HEK293T cells. Median values generated from n=3 biological replicates. [Figure 19] Figure 19 is a heatmap showing median A·T to G·C conversions of the core Sa-ABE8 construct (-NNGRRT PAM) at six genomic sites in HEK293T cells. Site positions within the 22 nt protospacer are numbered from -2 to 20 (5' to 3'). Position 20 is 5' of the NNGRRT PAM. Median values generated from n=3 biological replicates. [Figure 20] Figure 20 is a heatmap showing the median indel frequency of core sa-ABE8 tested at 8 genomic sites in HEK293T cells. Median values generated from n=3 biological replicates. [Figure 21] Figure 21 is a heatmap showing median A T to G C conversions of the core dC9-ABE8-m construct at eight genomic sites in HEK293T cells. Dead Cas9 (dC9) is defined as the D10A and H840A mutations in S. pyogenes Cas9. Median across biological replicates ≥3. [Figure 22] Figure 22 is a heatmap showing median A T to G C conversions of the core dC9-ABE8-d construct at 8 genomic sites in HEK293T cells. Dead Cas9 (dC9) is defined as the D10A and H840A mutations in S. pyogenes Cas9. Median values generated from n>3 biological replicates. [Figure 23]Figures 23A and 23B show the median indel frequency of core dC9-ABE8 tested at 8 genomic sites in HEK293T cells. Median values generated from n≧3 biological replicates. Figure 23A is a heat map showing indels shown for dC9-ABE8-m variants compared to ABE7.10. Figure 23B is a heat map showing indels shown for dC9-ABE8-d variants compared to ABE7.10. [Figure 24] Figure 24 shows C·G to T·A editing by Hek293T cells treated with ABE8 and ABE7.10. Editing frequency for each site averaged across all C positions within the target. Cytosines in the protospacer are shaded. [Diagram 25] Figures 25A-25H show DNA on-target editing and sgRNA-dependent DNA off-target editing by ABE8 constructs and ABE8 constructs with TadA mutations to improve specificity to DNA. Individual data points are shown and error bars represent sd for n=3 independent biological replicates performed on different days. Figures 25A and 25B are graphs showing on-target DNA editing frequency for core ABE8 constructs compared to ABE7. Figures 25C and 25D are graphs showing on-target DNA editing frequency for ABE8 with mutations that improve RNA off-target editing. Figures 25E and 25F are graphs showing sgRNA-guided DNA off-target editing frequency for core ABE8 constructs compared to ABE7. Figures 25G and 25H are graphs showing gRNA-guided DNA off-target editing frequency for ABE8 constructs with mutations that improve RNA off-target editing.
[0256] [Figure 26]FIG. 26 is a graph showing indel frequencies at 12 previously identified sgRNA-dependent Cas9 off-target loci in human cells; individual data points are shown and error bars represent the s.d. for n=3 independent biological replicates performed on different days. [Figure 27] Figures 27 A and 27 B show A·T to G·C conversion in primary cells and phenotypic results. Figure 27 A is a graph showing A·T to G·C conversion at the -198 HBG1 / 2 site in ABE-treated CD34+ cells from two separate donors. NGS analysis performed 48 and 144 hours after treatment. The -198 HBG1 / 2 target sequence is shown with A7 highlighted. Percent A·T→G·C plotted for A7. Figure 27 B is a graph showing the percentage of gamma globin formed as a percentage of alpha globin. Values shown from two different donors after ABE treatment and erythroid differentiation. [Figure 28] Figures 28A and 28B show A·T→G·C transversions at the -198 promoter site upstream of HBG1 / 2 in CD34+ cells treated with ABE8. Figure 28A is a heatmap showing ABE8 A→G edit frequency at 48 and 144 hours after editor treatment in CD34+ cells from two donors, where donor 2 is heterozygous for sickle cell disease. Figure 28B is a graphical representation of the distribution of all sequencing reads containing either the A7-only edit or the (A7+A8) combined edit. [Figure 29] Figure 29 is a heat map showing indel frequencies at -198 in the gamma globin promoter in ABE8-treated CD34+ cells. Frequencies shown from two donors at 48 and 144 hours. [Diagram 30] FIG. 30 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of untreated differentiated CD34+ cells (donor 1). [Diagram 31] FIG. 31 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE7.10-m. [Diagram 32] FIG. 32 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE7.10-d. [Diagram 33] FIG. 33 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE8.8-m.
[0257] [Diagram 34] FIG. 34 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE8.8-d. [Diagram 35] FIG. 35 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE8.13-m. [Diagram 36] FIG. 36 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE8.13-d. [Figure 37] FIG. 37 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE8.17-m. [Figure 38] FIG. 38 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE8.17-d. [Figure 39] FIG. 39 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE8.20-m. [Diagram 40]FIG. 40 shows the UHPLC UV-Vis trace (220 nm) and integration of globin chain levels of differentiated CD34+ cells (donor 1) treated with ABE8.20-d. [Diagram 41] Figure 41 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of untreated differentiated CD34+ cells (donor 2). Note: Donor 2 is heterozygous for sickle cell disease. [Diagram 42] Figure 42 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE7.10-m. Note: Donor 2 is heterozygous for sickle cell disease. [Diagram 43] Figure 43 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE7.10-d. Note: Donor 2 is heterozygous for sickle cell disease. [Diagram 44] Figure 44 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE8.8-m. Note: Donor 2 is heterozygous for sickle cell disease. [Diagram 45] Figure 45 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE8.8-d. Note: Donor 2 is heterozygous for sickle cell disease. [Figure 46] Figure 46 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE8.13-m. Note: Donor 2 is heterozygous for sickle cell disease.
[0258] [Figure 47]Figure 47 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE8.13-d. Note: Donor 2 is heterozygous for sickle cell disease. [Figure 48] Figure 48 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE8.17-m. Note: Donor 2 is heterozygous for sickle cell disease. [Figure 49] Figure 49 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE8.17-d. Note: Donor 2 is heterozygous for sickle cell disease. [Figure 50] Figure 50 shows the UHPLC UV-Vis trace (220 nm) and integral of globin chain levels of differentiated CD34+ cells (donor 2) treated with ABE8.20-m. Note: Donor 2 is heterozygous for sickle cell disease. [Figure 51] Figures 51 A-51 E show that editing with ABE8.8 at two independent sites reached over 90% editing before enucleation on day 11 after erythroid differentiation, and approximately 60% gamma globin relative to alpha globin or total beta family globins on day 18 after erythroid differentiation. Figure 51 A is a graph showing the average of ABE8.8 editing in two healthy donors in two independent experiments. Editing efficiency was measured with primers that distinguish between HBG1 and HBG2. Figure 51 B is a graph showing the average of one healthy donor in two independent experiments. Editing efficiency was measured with primers that recognize both HBG1 and HBG2. Figure 51 C is a graph showing ABE8.8 editing in a donor with a heterozygous E6V mutation. Figures 51 D and 51 E are graphs showing the increase in gamma globin in ABE8.8 edited cells. [Figure 52]Figures 52A and 52B show the percent editing (%Editing) with ABE variants to correct the sickle cell mutation. Figure 52A is a graph showing screening of different editor variants with about 70% editing in SCD patient fibroblasts. Figure 52B is a graph showing CD34 cells from a healthy donor edited with the lead ABE variant, targeting the synonymous mutation A13 at the adjacent proline that lies within the editing window and serves as a proxy for editing of the SCD mutation. The ABE8 variant showed an average editing frequency of about 40% at the proxy A13. [Figure 53] Figures 53A and 53B show RNA amplicon sequencing to detect intracellular A→I editing in RNA associated with ABE treatment. Individual data points are shown and error bars represent sd for n=3 independent biological replicates performed on different days. Figure 53A is a graph showing A→I editing frequency in target RNA amplicons for the core ABE8 construct compared to ABE7 and Cas9 (D10A) nickase controls. Figure 53B is a graph showing A→I editing frequency in target RNA amplicons for ABE8 with mutations reported to improve RNA off-target editing.
[0259] [Figure 54] FIG. 54 is a schematic diagram showing the loss of dopamine resulting from dopaminergic neuron loss in Parkinson's disease. [Figure 55] FIG. 55 is a schematic diagram showing guide RNA and target sequences for correction of the R1441C and R1441H mutations in LRRK2 associated with Parkinson's disease. [Figure 56] FIG. 56 is a schematic showing target sequences for correction of the Y1699C, G2019S, and I2020 mutations in LRRK2 associated with Parkinson's disease. [Figure 57]Figure 57A-C provide graphs, schematic diagrams and tables. Figure 57A quantifies the percent A to G conversion at nucleic acid position 7 of the LRRK2 target sequence. The editors used are referred to as PV1-PV14 and are described below. pCMV indicates the CMV promoter; bpNLS indicates the bipartite nuclear localization signal; monoABE8.1 indicates the monomeric form of the ABE8.1 base editor. Figure 57B shows the target sequence and guide RNA for correction of the R1441C mutation in LRRK2 associated with Parkinson's disease. Figure 57C shows the percent A to G conversion at nucleic acid position 7 of the LRRK2 target sequence. Editors PV1-14 were used to edit LRRK2 R1441C. Editors (15-28) were used to edit G2109. The editors (PV1-28) used to correct the LRRK2 mutation are as follows: PV1 (also called PV15). pCMV_monoABE8.1_bpNLS + Y147TMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCTFFRMPRQVFNAQKKAQSSTD PV2 (also called PV16). pCMV_monoABE8.1_bpNLS + Y147RMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCRFFRMPRQVFNAQKKAQSSTD PV3 (also called PV17). pCMV_monoABE8.pCMV_monoABE8.1_bpNLS + Q154SMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRSVFNAQKKAQSSTD PV4 (also called PV18). pCMV_monoABE8.1_bpNLS + Y123HMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD PV5 (also called PV19). pCMV_monoABE8.1_bpNLS + V82SMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYSTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD PV6 (also called PV20). pCMV_monoABE8.1_bpNLS + T166RMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSRD PV7 (also known as PV21). pCMV_monoABE8.pCMV_monoABE8.1_bpNLS + Q154RMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRRVFNAQKKAQSSTD PV8 (also called PV22). pCMV_monoABE8.1_bpNLS + Y147R_Q154R_Y123HMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLCRFFRMPRRVFNAQKKAQSSTD PV9 (also called PV23). pCMV_monoABE8.1_bpNLS + Y147R_Q154R_I76YMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLYDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCRFFRMPRRVFNAQKKAQSSTD PV10 (also called PV24). pCMV_monoABE8.1_bpNLS + Y147R_Q154R_T166RMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCRFFRMPRRVFNAQKKAQSSRD PV11 (also called PV25). pCMV_monoABE8.pCMV_monoABE8.1_bpNLS + Y147T_Q154RMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCTFFRMPRRVFNAQKKAQSSTD PV12 (also called PV26). pCMV_monoABE8.1_bpNLS + Y147T_Q154SMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCTFFRMPRSVFNAQKKAQSSTD PV13 (also called PV27). pCMV_monoABE8.1_bpNLS + H123Y123H_Y147R_Q154R_I76YMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLYDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLCRFFRMPRRVFNAQKKAQSSTD PV14 (also called PV28). pCMV_monoABE8.1_bpNLS + V82S + Q154RMSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYSTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRRVFNAQKKAQSSTD.
[0260] [Figure 58]Figure 58A-C provide graphs, schematics and tables. Figure 58A quantifies the percent A to G conversion at nucleic acid position 6 of the LRRK2 target sequence. The editors used were PV15-PV28, the description of which is provided above. pCMV indicates the CMV promoter; bpNLS indicates the bipartite nuclear localization signal; monoABE8.1 indicates the monomeric form of the ABE8.1 base editor. Figure 58B shows the target sequence and guide RNA for correction of the G2019S mutation in LRRK2 associated with Parkinson's disease. Figure 58C shows the percent A to G conversion at nucleic acid positions 4 and 6 of the LRRK2 target sequence. The A to G transition at position 4 is a bystander effect. [Figure 59] Figures 59A-59L show sequence reads for the A to G transition at position 7 of the LRRK2 target sequence encoding R1441C (see Figures 57A-57C). Editors have been displayed (PV1-14). Descriptions of PV1-28 are provided in Figure 56. [Figure 60] Figures 60 A-60 W show sequence reads for the A to G transition at positions 4 and 6 of the LRRK2 target sequence encoding G2019S (see Figures 58 A-58 C). [Figure 61]Figure 61 A provides a schematic showing a target sequence for correction of the pathogenic mutation A419V in LRRK2, encoded by an antisense strand G>A mutation. The mutation is corrected using an ABE targeting A at position 12 using an SpCas9 variant with specificity for TGG PAM. Figure 61 B is a schematic showing a target sequence for correction of the pathogenic mutation L1114L in LRRK2 associated with Parkinson's disease. This mutation is antisense strand T>C and is corrected using a base editor (CBE) with cytidine deaminase activity. Figure 61 C is a schematic showing a target sequence for correction of the pathogenic mutation I1122V in LRRK2 associated with Parkinson's disease. This mutation is antisense strand T>C and is corrected using a base editor (CBE) with cytidine deaminase activity. Figure 61 D provides a schematic showing a target sequence for correction of the pathogenic mutation M1869V in LRRK2 associated with Parkinson's disease. This mutation is an antisense strand T>C and is corrected using a base editor with cytidine deaminase activity (CBE). [Figure 62] Figures 62A and 62B show precise base editing correction of the Mus musculus IDUA W401X mutation in HEK293T cells. Figure 62A is a graph showing the percentage of base editing of the Mus musculus IDUA W401X mutation using ABE8 base editor variants with 21 nucleotide guide RNAs. Figure 62B is a graph showing the percentage of indels of ABE8 base editor variants with 21 nucleotide guide RNAs. [Figure 63] Figure 63 is a graph showing the rate of base editing of the Mus musculus IDUA W401X mutation using ABE8 base editor variants using either a 20 nucleotide guide RNA or a 21 nucleotide guide RNA. [Figure 64]Figure 64 shows a schematic diagram of the Homo sapiens IDUA genomic nucleic acid and amino acid sequence as a target for A→G nucleotide base editing to correct the W402X mutation. The diagram also shows the nucleic acid sequence of the corresponding guide RNA (gRNA). The diagram shows the target adenosine (A) nucleobase (boxed) in the IDUA nucleic acid sequence. [Figure 65] Figures 65 A and 65 B show precise base editing correction of the Homo sapiens IDUA W402X mutation in HEK293T cells. Figure 65 A is a graph showing the percentage of base edits of the Homo sapiens IDUA W402X mutation using an ABE8 base editor variant with a 20 nucleotide guide RNA. Figure 65 B is a graph showing the percentage of indels of the ABE8 base editor variant with a 20 nucleotide guide RNA. [Figure 66] Figure 66A-66O are tables showing the percentage efficiency of A to G nucleotide changes in IDUA nucleic acid sequences using ABE8 base editor variants, as detected by PCR of genomic DNA in cells where base editing was performed, followed by deep sequencing (MySeq). Figures 66A-66M show the percent A to G base editing at position 6 of the IDUA nucleic acid target site using three samples each of the ABE8 base editor variants ABE8.1-ABE8.13. Figure 66N shows the percent A → G base editing at position 6 of the IDUA nucleic acid target site using three samples of the positive control base editor ABE7.10. Figure 66O shows the percent A → G base editing at position 6 of the IDUA nucleic acid target site using two samples of the negative control. [Figure 67] Figure 67 shows Rett / MECP2: mutation correction. Loss of function of MECP2 can result from many different de novo mutations. X-linked: XX patients are mosaic for MECP2 deficiency; XY usually results in infantile lethality. [Figure 68]Figure 68 shows the Rett Syndrome R106W mutation correction for the top 3 Guide sequences. [Figure 69] Figure 69 shows Rett syndrome R255X mutation correction using an editor with NGTT PAM optimization. [Figure 70] Figures 70A-C: Hurler / IDUA mutation correction. Figure 70A shows the experimental design for IDUA W402X mutation correction. Figure 70B shows the percent editing of each editor construct. Figure 70C shows the specific activity (nmol / mg / h) for edited and unedited constructs. [Figure 71] Figure 71 shows in vivo base editing by ABE8.8. For each sample, from left to right, guide 11 (AAV9), guide 12 (AAV9), guide 11 (PHP.eB), guide 12 (PHP.eB), and control.
[0261] [Figure 72] Figure 72 A-72 B. A·T to G·C conversion by ABE7.10 and ABE8 variants at the ABCA4 G1961E allele in model cell lines. Figure 72 A: A·T to G·C conversion in HEK293T cells at the integrated disease allele and wobble base at the ABCA4 G1961E codon following plasmid lipofection of the 21 nt spacer sgRNA and base editor variants. Cells incubated for 5 days after lipofection were assessed for editing. Figure 72 B: DNA sequence at the site of interest, including the ABCA4 G1961E disease allele, the wobble base at the codon, and the -NGG PAM used by the 21 nt spacer sgRNA. Error bars represent the sd of three replicates. In each dataset, the disease allele is on the left and the wobble base is on the right. [Figure 73]A·T to G·C conversion by sgRNA spacer length variants at the ABCA4 G1961E allele in a model cell line. A·T to G·C conversion in HEK293T cells at the integrated disease allele and wobble base at the ABCA4 G1961E codon after plasmid lipofection of sgRNAs of various spacer lengths and ABE7.10. Cells incubated for 5 days after lipofection were assessed for editing. hRz = containing a self-cleaving hammerhead ribozyme at the 5' end of the sgRNA. Error bars represent the sd of three replicates. In each dataset, the disease allele is on the left and the wobble base is on the right. [Figure 74] Schematic of dual AAV delivery of split base editors using split intein reconstitution. Two AAV particles are packaged separately with the components required for base editing. One virus encodes the C-terminal region of the base editor with an N-terminal split intein fusion, and the complementary virus encodes the N-terminal region of the base editor with a C-terminal split intein fusion along with an sgRNA. Co-transduction of the complementary viruses transcribes the sgRNA and expresses each half of the base editor, which are recombined through split intein-mediated protein trans-splicing. [Figure 75]Figures 75 A-75 B. A·T to G·C conversion at ABCA4 G1961 in wild-type cells by dual AAV delivery of split ABE variants. Figure 75 A: A·T→G·C and C·G→T·A conversions at the wild-type ABCA4 G1961 target site in wild-type ARPE-19 cells, where editing at position 8A serves as a surrogate target for editing in these cells. Cells were infected at an MOI of 5E+4 viral genomes / virus / cell. Cells were incubated for 2 weeks post-infection and assessed for editing. Error bars represent the sd of six replicates. For each data point, samples treated with position 8 (A>G)-surrogate site are shown on the left and position 5 (C>T) on the right. Figure 75 B: DNA sequence at the wild-type target site, including the ABCA4 G 1961 allele and the -NGG PAM used by the 21 nt spacer sgRNA targeting the wild-type sequence. [Figure 76] Figures 76 A-76 B. Off-target base editing in wild-type ARPE-19 cells dually infected with AAV2 expressing split ABE7.10 and sgRNA targeting the ABCA4 G1961E disease allele. Figure 76 A: Maximum A·T→G·C conversion across on-target or off-target (OT) protospacers 2 weeks after coinfection with dual AAV (blue) compared to untreated control (gray). Figure 76 B: Maximum non-A·T→G·C conversion across on-target or off-target (OT) protospacers 2 weeks after coinfection with dual AAV (blue) compared to untreated control (gray). For each data point, treated wild-type (wt) ARPE-19 cells are shown on the left and untreated wt ARPE-19 cells are shown on the right. [Figure 77]Indel formation by base editing in wild-type ARPE-19 cells dually infected with AAV2 expressing split ABE7.10 and an sgRNA targeting the disease allele of ABCA4 G1961E. Percentage of indels formed within or proximal to the on-target or off-target protospacer 2 weeks after co-infection with dual AAVs (blue) compared to untreated controls (grey). For each data point, treated wild-type (wt) ARPE-19 cells are shown on the left and untreated wt ARPE-19 cells are shown on the right. [Figure 78] Primate retinal integrity and GFP expression at 22 days in culture. Sections were immunolabeled with anti-rhodopsin, anti-GFP, and biotinylated peanut agglutinin (PNA) antibodies overnight at 4°C. Anc80L65.hGRK.eGFP showed that GFP was observed only in the photoreceptor-containing outer nuclear layer (ONL), confirming photoreceptor-specific activity of the GRK promoter. Top row is untransduced day 0. Second row is untransduced day 22. Third row is day 22, GRK. Fourth row is day 22, CMB. Columns are unstained (1st column), DAPI (2nd column), GFP (3rd column), PNA (4th column), and rhodopsin (5th column). [Figure 79] Cas9 expression in NHPs. Cas9 expression is detected in primate retina as early as 6 days after culture. Results are shown for ABE7.10 (rows 1 and 2), ABE8.5 (rows 2 and 3), and ABE8.9 (rows 3 and 4). Top row: 6 days after culture. Bottom row: 17 days after culture. Results demonstrate that the AAV system delivers split intein expressing Cas9. Scale bar: 100 μm. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0262] The present invention provides compositions comprising novel adenine base editors (e.g., ABE8) with increased efficiency for generating targeted nucleobase sequence modifications and methods of their use.
[0263] [Nucleobase Editor] Disclosed herein is a base editor or nucleobase editor for editing, modifying or altering a target nucleotide sequence of a polynucleotide. Described herein is a nucleobase editor or base editor comprising a polynucleotide programmable nucleotide binding domain (e.g., Cas9) and a nucleobase editing domain (e.g., adenosine deaminase). The polynucleotide programmable nucleotide binding domain (e.g., Cas9), when combined with a bound guide polynucleotide (e.g., gRNA), can specifically bind to the target polynucleotide sequence (through complementary base pairing between the bases of the bound guide nucleic acid and the bases of the target polynucleotide sequence), thereby allowing the base editor to localize to the target nucleic acid sequence desired to be edited. In some embodiments, the target polynucleotide sequence comprises single-stranded DNA or double-stranded DNA. In some embodiments, the target polynucleotide sequence comprises RNA. In some embodiments, the target polynucleotide sequence comprises a DNA-RNA hybrid.
[0264] [Polynucleotide programmable nucleotide binding domain] It should be understood that polynucleotide programmable nucleotide binding domain can also include nucleic acid programmable protein that binds to RNA.For example, polynucleotide programmable nucleotide binding domain can be bound to nucleic acid that guides polynucleotide programmable nucleotide binding domain to RNA.Other nucleic acid programmable DNA binding proteins are also within the scope of this disclosure, but they are not specifically listed in this disclosure.
[0265] The polynucleotide programmable nucleotide binding domain of a base editor can itself comprise one or more domains. For example, the polynucleotide programmable nucleotide binding domain can comprise one or more nuclease domains. In an embodiment, the nuclease domain of a polynucleotide programmable nucleotide binding domain can comprise an endonuclease or an exonuclease. As used herein, the term "exonuclease" refers to a protein or polypeptide that can digest a nucleic acid (e.g., RNA or DNA) from a free end, and the term "endonuclease" refers to a protein or polypeptide that can catalyze (e.g., cleave) an internal region of a nucleic acid (e.g., DNA or RNA). In an embodiment, an endonuclease can cleave one strand of a double-stranded nucleic acid. In an embodiment, an endonuclease can cleave both strands of a double-stranded nucleic acid molecule. In an embodiment, the polynucleotide programmable nucleotide binding domain can be a deoxyribonuclease. In an embodiment, the polynucleotide programmable nucleotide binding domain can be a ribonuclease.
[0266] In some embodiments, the nuclease domain of the polynucleotide programmable nucleotide binding domain can cleave zero, one or two strands of a target polynucleotide. In some embodiments, the polynucleotide programmable nucleotide binding domain can include a nickase domain. As used herein, the term "nickase" refers to a polynucleotide programmable nucleotide binding domain that includes a nuclease domain that can cleave only one strand of a duplex in a double-stranded nucleic acid molecule (e.g., DNA). In some embodiments, a nickase can be derived from a fully catalytically active (e.g., native) form of a polynucleotide programmable nucleotide binding domain by introducing one or more mutations into the active polynucleotide programmable nucleotide binding domain. For example, when the polynucleotide programmable nucleotide binding domain includes a nickase domain derived from Cas9, the nickase domain derived from Cas9 can include a D10A mutation and a histidine at position 840. In such embodiments, residue H840 retains catalytic activity, thereby being capable of cleaving a single strand of a nucleic acid duplex. In another example, the Cas9-derived nickase domain can include an H840A mutation, while the amino acid residue at position 10 remains D. In some embodiments, a nickase can be derived from a fully catalytically active (e.g., native) form of a polynucleotide programmable nucleotide binding domain by removing all or a portion of a nuclease domain that is not required for nickase activity. For example, when a polynucleotide programmable nucleotide binding domain includes a nickase domain from Cas9, the nickase domain from Cas9 can include a deletion of all or a portion of the RuvC domain or the HNH domain.
[0267] An exemplary amino acid sequence of a catalytically active Cas9 is as follows:
[0268] Thus, base editors comprising a polynucleotide programmable nucleotide binding domain comprising a nickase domain can generate single-stranded DNA breaks (nicks) in a particular polynucleotide target sequence (e.g., as determined by the complementary sequence of the bound guide nucleic acid). In some embodiments, the strand of a nucleic acid double-stranded target polynucleotide sequence that is cleaved by a base editor comprising a nickase domain (e.g., a nickase domain from Cas9) is the strand that is not edited by the base editor (i.e., the strand that is cleaved by the base editor is the opposite strand to the strand that contains the base to be edited). In other embodiments, base editors comprising a nickase domain (e.g., a nickase domain from Cas9) can cleave the strand of a DNA molecule that is targeted for editing. In such embodiments, the non-target strand is not cleaved.
[0269] Also provided herein are base editors that include a polynucleotide programmable nucleotide binding domain that is catalytically dead (i.e., unable to cleave a target polynucleotide sequence). As used herein, the terms "catalytically dead" and "nuclease inactive" are used interchangeably to refer to a polynucleotide programmable nucleotide binding domain that has one or more mutations and / or deletions that result in an inability to cleave a strand of nucleic acid. In some embodiments, a catalytically dead polynucleotide programmable nucleotide binding domain base editor can lack nuclease activity as a result of specific point mutations in one or more nuclease domains. For example, in the case of a base editor that includes a Cas9 domain, Cas9 can include both a D10A mutation and an H840A mutation. Such mutations inactivate both nuclease domains, resulting in loss of nuclease activity. In other embodiments, a catalytically dead polynucleotide programmable nucleotide binding domain can include one or more deletions of all or part of a catalytic domain (e.g., RuvC1 and / or HNH domain). In further embodiments, the catalytically dead polynucleotide programmable nucleotide binding domain comprises a point mutation (e.g., D10A or H840A) as well as a deletion of all or part of the nuclease domain.
[0270] Also contemplated herein are mutations that can generate catalytically dead polynucleotide programmable nucleotide binding domains from previously functional versions of polynucleotide programmable nucleotide binding domains.For example, in the case of catalytically dead Cas9 ("dCas9"), variants are provided that have mutations other than D10A and H840A to result in nuclease-inactivated Cas9. Such mutations include, for example, other amino acid substitutions in D10 and H840, or other substitutions in the nuclease domain of Cas9 (e.g., substitutions in the HNH nuclease subdomain and / or RuvC1 subdomain).Further suitable nuclease-inactive dCas9 domains may be apparent to those skilled in the art based on this disclosure and knowledge in the art, and are within the scope of this disclosure. Such additional exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, D10A / H840A, D10A / D839A / H840A, and D10A / D839A / H840A / N863A mutant domains (see, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference).
[0271] Non-limiting examples of polynucleotide programmable nucleotide binding domains that can be incorporated into base editors include CRISPR protein-derived domains, restriction nucleases, meganucleases, TAL nucleases (TALENs), and zinc finger nucleases (ZFNs). In some embodiments, the base editor comprises a polynucleotide programmable nucleotide binding domain comprising a natural or modified protein or a portion thereof that can bind to a nucleic acid sequence via a binding guide nucleic acid during CRISPR (i.e., Clustered Regularly Interspaced Short Palindromic Repeats)-mediated modification of the nucleic acid. Such proteins are referred to herein as "CRISPR proteins." Thus, disclosed herein are base editors that comprise a polynucleotide programmable nucleotide binding domain comprising all or a portion of a CRISPR protein (i.e., a base editor that comprises all or a portion of a CRISPR protein as a domain (which is also referred to as the "CRISPR protein-derived domain" of the base editor). The CRISPR protein-derived domain incorporated into the base editor can be modified compared to a wild-type or natural CRISPR protein. For example, as described below, a domain derived from a CRISPR protein can contain one or more mutations, insertions, deletions, rearrangements and / or recombinations compared to a wild-type or naturally occurring CRISPR protein.
[0272] CRISPR is an adaptive immune system that provides defense against mobile genetic elements (viruses, transposable elements, conjugative plasmids). CRISPR clusters contain a spacer, a sequence complementary to the preceding mobile element, and a target invading nucleic acid. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems, correct processing of pre‐crRNA requires a transcoding small RNA (tracrRNA), endogenous ribonuclease 3 (rnc), and Cas9 protein. tracrRNA guides the processing of pre‐crRNA by ribonuclease 3. Cas9 / crRNA / tracrRNA then endonucleolytically cleaves linear or circular dsDNA targets that are complementary to the spacer. Target strands that are not complementary to the crRNA are first endonucleolytically cleaved and then exonucleolytically trimmed 3′-5′. In nature, both proteins and RNAs are required for DNA binding and cleavage. However, single guide RNAs ("sgRNAs", or simply "gRNAs") can be engineered to incorporate aspects of both crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M. et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Cas9 recognizes short motifs (PAM or protospacer adjacent motifs) in CRISPR repeats to help distinguish "self" from "non-self".
[0273] In some embodiments, the methods described herein can utilize engineered Cas proteins. Guide RNAs (gRNAs) are short synthetic RNAs consisting of a scaffold sequence required for Cas binding and a user-defined approximately 20-base spacer that defines the genome target to be modified. Thus, one skilled in the art can vary the genome target of Cas protein specificity, which is determined in part by how specific the gRNA targeting sequence is for the genome target compared to other parts of the genome.
[0274] In some embodiments, the gRNA scaffold sequence is: GUUUUAGAGC UAGAAAUAGC AAGUUAAAAU AAGGCUAGUC CGUUAUCAAC UUGAAAAAGU GGCACCGAGU CGGUGCUUUU.
[0275] In some embodiments, the domain derived from a CRISPR protein incorporated in the base editor is an endonuclease (e.g., a deoxyribonuclease or a ribonuclease) capable of binding to a target polynucleotide when combined with a bound guide nucleic acid. In some embodiments, the domain derived from a CRISPR protein incorporated in the base editor is a nickase capable of binding to a target polynucleotide when combined with a bound guide nucleic acid. In some embodiments, the domain derived from a CRISPR protein incorporated in the base editor is a catalytically dead domain capable of binding to a target polynucleotide when combined with a bound guide nucleic acid. In some embodiments, the target polynucleotide that binds to the CRISPR protein-derived domain of the base editor is DNA, and in some embodiments, the target polynucleotide that binds to the CRISPR protein-derived domain of the base editor is RNA.
[0276] CAs proteins that can be used herein include class 1 and class 2. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas9 (also called Csn1 or Csx12), Cas10, Csy1, Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5, Csn1, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Cssx16, Cx16, Cx, Csx3, Csx1, Csx1S, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, Cas12a / Cpf1, Cas12b / C2c1, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i, CARF, DinG, their homologs, or their variants. Unmodified CRISPR enzymes can have DNA cleavage activity, like Cas9, with two functional endonuclease regions, RuvC and HNH. CRISPR enzymes can induce cleavage of one or both strands in a target sequence, such as within the target sequence and / or within the complementary strand of the target sequence. For example, CRISPR enzymes can induce cleavage of one or both strands at about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500 or more base pairs from the first or last nucleotide of the target sequence.
[0277] Vectors can be used that encode CRISPR enzymes that are mutated relative to the corresponding wild-type enzyme so as to lack the ability to cleave one or both strands of a target polynucleotide that contains a target sequence. Cas9 can refer to a polypeptide that has at least, or at least about, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity and / or sequence homology with a wild-type exemplary Cas9 polypeptide (e.g., Cas9 from S. pyogenes). Cas9 can refer to a polypeptide having at most, or at most, about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity and / or sequence homology to a wild-type exemplary Cas9 polypeptide (e.g., from S. pyogenes). Cas9 can refer to wild-type or modified forms of the Cas9 protein, which may include amino acid changes, such as deletions, insertions, substitutions, variants, mutations, fusions, chimeras, or any combination thereof.
[0278] In some embodiments, the base editor CRISPR protein-derived domains are derived from Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquis (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1); Campylobacter jejuni (NCBI Ref: YP_002344900.1); Neisseria meningitidis (NCBI Ref: YP_002342100.1), Streptococcus pyogenes, or Staphylococcus aureus.
[0279] [Cas9 domain of nucleobase editor] The sequence and structure of Cas9 nuclease are well known to those of skill in the art (see, e.g., “Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti et al., Proc. Natl. Acad. Sci. USA 98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E. et al., Nature 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M. et al., Science 337:816-821(2012), the entire contents of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, including Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737, the entire contents of which are incorporated herein by reference.
[0280] In some embodiments, the nucleic acid programmable DNA binding protein (napDNAbp) is a Cas9 domain. Non-limiting exemplary Cas9 domains are provided herein. The Cas9 domain can be a nuclease-active Cas9 domain, a nuclease-inactive Cas9 domain (dCas9), or a Cas9 nickase (nCas9). In some embodiments, the Cas9 domain is a nuclease-active domain. For example, the Cas9 domain can be a Cas9 domain that cleaves both strands of a double-stranded nucleic acid (e.g., both strands of a double-stranded DNA molecule). In some embodiments, the Cas9 domain comprises any one of the amino acid sequences described herein. In some embodiments, the Cas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences described herein. In some embodiments, the Cas9 domain comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more mutations compared to any one of the amino acid sequences described herein.In some embodiments, the Cas9 domain comprises an amino acid sequence having at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical consecutive amino acid residues compared to any one of the amino acid sequences described herein.
[0281] In some embodiments, a protein is provided that comprises a fragment of Cas9. For example, in some embodiments, the protein comprises one of the following two Cas9 domains: (1) the gRNA binding domain of Cas9; (2) the DNA cleavage domain of Cas9. In some embodiments, the protein that comprises Cas9 or a fragment thereof is referred to as a "Cas9 variant". The Cas9 variant shares homology with Cas9 or a fragment thereof. For example, the Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild-type Cas9. In some embodiments, the Cas9 mutant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to wild-type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA cleavage domain) that is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild-type Cas9. In certain embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of the corresponding wild-type Cas9.In some embodiments, the fragments are at least 100 amino acids in length. In some embodiments, the fragments are at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length.
[0282] In some embodiments, the Cas9 fusion proteins provided herein comprise the full-length amino acid sequence of a Cas9 protein, e.g., one of the Cas9 sequences provided herein. However, in other embodiments, the fusion proteins provided herein do not comprise the full-length Cas9 sequence, but only one or more fragments thereof. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein, and further suitable sequences of Cas9 domains and fragments will be apparent to one of skill in the art.
[0283] Cas9 protein can bind to guide RNA, which guides Cas9 protein to a specific DNA sequence complementary to the guide RNA. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 domain, such as nuclease-active Cas9, Cas9 nickase (nCas9), or nuclease-inactive Cas9 (dCas9). Examples of nucleic acid programmable DNA binding proteins include, but are not limited to, Cas9 (e.g., dCas9 and nCas9), CasX, CasY, Cpf1, Cas12b / C2C1, and Cas12c / C2C3. In some embodiments, wild-type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_017053.1, nucleotide and amino acid sequences are as follows):
[0284] TIFF0007586601000008.tif168169 (single underline: HNH domain; double underline: RuvC domain)
[0285] In some embodiments, the wild-type Cas9 corresponds to or comprises the following nucleotide and / or amino acid sequence: TIFF0007586601000009.tif164169 (single underline: HNH domain; double underline: RuvC domain)
[0286] In some embodiments, the wild-type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_002737.2 (the nucleotide sequence is as follows) and Uniprot Reference Sequence: Q99ZW2 (the amino acid sequence is as follows): TIFF0007586601000010.tif168169 (single underline: HNH domain; double underline: RuvC domain)
[0287] In some embodiments, Cas9 is Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1), Listeria innocua (NCBI Ref: NP_472073.1), Campylobacter jejuni (NCBI Ref: YP_002344900.1) or Neisseria meningitidis (NCBI Ref: YP_002342100.1), or represents Cas9 from any other organism.
[0288] It is understood that additional Cas9 proteins (e.g., nuclease-dead Cas9 (dCas9), Cas9 nickase (nCas9), or nuclease-active Cas9), including variants and homologs thereof, are within the scope of this disclosure. Exemplary Cas9 proteins include, but are not limited to, those provided below. In some embodiments, the Cas9 protein is nuclease-dead Cas9 (dCas9). In some embodiments, the Cas9 protein is Cas9 nickase (nCas9). In some embodiments, the Cas9 protein is nuclease-active Cas9.
[0289] In some embodiments, the Cas9 domain is a nuclease-inactive Cas9 domain (dCas9). For example, the dCas9 domain can bind to a double-stranded nucleic acid molecule (e.g., via a gRNA molecule) without cleaving either strand of the double-stranded nucleic acid molecule. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10X mutation and a H840X mutation of the amino acid sequence described herein, or a corresponding mutation in any of the amino acid sequences provided herein, where X is any amino acid change. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10A mutation and a H840A mutation of the amino acid sequence described herein, or a corresponding mutation in any of the amino acid sequences provided herein. As an example, the nuclease-inactive Cas9 domain comprises the following amino acid sequence provided in the cloning vector pPlatTET-gRNA 2 (Accession No. BAV54124):
[0290] An exemplary amino acid sequence of a catalytically inactive Cas9 (dCas9) is as follows: (See, e.g., Qi et al., "Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression." Cell. 2013; 152(5):1173-83, the entire contents of which are incorporated herein by reference).
[0291] Further suitable nuclease-inactive dCas9 domains will be apparent to those skilled in the art based on this disclosure and knowledge in the art, and are within the scope of this disclosure.Such further exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, D10A / H840A, D10A / D839A / H840A, and D10A / D839A / H840A / N863A mutant domains (see, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference).
[0292] In some embodiments, the Cas9 nuclease has an inactive (e.g., inactivated) DNA cleavage domain, i.e., Cas9 is a nickase, referred to as a "nCas9" protein (for "nickase" Cas9). A nuclease-inactivated Cas9 protein may be interchangeably referred to as a "dCas9" protein (for nuclease-"dead" Cas9) or catalytically inactive Cas9. Methods for generating Cas9 proteins (or fragments thereof) with inactive DNA cleavage domains are known (see, e.g., Jinek et al, Science. 337:816-821(2012); Qi et al, "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression"(2013) Cell. 28; 152(5): 1173-83, the contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to contain two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, and the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can suppress the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al, Science. 337:816-821(2012); Qi et al, Cell. 28;152(5): 1173-83 (2013)).
[0293] In some embodiments, the dCas9 domain comprises an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to any of the dCas9 domains provided herein. In some embodiments, the Cas9 domain comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to any of the amino acid sequences described herein. In some embodiments, the Cas9 domain comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues compared to any of the amino acid sequences described herein.
[0294] In some embodiments, the dCas9 corresponds to or comprises a portion or all of a Cas9 amino acid sequence having one or more mutations that inactivate Cas9 nuclease activity. For example, in some embodiments, the dCas9 domain comprises D10A and H840A mutations or corresponding mutations in another Cas9.
[0295] In some embodiments, the dCas9 comprises the amino acid sequence of dCas9 (D10A and H840A): TIFF0007586601000011.tif163168 (single underline: HNH domain; double underline: RuvC domain)
[0296] In some embodiments, the Cas9 domain comprises a D10A mutation, while the residue at position 840 in the amino acid sequence provided above, or the residue at the corresponding position in any of the amino acid sequences provided herein, remains a histidine.
[0297] In other embodiments, dCas9 variants are provided that have mutations other than D10A and H840A, e.g., that result in nuclease-inactivated Cas9 (dCas9). Such mutations include, for example, other amino acid substitutions at D10 and H840, or other substitutions within the nuclease domain of Cas9 (e.g., substitutions in the HNH nuclease subdomain and / or the RuvC1 subdomain). In some embodiments, variants or homologs of dCas9 are provided that have at least about 70% identity, at least about 80% identity, at least about 90% identity, at least about 95% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, or at least about 99.9% identity. In some embodiments, variants of dCas9 are provided that have amino acid sequences that are shorter or longer by about 5 amino acids, about 10 amino acids, about 15 amino acids, about 20 amino acids, about 25 amino acids, about 30 amino acids, about 40 amino acids, about 50 amino acids, about 75 amino acids, about 100 amino acids or more.
[0298] In some embodiments, the Cas9 domain is a Cas9 nickase. The Cas9 nickase can be a Cas9 protein that can cleave only one strand of a double-stranded nucleic acid molecule (e.g., a double-stranded DNA molecule). In some embodiments, the Cas9 nickase cleaves the target strand of a double-stranded nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is base-paired (complementary) to the gRNA (e.g., sgRNA) that is bound to the Cas9. In some embodiments, the Cas9 nickase cleaves the non-target, non-base-edited strand of a double-stranded nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is not base-paired to the gRNA (e.g., sgRNA) that is bound to the Cas9. In some embodiments, the Cas9 nickase cleaves the non-target, non-base-edited strand of a double-stranded nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is not base-paired to the gRNA (e.g., sgRNA) that is bound to the Cas9. In some embodiments, the Cas9 nickase cleaves the H840A mutation and has an aspartic acid residue at position 10, or a corresponding mutation. In some embodiments, the Cas9 nickase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any of the Cas9 nickases provided herein. Additional suitable Cas9 nickases will be apparent to one of skill in the art based on this disclosure and knowledge in the art, and are within the scope of this disclosure.
[0299] The amino acid sequence of an exemplary catalytic Cas9 nickase (nCas9) is as follows:
[0300] In some embodiments, Cas9 refers to Cas9 from Archaea (e.g., Nanoarchaea), which constitute the domain and kingdom of unicellular prokaryotic microorganisms. In some embodiments, the programmable nucleotide-binding protein can be CasX or CasY protein, e.g., as described in Burstein et al., "New CRISPR-Cas systems from uncultivated microbes." Cell Res. 2017 Feb 21. doi: 10.1038 / cr.2017.21, the entire contents of which are incorporated herein by reference. Using genome-resolved metagenomics, many CRISPR-Cas systems have been identified, including the first reported Cas9 in the Archaea domain of life. This divergent Cas9 protein was discovered as part of an active CRISPR-Cas system in the little-studied Nanoarchaea. In bacteria, two previously unknown systems, CRISPR-CasX and CRISPR-CasY, have been discovered, which are among the most compact systems ever discovered. In some embodiments, in the base editor systems described herein, Cas9 is replaced by CasX or a variant of CasX. In some embodiments, in the base editor systems described herein, Cas9 is replaced by CasY or a variant of CasY. It should be understood that other RNA-guided DNA binding proteins can also be used as nucleic acid programmable DNA binding proteins (napDNAbp) and are within the scope of the present disclosure.
[0301] In some embodiments, the nucleic acid programmable DNA binding protein (napDNAbp) of any of the fusion proteins provided herein can be a CasX or CasY protein. In some embodiments, the napDNAbp is a CasX protein. In some embodiments, the napDNAbp is a CasY protein. In some embodiments, the napDNAbp comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to a naturally occurring CasX or CasY protein. In some embodiments, the programmable nucleotide binding protein is a naturally occurring CasX or CasY protein. In some embodiments, the programmable nucleotide binding protein comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to any CasX or CasY protein described herein. It should be understood that CasX and CasY from other bacterial species may also be used in accordance with the present disclosure.
[0302] In some embodiments, the Cas9 is Neisseria menigitidis Cas9 (NmeCas9) or a variant thereof. The characteristics and PAM sequences of NmeCas9 described in Edraki et al. Mol. Cell. (2019) 73(4): 714-726 are incorporated herein by reference in their entirety.
[0303] An exemplary amino acid sequence of Nme1Cas9 is provided below: type II CRISPR RNA-guided endonuclease Cas9 [Neisseria meningitidis] WP_002235162.1 1 maafkpnpin yilgldigia svgwamveid edenpiclid lgvrvferae vpktgdslam 61 arrlarsvrr ltrrrahrll rarrllkreg vlqaadfden glikslpntp wqlraaaldr 121 kltplewsav llhlikhrgy lsqrkneget adkelgallk gvadnahalq tgdfrtpael 181 alnkfekesg hirnqrgdys htfsrkdlqa elillfekqk efgnphvsgg lkegietllm 241 tqrpalsgda vqkmlghctf epaepkaakn tytaerfiwl tklnnlrile qgserpltdt 301 eratlmdepy rkskltyaqa rkllgledta ffkglrygkd naeastlmem kayhaisral 361 ekeglkdkks plnlspelqd eigtafslfk tdeditgrlk driqpeilea llkhisfdkf 421 vqislkalrr ivplmeqgkr ydeacaeiyg dhygkkntee kiylppipad eirnpvvlra 481 lsqarkving vvrrygspar ihietarevg ksfkdrkeie krqeenrkdr ekaaakfrey 541 fpnfvgepks kdilklrlye qqhgkclysg keinlgrlne kgyveidhal pfsrtwddsf 601 nnkvlvlgse nqnkgnqtpy eyfngkdnsr ewqefkarve tsrfprskkq rillqkfded 661 gfkernlndt ryvnrflcqf vadrmrltgk gkkrvfasng qitnllrgfw glrkvraend 721 rhhaldavvv acstvamqqk itrfvrykem nafdgktidk etgevlhqkt hfpqpweffa 781 qevmirvfgk pdgkpefeea dtpeklrtll aeklssrpea vheyvtplfv srapnrkmsg 841 qghmetvksa krldegvsvl rvpltqlklk dlekmvnrer epklyealka rleahkddpa 901 kafaepfyky dkagnrtqqv kavrveqvqk tgvwvrnhng iadnatmvrv dvfekgdkyy 961 lvpiyswqva kgilpdravv qgkdeedwql iddsfnfkfs lhpndlvevi tkkarmfgyf 1021 aschrgtgni nirihdldhk igkngilegi gvktalsfqk yqidelgkei rpcrlkkrpp 1081vr
[0304] An exemplary amino acid sequence of Nme2Cas9 is provided below: type II CRISPR RNA-guided endonuclease Cas9 [Neisseria meningitidis] WP_002230835.1 1 maafkpnpin yilgldigia svgwamveid eeenpirlid lgvrvferae vpktgdslam 61 arrlarsvrr ltrrrahrll rarrllkreg vlqaadfden glikslpntp wqlraaaldr 121 kltplewsav llhlikhrgy lsqrkneget adkelgallk gvannahalq tgdfrtpael <h2 style=";text-align:left;direction:ltr">181 alnkfekesg hirnqrgdys htfsrkdlqa elillfekqk efgnphvsgg lkegietllm<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 241 tqrpalsgda vqkmlghctf epaepkaakn tytaerfiwl tklnnlrile qgserpltdt<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 301 eratlmdepy rkskltyaqa rkllgledta ffkglrygkd naeastlmem kayhaisral<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 361 ekeglkdkks plnlsselqd eigtafslfk tdeditgrlk drvqpeilea llkhisfdkf<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 421 vqislkalrr ivplmeqgkr ydeacaeiyg dhygkkntee kiylppipad eirnpvvlra<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 481 lsqarkving vvrrygspar ihietarevg ksfkdrkeie krqeenrkdr ekaaakfrey<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 541 fpnfvgepks kdilklrlye qqhgkclysg keinlvrlne kgyveidhal pfsrtwddsf<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 601 nnkvlvlgse nqnkgnqtpy eyfngkdnsr ewqefkarve tsrfprskkq rillqkfded<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 661 gfkecnlndt ryvnrflcqf vadhilltgk gkrrvfasng qitnllrgfw glrkvraend<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 721 rhhaldavvv acstvamqqk itrfvrykem nafdgktidk etgkvlhqkt hfpqpweffa<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 781 qevmirvfgk pdgkpefeea dtpeklrtll aeklssrpea vheyvtplfv srapnrkmsg<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 841 ahkdtlrsak rfvkhnekis vkrvwlteik ladlenmvny kngreielye alkarleayg<h2 style=";text-align:left;direction:ltr"> 901 gnakqafdpk dnpfykkggq lvkavrvekt qesgvllnkk naytiadngd mvrvdvfckv 961 dkkgknqyfi vpiyawqvae nilpdidckg yriddsytfc fslhkydlia fqkdekskve 1021 fayyincdss ngrfylawhd kgskeqqfri stqnlvliqk yqvnelgkei rpcrlkkrpp 1081vr
[0305] In some embodiments, the Cas protein is CasX or CasY. An exemplary CasX ((uniprot.org / uniprot / F0NN87; uniprot.org / uniprot / F0NH53) tr|F0NN87|F0NN87_SULIH CRISPR-associated Casx protein OS = Sulfolobus islandicus (strain HVE10 / 4) GN = SiH_0402 PE=4 SV=1) amino acid sequence is as follows: MEVPLYNIFGDNYIIQVATEAENSTIYNNKVEIDDEELRNVLNLAYKIAKNNEDAAAERRGKAKKKKGEEGETTTSNIILPLSGNDKNPWTETLKCYNFPTTVALSEVFKNFSQVKECEEVSAPSFVKPEFYEFGRSPGMVERTRRVKLE VEPHYLIIAAAGWVLTRLGKAKVSEGDYVGVNVFTPTRGILYSLIQNVNGIVPGIKPETAFGLWIARKVVSSVTNPNVSVVRIYTISDAVGQNPTTINGGFSIDLTKLLEKRYLLSERLEAIARNALSISSNMRERYIVLANYIYEYLTG SKRLEDLLYFANRDLIMNLNSDDGKVRDLKLISAYVNGELIRGEG.
[0306] An exemplary CasX (>tr|F0NH53|F0NH53_SULIR CRISPR associated protein, Casx OS = Sulfolobus islandicus (strain REY15A) GN=SiRe_0771 PE=4 SV=1) amino acid sequence is as follows: MEVPLYNIFGDNYIIQVATEAENSTIYNNKVEIDDEELRNVLNLAYKIAKNNEDAAAERRGKAKKKKGEEGETTTSNIILPLSGNDKNPWTETLKCYNFPTTVALSEVFKNFSQVKCEEVSAPSFVKPEFYKFGRSPGMVERTRRVKLEVEPHYLIMAAAGWVLTRLGKAKV SEGDYVGVNVFTPTRGILYSLIQNVNGIVPGIKPETAFGLWIARKVVSSVTNPNVSVVSIYTISDAVGQNPTTINGGFSIDLTKLLEKRDLLSERLEAIARNALSISSNMRERYIVLANYIYEYLTGSKRLEDLLYFANRDLIMNLNSDDGKVRDLKLISAYVNGELIRGEG.
[0307] Deltaproteobacteria CasX MEKRINKIRKKLSADNATKPVSRSGPMKTLLVRVMTDDLKKRLEKRRKKPEVMPQVISNNAANNLRMLLDDYTKMKEAILQVYWQEFKDDHVGLMCKFAQPASKKIDQNKLKPEMDEKGNLTTAGFACSQCGQPLFVYKLEQVSEKGKAYTNYFGRCNVAEHEKLILLAQLKPVKDSDEAVTYSLGKFGQRALDFYSIHVTKESTHPVKPLAQIAGNRYASGPVGKALSDACMGTIASFLSKYQDIIIEHQKVVKGNQKRLESLRELAGKENLEYPSVTLPPQPHTKEGVDfAYNEVIARVRMWVNLLWQKLKLSRDDAKPLLRLKGFPSFPVVERRENEVDWWNTINEVKKLIDAKRDMGRVFWSGVTAEKRNTILEGYNYLPNENDHKKREGSLENPKKPAKRQFGDLLLYLEKKYAGDWGKVFDEAWERIDKKIAGLTSHIEREEARNAEDAQSKAVLTDWLRAKASFVLERLKEMDEKEFYACEIQLQ KWYGDLRGNPFAVEAENRVVDISGFSIGSDGHSIQYRNLLAWKYLENGKREFYLLMNYGKKGRIRFTDGTDIKKSGKWQGLLYGGGGKAKVIDLTFDPDDEQLIILPLAFGTRQGREFIWNDLLSLETGLIKLANGRVIEKTIYNKKIGRDEPALFVALTFERREVVDPSNIKPVNLIGVARGENIPAVIALTDPEGCPLPEFKDSSGGPTDILRIGEGYKEKQRAIQAAKEVEQRRAGGYSRKFASKSRNLADDMVRNSARDLFYHAVTHDAVLVFANLSRGFGRQGKRTFMTERQYTKMEDWLTAKLAYEGLTSKTYLSKTLAQYTSKTCSNCGFTITYADMDVMLVRLKKTSDGWATTLNNKELKAEYQITYYNRYKRQTVEKELSAELDRLSEESGNNDISKWTKGRRDEALFLLKKRFSHRPVQEQFVCLDCGHEVHAAEQAALNIARSWLFLNSNSTEFKSYKSGKQPFVGAWQAFYKRRLKEVWKPNA
[0308] An exemplary CasY ((ncbi.nlm.nih.gov / protein / APG80656.1) >APG80656.1 CRISPR-associated protein CasY [uncultured Parcubacteria group bacterium]) amino acid sequence is as follows:
[0309] The Cas9 nuclease has two functional endonuclease domains, RuvC and HNH. Upon binding to target DNA, Cas9 undergoes a conformational change that positions the nuclease domain to cleave the opposite strand of the target DNA. The end result of Cas9-mediated DNA cleavage is a double-strand break (DSB) in the target DNA (approximately 3-4 nucleotides upstream of the PAM sequence). The resulting DSB can be repaired by one of two general repair pathways: (1) the efficient but error-prone non-homologous end joining (NHEJ) pathway; or (2) the less efficient but high-fidelity homology-guided repair (HDR) pathway.
[0310] The "efficiency" of non-homologous end joining (NHEJ) and / or homology directed repair (HDR) can be calculated by any convenient method. For example, in an embodiment, the efficiency can be expressed as a percentage of successful HDR. For example, a test nuclease assay can be used to generate cleavage products, and the ratio of products to substrate can be used to calculate the percentage. For example, a test nuclease enzyme can be used that directly cleaves the DNA containing the newly incorporated restriction sequence as a result of successful HDR. More substrates cleaved indicates a higher rate of HDR (more efficient HDR). As an illustrative example, the rate (percentage) of HDR can be calculated using the following formula [(cleavage products) / (substrate+cleavage products)] (e.g., (b+c) / (a+b+c) where "a" is the band intensity of the DNA substrate and "b" and "c" are the cleavage products).
[0311] In one embodiment, efficiency can be expressed as the success rate of NHEJ. For example, a T7 endonuclease I assay can be used to generate cleavage products, and the ratio of products to substrates can be used to calculate the percentage of NHEJ. T7 endonuclease I cleaves mismatched heteroduplex DNA resulting from hybridization of wild-type and mutant DNA strands (NHEJ produces small random insertions or deletions (indels) at the site of the initial cleavage). More cleavage indicates a higher rate of NHEJ (higher efficiency of NHEJ). As an illustrative example, the rate (percentage) of NHEJ can be calculated using the formula (1-(1-(b+c) / (a+b+c)) 1 / 2 ) × 100, where "a" is the band intensity of the DNA substrate and "b" and "c" are the cleavage products (Ran et. al., Cell. 2013 Sep. 12; 154(6):1380-9; and Ran et al., Nat Protoc. 2013 Nov.; 8(11): 2281-2308).
[0312] The NHEJ repair pathway is the most active repair mechanism, frequently causing small nucleotide insertions or deletions (indels) at DSB sites. The random nature of NHEJ-mediated DSB repair has important practical implications, as a cell population expressing Cas9 and gRNA or guide polynucleotide can result in an array of diverse mutations. In most embodiments, NHEJ generates small indels in the target DNA, resulting in amino acid deletions, insertions, or frameshift mutations that result in premature stop codons in the open reading frame (ORF) of the target gene. The ideal end result is a loss-of-function mutation in the target gene.
[0313] While NHEJ-mediated DSB repair often disrupts the open reading frame of a gene, homology-directed repair (HDR) can be used to generate specific nucleotide changes ranging from single nucleotide changes to larger insertions such as the addition of fluorophores or tags.
[0314] To utilize HDR for gene editing, a DNA repair template containing the desired sequence can be delivered to a cell type of interest along with gRNA and Cas9 or Cas9 nickase. The repair template can contain additional homologous sequences immediately upstream and downstream (called left and right homologous arms) of the desired edit as well as its target. The length of each homologous arm can depend on the magnitude of the change to be introduced, with larger insertions requiring longer homologous arms. The repair template can be a single-stranded oligonucleotide, a double-stranded oligonucleotide, or a double-stranded DNA plasmid. The efficiency of HDR is generally low (less than 10% corrected alleles), even in cells expressing Cas9, gRNA, and an exogenous repair template. Because HDR occurs between the S and G2 phases of the cell cycle, the efficiency of HDR can be increased by synchronizing the cells. Chemical or genetic inhibition of genes involved in NHEJ can also increase HDR frequency.
[0315] In some embodiments, Cas9 is a modified Cas9. A given gRNA target sequence may have additional sites with partial homology throughout the genome. These sites are called off-targets and need to be considered when designing gRNA, but in addition to optimizing gRNA design, Cas9 can also be modified to increase CRISPR specificity. Cas9 generates double-strand breaks (DSBs) through the combined activity of two nuclease domains, RuvC and HNH. Cas9 nickase, the D10A mutant of SpCas9, retains one nuclease domain and generates DNA nicks instead of DSBs. Nickase can also be combined with HDR-mediated gene editing for specific gene editing.
[0316] In some embodiments, the Cas9 is a variant Cas9 protein. The variant Cas9 polypeptide has an amino acid sequence that differs by one amino acid (e.g., has a deletion, insertion, substitution, fusion) compared to the amino acid sequence of the wild-type Cas9 protein. In some examples, the variant Cas9 polypeptide has an amino acid change (e.g., a deletion, insertion, or substitution) that reduces the nuclease activity of the Cas9 polypeptide. For example, in some examples, the variant Cas9 polypeptide has less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the nuclease activity of the corresponding wild-type Cas9 protein. In some embodiments, the variant Cas9 protein does not have substantial nuclease activity. When the subject Cas9 protein is a variant Cas9 protein that does not have substantial nuclease activity, it can be referred to as "dCas9".
[0317] In some embodiments, the variant Cas9 protein has reduced nuclease activity, for example, the variant Cas9 protein exhibits less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or less than about 0.1% of the endonuclease activity of a wild-type Cas9 protein (e.g., a wild-type Cas9 protein).
[0318] In some embodiments, the variant Cas9 protein can cleave the complementary strand of the guide target sequence, but has a reduced ability to cleave the non-complementary strand of the double-stranded guide target sequence. For example, the variant Cas9 protein can have a mutation (amino acid substitution) that reduces the function of the RuvC domain. As a non-limiting example, in some embodiments, the variant Cas9 protein has D10A (aspartic acid to alanine at amino acid position 10), and thus can cleave the complementary strand of the double-stranded guide target sequence, but has a reduced ability to cleave the non-complementary strand of the double-stranded guide target sequence (and thus, when the variant Cas9 protein cleaves the double-stranded target nucleic acid, it generates a single-strand break (SSB) instead of a double-strand break (DSB)) (see, for example, Jinek et al., Science. 2012 Aug. 17; 337(6096):816-21).
[0319] In some embodiments, the variant Cas9 protein can cleave the non-complementary strand of the double-stranded guide target sequence, but has a reduced ability to cleave the complementary strand of the guide target sequence. For example, the variant Cas9 protein can have a mutation (amino acid substitution) that reduces the function of the HNH domain (RuvC / HNH / RuvC domain motif). As a non-limiting example, in some embodiments, the variant Cas9 protein has a H840A (histidine to alanine at amino acid position 840) mutation, and thus can cleave the non-complementary strand of the guide target sequence, but has a reduced ability to cleave the complementary strand of the guide target sequence (so that when the variant Cas9 protein cleaves the double-stranded guide target sequence, an SSB occurs instead of a DSB). Such a Cas9 protein has a reduced ability to cleave the guide target sequence (e.g., a single-stranded guide target sequence), but retains the ability to bind to the guide target sequence (e.g., a single-stranded guide target sequence).
[0320] In some embodiments, the variant Cas9 protein has a reduced ability to cleave both complementary and non-complementary strands of double-stranded target DNA.As a non-limiting example, in some embodiments, the variant Cas9 protein has both D10A and H840A mutations, so that the polypeptide has a reduced ability to cleave both complementary and non-complementary strands of double-stranded target DNA.Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA), but retain the ability to bind to target DNA (e.g., single-stranded target DNA).
[0321] As another non-limiting example, in some embodiments, a variant Cas9 protein has a W476A and a W1126A mutation such that the polypeptide has a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retains the ability to bind to target DNA (e.g., single-stranded target DNA).
[0322] As another non-limiting example, in some embodiments, a variant Cas9 protein has P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations such that the polypeptide has a reduced ability to cleave target DNA. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA).
[0323] As another non-limiting example, in some embodiments, a variant Cas9 protein has H840A, W476A, and W1126A mutations, such that the polypeptide has a reduced ability to cleave target DNA (e.g., single-stranded target DNA), but retains the ability to bind to target DNA (e.g., single-stranded target DNA). As another non-limiting example, in some embodiments, a variant Cas9 protein has H840A, D10A, W476A, and W1126A mutations, such that the polypeptide has a reduced ability to cleave target DNA. Such a Cas9 protein has a reduced ability to cleave target DNA (e.g., single-stranded target DNA), but retains the ability to bind to target DNA (e.g., single-stranded target DNA). In some embodiments, a variant Cas9 has a restored catalytic His residue at position 840 of the Cas9 HNH domain (A840H).
[0324] As another non-limiting example, in some embodiments, the variant Cas9 protein has H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations, such that the polypeptide has a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retains the ability to bind to target DNA (e.g., single-stranded target DNA). As another non-limiting example, in some embodiments, the variant Cas9 protein has D10A, H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations, such that the polypeptide has a reduced ability to cleave target DNA. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA). In some embodiments, when the variant Cas9 protein has W476A and W1126A mutations, or when the variant Cas9 protein has P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations, the variant Cas9 protein does not bind efficiently to the PAM sequence. Thus, in some such embodiments, when such variant Cas9 protein is used in a method of binding, the method does not require a PAM sequence. In other words, in some embodiments, when such variant Cas9 protein is used in a method of binding, the method may include a guide RNA, but the method can be performed in the absence of a PAM sequence (therefore, the specificity of binding is provided by the target segment of the guide RNA). To achieve the above effect, other residues can be mutated (i.e., inactivate one or the other nuclease part). As non-limiting examples, residues D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and / or A987 can be altered (i.e., substituted). Mutations other than alanine substitutions are also suitable.
[0325] In some embodiments, a variant Cas9 protein with reduced catalytic activity (e.g., when the Cas9 protein has D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and / or A987 mutations, such as D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A, and / or D986A) can bind to the target DNA in a site-specific manner, as long as it retains the ability to interact with the guide RNA (since it is guided to the target DNA sequence by the guide RNA).
[0326] In some embodiments, the variant Cas protein can be spCas9, spCas9-VRQR, spCas9-VRER, xCas9 (sp), saCas9, saCas9-KKH, spCas9-MQKSER, spCas9-LRKIQK, or spCas9-LRVSQL.
[0327] In some embodiments, a modified SpCas9 was used that contains the amino acid substitutions D1135M, S1136Q, G1218K, E1219F, A1322R, D1332A, R1335E, and T1337R (SpCas9-MQKFRAER) and has specificity for a modified PAM5'-NGC-3'.
[0328] Alternatives to S. pyogenes Cas9 could include RNA-guided endonucleases from the Cpf1 family that show cleavage activity in mammalian cells. CRISPR from Prevotella and Francisella 1 (CRISPR / Cpf1) is a DNA editing technology similar to the CRISPR / Cas9 system. Cpf1 is an RNA-guided endonuclease of a class II CRISPR / Cas system. This adaptive immunity mechanism is found in Prevotella and Francisella bacteria. The Cpf1 gene is associated with the CRISPR locus and encodes an endonuclease that uses guide RNA to find and cleave viral DNA. Cpf1 is a smaller and simpler endonuclease than Cas9, overcoming some of the limitations of the CRISPR / Cas9 system. Unlike Cas9 nuclease, the result of Cpf1-mediated DNA cleavage is a double-stranded break with a short 3' overhang. The staggered cleavage pattern of Cpf1 can open up the possibility of directional gene transfer, similar to traditional restriction enzyme cloning, which may increase the efficiency of gene editing. Similar to the Cas9 variants and orthologues mentioned above, Cpf1 can also expand the number of sites that CRISPR can target to AT-rich regions or AT-rich genomes that lack the NGG PAM sites preferred by SpCas9. The Cpf1 locus contains an α / β mixed domain, a RuvC-I followed by a helical region, a RuvC-II and a zinc finger-like domain. The Cpf1 protein has a RuvC-like endonuclease domain similar to the RuvC domain of Cas9. In addition, Cpf1 does not have the HNH endonuclease region, and the N-terminus of Cpf1 does not have the α-helical recognition lobe of Cas9. The Cpf1 CRISPR-Cas domain organization showed that Cpf1 is functionally unique and classified as a class 2, type V CRISPR system. The Cpf1 locus encoded Cas1, Cas2 and Cas4 proteins that were more similar to type I and III systems than to type II systems. Functional Cpf1 does not require trans-activating CRISPR RNA (tracrRNA); therefore, it only requires CRISPR (crRNA).This is beneficial for genome editing because Cpf1 is not only smaller than Cas9 but also has a smaller sgRNA molecule (approximately half the number of nucleotides as Cas9). In contrast to the G-rich PAM targeted by Cas9, the Cpf1-crRNA complex cleaves the target DNA or RNA by identification of a protospacer adjacent to the motif 5'-YTN-3'. After identification of the PAM, Cpf1 introduces a sticky-end-like DNA double-strand break with a 4- or 5-nucleotide overhang.
[0329] [Cas12 domain of nucleobase editor] Microbial CRISPR-Cas systems are usually divided into class 1 and class 2 systems. Class 1 systems have a multisubunit effector complex, whereas class 2 systems have a single protein effector. For example, Cas9 and Cpf1 are class 2 effectors, albeit of different types (type II and type V, respectively). In addition to Cpf1, class 2, type V CRISPR-Cas systems also contain Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i. See, e.g., Shmakov et al., "Discovery and Functional Characterization of Diverse Class 2 CRISPR Cas Systems," Mol. Cell, 2015 Nov. 5; 60(3): 385-397; Makarova et al., "Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?" CRISPR Journal, 2018, 1(5): 325-336; and Yan et al., "Functionally Diverse Type V CRISPR-Cas Systems," Science, 2019 Jan. 4; 363: 88-91; the entire contents of each of which are incorporated herein by reference. Type V Cas proteins contain a RuvC (or RuvC-like) endonuclease domain. The production of mature CRISPR RNA (crRNA) is generally independent of tracrRNA, but for example, Cas12b / C2c1 requires tracrRNA for the production of crRNA. Cas12b / C2c1 depends on both crRNA and tracrRNA for DNA cleavage.
[0330] The nucleic acid programmable DNA binding proteins contemplated by the present invention include Cas proteins classified as class 2, type V (Cas12 proteins). Non-limiting examples of Cas class 2, type V proteins include Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i, their homologs, or modified versions thereof. As used herein, Cas12 proteins may also be referred to as Cas12 nuclease, Cas12 domain, or Cas12 protein domain. In some embodiments, the Cas12 proteins of the present invention comprise an amino acid sequence interrupted by an internally fused protein domain, such as a deaminase domain.
[0331] In some embodiments, the Cas12 domain is a nuclease-inactive Cas12 domain or a Cas12 nickase. In some embodiments, the Cas12 domain is a nuclease-active domain. For example, the Cas12 domain can be a Cas12 domain that nicks one strand of a double-stranded nucleic acid (e.g., a double-stranded DNA molecule). In some embodiments, the Cas12 domain comprises any one of the amino acid sequences described herein. In some embodiments, the Cas12 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences described herein. In some embodiments, the Cas12 domain comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to any one of the amino acid sequences described herein. In some embodiments, the Cas12 domain comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues compared to any one of the amino acid sequences described herein.
[0332] In some embodiments, a protein is provided that comprises a fragment of Cas12. For example, in some embodiments, the protein comprises one of the following two Cas12 domains: (1) the gRNA binding domain of Cas12, or (2) the DNA cleavage domain of Cas12. In some embodiments, a protein that comprises Cas12 or a fragment thereof is referred to as a "Cas12 variant." A Cas12 variant shares homology with Cas12 or a fragment thereof. For example, a Cas12 variant is at least about 70% identical to wild-type Cas12, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical. In some embodiments, the Cas12 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to wild-type Cas12. In some embodiments, a Cas12 variant comprises a fragment of Cas12 (e.g., a gRNA binding domain or a DNA cleavage domain) such that the fragment has at least about 70% identity, at least about 80% identity, at least about 90% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, or at least about 99.9% identity to the corresponding fragment of wild-type Cas12.In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of the corresponding wild-type Cas12. In some embodiments, the fragment is at least 100 amino acids in length. In some embodiments, fragments are at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length.
[0333] In some embodiments, Cas12 corresponds to or includes a portion or the entirety of a Cas12 amino acid sequence with one or more mutations that alter Cas12 nuclease activity. Such mutations include, by way of example, amino acid substitutions within the RuvC nuclease domain of Cas12. In some embodiments, variants or homologs of Cas12 are provided that are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild-type Cas12. In some embodiments, variants of Cas12 are provided that have amino acid sequences that are shorter or longer by about 5 amino acids, about 10 amino acids, about 15 amino acids, about 20 amino acids, about 25 amino acids, about 30 amino acids, about 40 amino acids, about 50 amino acids, about 75 amino acids, about 100 amino acids, or more.
[0334] In some embodiments, the Cas12 fusion proteins provided herein comprise the full-length amino acid sequence of a Cas12 protein, e.g., one of the Cas12 sequences provided herein. However, in other embodiments, the fusion proteins provided herein do not comprise the full-length Cas12 sequence, but only one or more fragments thereof. Exemplary amino acid sequences of suitable Cas12 domains are provided herein, and additional suitable sequences of Cas12 domains and fragments will be apparent to one of skill in the art.
[0335] Generally, Class 2, Type V Cas proteins have a single functional RuvC endonuclease domain (see, e.g., Chen et al., "CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity," Science 360:436-439 (2018)). In some cases, the Cas12 protein is a variant Cas12b protein. (See, Strecker et al., Nature Communications, 2019, 10(1): Art. No.: 212). In one embodiment, a variant Cas12 polypeptide has an amino acid sequence that differs by 1, 2, 3, 4, 5 or more amino acids (e.g., has a deletion, insertion, substitution, fusion) when compared to the amino acid sequence of a wild-type Cas12 protein. In some cases, a variant Cas12 polypeptide has an amino acid change (e.g., a deletion, insertion, or substitution) that reduces the activity of the Cas12 polypeptide. For example, in some cases, a variant Cas12 is a Cas12b polypeptide that has less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the nickase activity of a corresponding wild-type Cas12b protein. In some cases, a variant...
Claims
1. 1. A pharmaceutical composition for treating a neurological disorder in a subject, comprising: (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same; the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain; the adenosine deaminase domain comprises a V82S modification at or corresponding to amino acid position 82 in the numbering of SEQ ID NO:2; wherein the guide polynucleotide induces the adenosine base editor to effect an A to G nucleobase modification in a target gene or a regulatory element thereof associated with the neurological disorder, thereby treating the neurological disorder, i) the target gene is the alpha-L-iduronidase (IDUA) gene and the neurological disorder is Hurler syndrome; or ii) the target gene is the leucine-rich repeat kinase 2 (LRRK2) gene and the neurological disorder is Parkinson's disease; or iii) the target gene is the methyl-CpG binding protein 2 (MECP2) gene and the neurological disorder is Rett syndrome; or iv) the target gene is the ATP-binding cassette subfamily member 4 (ABCA4) gene and the neurological disorder is Stargardt's disease; Pharmaceutical compositions.
2. (i) the IDUA gene or a regulatory element thereof contains a SNP associated with Hurler syndrome; or (ii) the LRRK2 gene or a regulatory element thereof contains a SNP associated with Parkinson's disease; or (iii) the MECP2 gene or a regulatory element thereof contains a SNP associated with Rett Syndrome; or (iv) the ABCA4 gene or a regulatory element thereof contains a SNP associated with Stargardt disease; The pharmaceutical composition of claim 1.
3. 3. The pharmaceutical composition of claim 2, wherein the A to G nucleobase modification is in a SNP associated with Hurler syndrome, Parkinson's disease, Rett syndrome, or Stargardt disease.
4. (i) the Hurler syndrome-associated SNP results in a W402X or W401X amino acid variant in the IDUA polypeptide as numbered in SEQ ID NO:4, or a variant thereof encoded by the IDUA gene, where X is a stop codon; or (ii) the SNP associated with Parkinson's disease results in an A419V, R1441C, R1441H, or G2019S amino acid variant in the LRRK2 polypeptide as numbered in SEQ ID NO:3, or a variant thereof encoded by the LRRK2 gene; or (iii) the Rett Syndrome-associated SNP results in a R106W or T158M amino acid variant in an MECP2 polypeptide as numbered in SEQ ID NO:5, or a variant thereof encoded by the MECP2 gene; or (iv) the SNP associated with Stargardt disease results in an A1038V or G1961E amino acid variant in the ABCA4 polypeptide as numbered in SEQ ID NO: 6, or a variant thereof encoded by the ABCA4 gene; The pharmaceutical composition according to claim 2 or 3.
5. 3. The pharmaceutical composition of claim 2, wherein the A to G nucleobase modification changes a SNP associated with Hurler syndrome, Parkinson's disease, Rett syndrome, or Stargardt disease to a wild-type nucleobase.
6. 3. The pharmaceutical composition of claim 2, wherein the A to G nucleobase modification changes the SNP associated with Hurler Syndrome to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Hurler Syndrome.
7. The pharmaceutical composition of claim 2, wherein the A to G modification in the SNP associated with Hurler syndrome changes the stop codon encoded by the IDUA gene to tryptophan in the IDUA polypeptide.
8. The guide polynucleotide the group consisting of 5′- GACUCUAGGCAGAGGUCUCAA -3′, 5′- ACUCUAGGCAGAGGUCUCAA-3′, 5′- CUCUAGGCCGAAGUGUCGC -3′, and 5′-GCUCUAGGCCGAAGUGUCGC-3′ for Hurler syndrome; the group consisting of 5′-AAGCGCAAGCCUGGAGGGAA -3′, 5′-ACUACAGCAUUGCUCAGUAC-3′ for Parkinson's disease; the group consisting of 5′- CUUUUCACUUCCUGCCGGGG-3′, 5′-AGCUUCCAUGUCCAGCCUUC-3′, 5′- ACCAUGAAGUCAAAAUCAUU-3′, and 5′- GCUUUCAGCCCCGUUUCUUG-3′ for Rett syndrome; and 5′-CUCCAGGGCGAACUUCGACACACAGC-3′ for Stargardt disease The pharmaceutical composition according to any one of claims 1 to 7, which is an sgRNA comprising a nucleic acid sequence selected from the following:
9. a) the A to G nucleobase modification changes a cysteine or histidine to an arginine in an LRRK2 polypeptide encoded by the LRRK2 gene; or b) said A to G nucleobase modification changes a serine to a glycine in the LRRK2 polypeptide encoded by the LRRK2 gene; or c) the A to G nucleobase modification substitutes arginine for cysteine or histidine at position 144 or substitutes glycine for serine at position 2019 of the LRRK2 polypeptide or a variant thereof encoded by the LRRK2 gene as numbered in SEQ ID NO: 3; The pharmaceutical composition according to claim 2.
10. a) the Rett Syndrome-associated SNP results in a R255X or R270X amino acid variant in an MECP2 polypeptide encoded by the MECP2 gene, where X is a stop codon; or b) the A to G nucleobase alteration in a SNP associated with Rett Syndrome changes a stop codon to a tryptophan in the MECP2 polypeptide; The pharmaceutical composition according to claim 2.
11. 1. An in vitro or ex vivo method of editing a target gene or a regulatory element thereof associated with a neurological disorder, comprising contacting the target gene or a regulatory element thereof with (i) an adenosine base editor and (ii) a guide polynucleotide; the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain; the adenosine deaminase domain comprises a V82S amino acid substitution at or corresponding to amino acid position 82 in the numbering of SEQ ID NO:2; wherein the guide polynucleotide directs the adenosine base editor to effect an A to G nucleobase modification in a target gene associated with the neurological disorder or a regulatory element thereof, i) the target gene is the alpha-L-iduronidase (IDUA) gene and the neurological disorder is Hurler syndrome; or ii) the target gene is the leucine-rich repeat kinase 2 (LRRK2) gene and the neurological disorder is Parkinson's disease; or iii) the target gene is the methyl-CpG binding protein 2 (MECP2) gene and the neurological disorder is Rett syndrome; or iv) the target gene is the ATP-binding cassette subfamily member 4 (ABCA4) gene and the neurological disorder is Stargardt's disease; method.
12. a) the A to G nucleobase modification changes the SNP associated with the neurological disorder to a wild-type nucleobase; or b) the A to G nucleobase alteration changes the SNP associated with the neuropathy to a non-wild-type nucleobase that results in amelioration of one or more symptoms of the neuropathy. The method of claim 11.
13. An in vitro or ex vivo method for editing a Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) gene or a regulatory element thereof, comprising contacting the LRRK2 gene or a regulatory element thereof with: (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same; the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain; the adenosine deaminase domain comprises a V82S modification at or corresponding to amino acid position 82 in the numbering of SEQ ID NO:2; wherein said guide polynucleotide directs said adenosine base editor to result in an A to G nucleobase alteration at a SNP in the LRRK2 gene, and said SNP does not encode a G2019S mutation in an LRRK2 polypeptide as numbered in SEQ ID NO:3, or a variant thereof.
14. The method of claim 13 , wherein the contacting occurs intracellularly.
15. the adenosine deaminase domain further comprises an amino acid substitution at or corresponding to amino acid position 166 in the numbering of SEQ ID NO:2; and / or The guide polynucleotide is an sgRNA comprising the nucleic acid sequence 5'-AAGCGCAAGCCUGGAGGGAA-3' or 5'-ACUACAGCAUUGCUCAGUAC-3'; 15. The method according to claim 13 or 14. (i) the SNP results in an A419V, R1441C, R1441H, or G2019S amino acid variant in the LRRK2 polypeptide as numbered in SEQ ID NO:3, or a variant thereof encoded by the LRRK2 gene; or (ii) the A to G nucleobase modification changes a cysteine or histidine to an arginine in the LRRK2 polypeptide encoded by the LRRK2 gene; or (iii) the A to G nucleobase modification changes a serine to a glycine in an LRRK2 polypeptide encoded by the LRRK2 gene; or (iv) the A to G nucleobase modification replaces the cysteine or histidine at position 144 with arginine or replaces the serine at position 2019 with glycine of the LRRK2 polypeptide or a variant thereof encoded by the LRRK2 gene as numbered in SEQ ID NO: 3; The method according to any one of claims 13 to 15.
17. An in vitro or ex vivo method for editing an alpha-L-iduronidase (IDUA) gene associated with Hurler syndrome, or a regulatory element thereof, comprising contacting the IDUA gene, or a regulatory element thereof, with: (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same; the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain; the adenosine deaminase domain comprises a V82S amino acid substitution at or corresponding to amino acid position 82 in the numbering of SEQ ID NO:2; the guide polynucleotide induces the adenosine base editor to effect an A to G nucleobase modification in the IDUA gene or a regulatory element thereof; method.
18. The method of claim 17 , wherein the contacting occurs intracellularly.
19. (i) the IDUA gene or a regulatory element thereof contains a SNP associated with Hurler syndrome; or (ii) the A to G nucleobase alteration is in a SNP associated with Hurler syndrome; or (iii) the IDUA gene or a regulatory element thereof contains a SNP associated with Hurler syndrome that results in a W402X or W401X amino acid variant in the IDUA polypeptide or a variant thereof encoded by the IDUA gene, as numbered in SEQ ID NO:4, where X is a stop codon; or (iv) the IDUA gene or a regulatory element thereof comprises a SNP associated with Hurler syndrome, and the A to G nucleobase modification changes the SNP associated with Hurler syndrome to a wild-type nucleobase; or (v) the IDUA gene or a regulatory element thereof contains a SNP associated with Hurler Syndrome, and the A to G nucleobase modification changes the SNP associated with Hurler Syndrome to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Hurler Syndrome; or (vi) the IDUA gene or a regulatory element thereof contains a SNP associated with Hurler syndrome, and the A to G modification in the SNP associated with Hurler syndrome changes a stop codon encoded by the IDUA gene to tryptophan in the IDUA polypeptide; or (vii) the IDUA gene or a regulatory element thereof comprises a SNP associated with Hurler syndrome, and the guide polynucleotide comprises a nucleic acid sequence complementary to the IDUA gene or a regulatory element thereof comprising a SNP associated with Hurler syndrome; or (viii) the IDUA gene, or a regulatory element thereof, comprises a SNP associated with Hurler Syndrome, and the adenosine base editor is complexed with a single guide RNA comprising a nucleic acid sequence that is complementary to the IDUA gene, or a regulatory element thereof, that comprises a SNP associated with Hurler Syndrome; or (ix) the guide polynucleotide is an sgRNA comprising a nucleic acid sequence selected from the group consisting of 5'-GACUCUAGGCAGAGGUCUCAA-3', 5'-ACUCUAGGCAGAGGUCUCAA-3', 5'-CUCUAGGCCGAAGUGUCGC-3', and 5'-GCUCUAGGCCGAAGUGUCGC-3'; 19. The method of claim 17 or 18.
20. An in vitro or ex vivo method for editing a Rett syndrome-associated methyl-CpG binding protein 2 (MECP2) gene or a regulatory element thereof, comprising contacting the MECP2 gene or a regulatory element thereof with (i) an adenosine base editor, or a nucleic acid sequence encoding same, and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same; the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain; the adenosine deaminase domain comprises a V82S modification at or corresponding to amino acid position 82 in the numbering of SEQ ID NO:2; the guide polynucleotide directs the adenosine base editor to effect an A to G nucleobase modification in the MECP2 gene or a regulatory element thereof. method.
21. 21. The method of claim 20, wherein the contacting occurs intracellularly.
22. (i) the MECP2 gene or a regulatory element thereof contains a SNP associated with Rett Syndrome; and / or (ii) the MECP2 gene or a regulatory element thereof comprises a SNP associated with Rett Syndrome, and the A to G nucleobase alteration is in a SNP associated with Rett Syndrome; and / or (iii) the MECP2 gene or a regulatory element thereof comprises a SNP associated with Rett Syndrome, wherein the SNP associated with Rett Syndrome results in a R106W or T158M amino acid variant in an MECP2 polypeptide, or a variant thereof encoded by the MECP2 gene, as numbered in SEQ ID NO:5; or results in a R255X or R270X amino acid variant in an MECP2 polypeptide encoded by the MECP2 gene, where X is a stop codon; and / or (iv) the MECP2 gene or a regulatory element thereof comprises a SNP associated with Rett Syndrome, and the A to G nucleobase modification changes the SNP associated with Rett Syndrome to a wild-type nucleobase; and / or (v) the MECP2 gene or a regulatory element thereof comprises a SNP associated with Rett Syndrome, and the A to G nucleobase modification changes the SNP associated with Rett Syndrome to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Rett Syndrome; and / or (vi) the MECP2 gene or a regulatory element thereof comprises a SNP associated with Rett Syndrome, and the A to G nucleobase alteration in the SNP associated with Rett Syndrome changes a stop codon to tryptophan in an MECP2 polypeptide; and / or (vii) the MECP2 gene or a regulatory element thereof comprises a SNP associated with Rett Syndrome, and the guide polynucleotide comprises a nucleic acid sequence complementary to the MECP2 gene or a regulatory element thereof comprising a SNP associated with Rett Syndrome; and / or (viii) the MECP2 gene, or a regulatory element thereof, comprises a SNP associated with Rett Syndrome, and the adenosine base editor is complexed with a single guide RNA comprising a nucleic acid sequence that is complementary to the MECP2 gene, or a regulatory element thereof, that comprises a SNP associated with Rett Syndrome; and / or (ix) the guide polynucleotide comprises a nucleic acid sequence selected from the group consisting of 5'-CUUUUCACUUCCUGCCGGGG-3', 5'-AGCUUCCAUGUCCAGCCUUC-3', 5'-ACCAUGAAGUCAAAAUCAUU-3', and 5'-GCUUUCAGCCCCGUUUCUUG-3'; 22. The method of claim 20 or 21.
23. An in vitro or ex vivo method for editing a Stargardt disease-associated ATP-binding cassette subfamily member 4 (ABCA4) gene or a regulatory element thereof, comprising contacting the ABCA4 gene or a regulatory element thereof with: (i) an adenosine base editor, or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide, or a nucleic acid sequence encoding same; the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain; the adenosine deaminase domain comprises a V82S amino acid substitution at or corresponding to amino acid position 82 in the numbering of SEQ ID NO:2; the guide polynucleotide induces the adenosine base editor to effect an A to G nucleobase modification in the ABCA4 gene or a regulatory element thereof. method.
24. 24. The method of claim 23, wherein the contacting occurs intracellularly.
25. (i) the ABCA4 gene contains a SNP associated with Stargardt disease; and / or (ii) the ABCA4 gene comprises a SNP associated with Stargardt disease, and the A to G nucleobase modification is in the SNP associated with Stargardt disease; and / or (iii) the ABCA4 gene contains a SNP associated with Stargardt disease, the SNP associated with Stargardt disease resulting in an A1038V or G1961E amino acid variant in the ABCA4 polypeptide, as numbered in SEQ ID NO: 6, or a variant thereof encoded by the ABCA4 gene; and / or (iv) the ABCA4 gene contains a SNP associated with Stargardt disease, and said A to G nucleobase modification changes the SNP associated with Stargardt disease to a wild-type nucleobase; and / or (v) the ABCA4 gene contains a SNP associated with Stargardt disease, and said A to G nucleobase modification changes the SNP associated with Stargardt disease to a non-wild-type nucleobase that results in amelioration of one or more symptoms of Stargardt disease; and / or (vi) the ABCA4 gene comprises a SNP associated with Stargardt disease, and the guide polynucleotide comprises a nucleic acid sequence complementary to the ABCA4 gene or a regulatory element thereof comprising the SNP associated with Stargardt disease; and / or (vii) the ABCA4 gene comprises a SNP associated with Stargardt disease, and the adenosine base editor is complexed with a single guide RNA comprising a nucleic acid sequence complementary to the ABCA4 gene or a regulatory element thereof that comprises the SNP associated with Stargardt disease; and / or (viii) the guide polynucleotide is an sgRNA comprising the sequence 5'-CUCCAGGGCGAACUUCGACACACAGC-3'; 25. The method of claim 23 or 24.
26. A cell produced by the method of any one of claims 11 to 25.
27. A base editor system comprising: (i) an adenosine base editor or a nucleic acid sequence encoding same; and (ii) a guide polynucleotide or a nucleic acid sequence encoding same, the adenosine base editor comprises a programmable DNA binding domain and an adenosine deaminase domain; the adenosine deaminase domain comprises a V82S amino acid substitution at or corresponding to amino acid position 82 in the numbering of SEQ ID NO:2; wherein the guide polynucleotide directs the adenosine base editor to effect an A to G nucleobase modification in a target gene or a regulatory element thereof associated with a neurological disorder selected from the group consisting of: LRRK2, IDUA, MECP2, and ABCA4, i) the target gene is the alpha-L-iduronidase (IDUA) gene and the neurological disorder is Hurler syndrome; or ii) the target gene is the leucine-rich repeat kinase 2 (LRRK2) gene and the neurological disorder is Parkinson's disease; or iii) the target gene is the methyl-CpG binding protein 2 (MECP2) gene and the neurological disorder is Rett syndrome; or iv) the target gene is the ATP-binding cassette subfamily member 4 (ABCA4) gene and the neurological disorder is Stargardt's disease; Base editor system.
28. 28. The base editor system of claim 27, wherein the polynucleotide-programmable DNA binding domain is Cas9.
29. 29. The base editor system of claim 28, wherein the Cas9 is SpCas9 or SaCas9.
30. 30. The base editor system of any one of claims 27-29, wherein the polynucleotide-programmable DNA-binding domain comprises SpCas9 with protospacer adjacent motif specificity for a nucleotide sequence selected from the group consisting of NGG, NGA, NGCG, NGN, NNGRRT, NNNRRT, NGCG, NGCN, NGTN, and NGC, where N is A, G, C, or T and R is A or G.
31. the polynucleotide-programmable DNA binding domain comprising: (i) is nuclease inactive; or (ii) nickase; A base editor system according to any one of claims 27 to 30.
32. (i) the adenosine deaminase further comprises a T166R modification; or (ii) the adenosine deaminase further comprises one or more of the following modifications: Y147T, Y147R, Q154S, Y123H, Q154R, or a combination thereof; or (iii) the adenosine deaminase further comprises a combination of modifications selected from the group consisting of: Y147R + Q154R + Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y147T + Q154R; Y147T + Q154S; and Y123H + Y147R + Q154R + I76Y; or (iv) the adenosine base editor domain comprises an adenosine deaminase monomer; or (v) the adenosine base editor comprises an adenosine deaminase dimer. The base editor system of any one of claims 27 to 31.
33. 33. An in vitro or ex vivo cell comprising the base editor system of any one of claims 27 to 32.
34. A pharmaceutical composition comprising the base editor system of any one of claims 27 to 32, or the cell of claim 33, and a pharma- ceutically acceptable carrier.
35. 35. The pharmaceutical composition of claim 34, further comprising a lipid.
36. A kit comprising the base editor system of any one of claims 27 to 32, or the cell of claim 33.
Citation Information
Patent Citations
Adenosine nucleobase editors and uses thereof
WO2018027078A1
Systems, methods, and compositions for targeted nucleic acid editing
WO2018213708A1
Crispr / CAS-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
WO2019005884A1
Cited By
Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
JP2025032080A
